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Abstract 
Immune-mediated hypersensitivity reactions to the antiretroviral drug abacavir are observed 
exclusively in individuals carrying the HLA-B*57:01 risk allele. Abacavir is hypothesised to 
bind within the peptide binding groove of HLA-B*57:01 and alter the array of peptides 
presented on the cell surface. Indeed, presentation of these unique abacavir-self-peptide 
complexes is thought to initiate a CD8+ mediated T-cell response to the drug in hypersensitive 
patients.  
Consistent with previous findings abacavir-specific T-cell clones from healthy donors 
expressing HLA-B*57:01 were found to be activated via 2 independent mechanisms, relying 
on and exclusive of antigen processing respectively. Furthermore, clones yielded a varied T-
cell receptor expression and cytokine secretion properties when stimulated with abacavir, 
indicating the presence of multiple unique subsets of abacavir-responsive T-cells.  
Eighteen abacavir substituted analogues were synthesised with modifications to the 
cyclopropyl moiety of the compound, namely derivatives of the azetidine group. Eight of 
these analogues completely lacked any T-cell activity, while others strongly induced IFN-γ 
secretion from the abacavir-responsive clones. Interestingly, activation of T-cells was 
demonstrated to be enantiomeric-specific around the cyclopropyl and cyclopentyl moiety. 
However, no analogue bereft of T-cell activity possessed sufficient antiviral potency to be 
considered a replacement for abacavir in the therapeutic setting. Molecular modelling 
revealed the unfavourable binding characteristics of non-cross-reacting analogues within the 
peptide binding groove of HLA-B*57:01, something not observed with T-cell activating 
analogues. Furthermore, peptide elution studies revealed a distinct shift towards small chain 
terminating peptides in the presence of cross-reacting abacavir analogues but not non-cross 
reactive analogues. Raising clones to the respective analogues of abacavir yielded a plethora 
of T-cells with reactivity towards the analogues including those that initially did not cross 
react with abacavir clones, indicating the importance of T-cell cloning assays in the analysis 
of the immunogenicity of HLA-binding drugs.   
While the role of altered self-peptides presented on the surface of the MHC in the presence 
of abacavir is thought to drive the CD8+ mediated T-cell reactions, the peptide sequences 
that activate T-cells in the presence of abacavir has not been fully defined. Further studies 
with a previously presumed immunogenic peptide (NTVELRVKI) demonstrated little to no 
reactivity towards abacavir clones in its natural form, whilst producing non-specific T-cell 
activity in the amidated form. Dissecting the contribution of the abacavir-induced-self-
peptides in T-cell responses to abacavir is difficult as these peptides are naturally loaded onto 
MHCs for presentation on the cell surface. However, using a panel of five abacavir induced-
self peptides which had underwent kinetic studies previously to examine their dependence 
on abacavir for presentation on the surface of antigen presenting cells over time, peptide 
responsive T-cell clones were generated in the presence of abacavir. At low concentrations 
of the drug, these clones demonstrated an enhanced response to abacavir in the presence 
of the individual self-peptides. Finally, two clones raised solely to abacavir, displayed strong 
IFN-γ secretion to two of the self-peptides in the absence of the drug. These findings suggest 
that the abacavir-dependent self-peptides do seem to contribute to the activation of T-cells.  
This work highlights the involvement of peptides in the CD8+ T-cell-mediated hypersensitivity 
reactions to abacavir in HLA-B*57:01+ individuals. Furthermore, it emphasises the 
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importance of a holistic approach to the design and subsequent analysis of the safety of a 
new compound for integration into the therapeutic setting.  
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1.1. Adverse drug reactions  
 
The definition of adverse drug reactions (ADRs) given by the World Health Organisation 
(WHO), which has been used for over 30 years, is “a response to a drug that is noxious, 
unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or 
therapy of a disease, or for the modification of physiological function” (WHO, 1972). 
However in 2000, Edwards & Aronson criticised WHO’s definition of ADRs due to the 
ambiguity of the word “noxious”. They argued that this word did not encompass all adverse 
reactions, specifically those which are an inconvenience to the patient but not necessarily 
harmful. They also stated that this particular definition did not include reactions that occur 
to drugs at a dose out of the therapeutic range i.e. overdoses and trace amounts (Edwards 
& Aronson 2000). Therefore it was proposed that ADRs be defined as “an appreciably 
harmful or unpleasant reaction, resulting from an intervention related to the use of a 
medicinal product which predicts hazard from future administration and warrants 
prevention of specific treatment, alteration of the dosage regimen or withdrawal of the 
product” (Edwards & Aronson 2000).  
ADRs represent a major problem both clinically and financially due to the increase in 
morbidity and mortality that they cause. ADRs account for 6.5% of hospital admissions in 
adults in the UK and 2.1% in children (Pirmohamed et al. 2004). Furthermore 6.7% of patients 
will suffer a serious ADR whilst in hospital, 0.15% of which will be fatal, accounting for 5700 
deaths per year (Lazarou et al. 2015). ADRs account for 1 in 16 hospital admissions in the UK, 
and on average prompt a hospital stay of around 8 days. This represents around 4% of the 
total capacity of all hospital beds, translating to a financial burden of £466 million on the 
National Health Service (NHS) (Pirmohamed et al. 2004).   
ADRs can also significantly affect a patient’s compliance to drug therapy which can have a 
detrimental effect on their quality of life. Furthermore, the incidence of ADRs signi ficantly 
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reduce the availability of the choice of drug treatment for the patient, as well as leading to 
diagnostic confusion. This may reduce the patient’s confidence in the healthcare 
professionals leading to further compliance issues.  
1.2. Classification. 
 
ADRs can be classified under two main headings, common and uncommon ADRs and can be 
categorised using the A-G classification system. 
Type A (Augmented) reactions are predictable, dose related ADRs which are generally 
related to the pharmacology of the drug. These reactions are usually less severe than type B 
reactions but are more frequent. They account for 80% of the overall proportion of ADRs 
(Farcas & Bojita 2009). Type A reactions are related to the primary pharmacology and the 
secondary actions of the drug which may differ from its therapeutic action but is still known 
from the drugs pharmacological profile. For example, the treatment of hypertension with β-
blockers is known to induce bradycardia due to the blockade of β-adrenergic receptors in 
cardiac tissues leading to a reduction in heart rate. However non-selective β-blockers can 
block β2 receptors in pulmonary tissues, thereby preventing the binding of epinephrine and 
norepinephrine leading to bronchospasm (Ahmed & Branley 2009).     
Type B (Bizarre) reactions are uncommon but often well recognised ADRs. These manifest 
in a minority of patients and usually consist of sensitive or idiosyncratic reactions (Rohilla & 
Yadav 2013). Type B reactions are not obviously dose dependent or related to the primary 
pharmacology of the drug making them difficult to predict during drug development. 
Therefore, these reactions may only be recognised following licensing as a result of post 
marketing pharmacovigilance (Pirmohamed & Park 2003). Type B reactions are very 
important as they are often severe and in some cases can result in mortality (Farcas & Bojita 
2009) (Pirmohamed 2005). Type B reactions can affect multiple organs within the body an 
include reactions such as hypersensitivity, Stevens Johnson syndrome (SJS), toxic epidermal 
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necrolysis (TEN), anaphylaxis and drug induced liver injury (DILI) (Wei, Michael lee, et al. 
2012). These reactions often occur in susceptible individuals with an association between 
specific HLA-alleles and a range of culprit drugs being a prime example. This includes 
antibiotics (e.g. penicillins), non-steroidal anti-inflammatory drugs (NSAIDs e.g. celecoxib), 
anti-convulsants (e.g. carbamazepine), allopurinol and anti-retrovirals (e.g. abacavir). These 
reactions are mediated by the adaptive immune system involving the presentation of drug 
antigens by major histocompatibility complexes (MHC) leading to the subsequent activation 
of T-cells.  
Type C (Chronic) reactions are caused by repeated exposure to a drug over a long period of 
time. They are uncommon reactions and are related to the aggregating dose of the drug 
(Farcas & Bojita 2009). For example, glucocorticoids are prescribed to patients for their 
immunosuppressive and anti-inflammatory properties to treat auto-immune diseases. 
However, chronic use of these glucocorticoids induces a decrease in calcium absorption in 
bones leading to a reduction in bone remodelling and a decrease in bone turnover which can 
result in osteoporosis (Fraser & Adachi 2009). 
Type D (Delayed) reactions are uncommon, usually dose-dependent reactions only detected 
following repeated exposure to the drug or exposure at a critical time point in a patient’s life. 
Immunosuppressant drugs prescribed to treat inflammatory bowel disease (IBD) has been 
shown to be associated with an increase in incidence of lymphoma in patients subjected to 
repeated exposure (Farrell et al. 2000; Bewtra & Lewis 2011). 
Type E (End of Treatment) reactions are uncommon reactions that can occur following 
cessation of the drug therapy. This generally refers to negative symptoms experienced upon 
withdrawal of drugs such as opiates and selective serotonin reuptake inhibitors (SSRI’s). 
Opiate withdrawal syndrome is a prime example of this kind of reaction where patients will 
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often experience symptoms such as headaches, muscle aches and cramps, hot and cold 
sweats and irritability upon withdrawal of drugs such as morphine (Farcas & Bojita 2009). 
Type F (Failure of Therapy) reactions are more common dose-related reactions that are 
often caused by drug-drug interactions. These reactions have been described as an 
“unexpected failure of therapy” (Hartigan-Go & Wong 2000). For example antibiotics such as 
rifampicin and some anti-convulsants such as phenytoin, which possess enzyme inducing 
activity, can lead to an inadequate dosage of the female oral contraceptive pill hindering its 
ability to suppress ovulation, which may result in unwanted pregnancy (D’Arcy 1986). 
Indeed, female patients are now advised to seek other forms of contraception when 
prescribed enzyme inducing therapeutics.  
Type G (Genetic) reactions are very rare but still important as they cause irreversible genetic 
and DNA damage. An obvious example of this is the teratogenic reactions caused by anti-
emetic drug thalidomide on unborn foetuses including limb anomalies, congenital heart 
disease, deformation of the inner and outer ear and malformations in the eyes (Kim & Scialli 
2011).  
The A-G adverse drug reaction classifications is summarised in Table 1.1.  
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Type of Reaction Drugs Example 
Augmented β-blockers Bronchospasm 
Bizarre Anti-epileptics 
(Carbamazepine) 
Stevens Johnsons  
syndrome 
Chronic Glucocorticoids Osteoporosis 
Delayed Immunosuppressants Lymphoma 
End of Treatment Opiates, Benzodiazepines Withdrawal syndrome 
Failure of Therapy Rifampicin, Phenytoin Unwanted pregnancy 
Genetic Thalidomide Teratogenicity 
      
1.3. Dose, time and susceptibility used as tools for classifying ADRs 
 
In 2003 Aronson & Ferner indicated that the traditional A-G classification system of adverse 
drug reactions only took into consideration the properties of the drug and the dose 
dependence of its effects. They suggested other factors should be considered including the 
time course and severity of the reaction along with the properties of the individual 
concerned including genetic, pathological and biological factors. All of which may increase 
an individual’s susceptibility to a reaction (Aronson & Ferner 2003). Therefore, a 
classification system comprising of three main factors: dose, time and susceptibility (DoTS) 
was proposed. 
 
 
 
Table 1.1. Classifications of adverse drug reactions with culprit drugs and examples. 
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1.3.1. Dose 
 
This approach assumes that all ADRs, including those that are immunologically mediated, are 
dose dependent. These reactions are split into those that occur at doses above the 
therapeutic index (supratherapeutic) including toxicity and overdosage effects, standard 
therapeutic doses including collateral effects and doses below the therapeutic index 
(subtherapeutic) such as hypersensitivity reactions occurring in susceptible individuals 
(Callreus 2006).  
1.3.2. Time 
 
Two categories exist for the classification of ADRs based on their time course, time 
dependent reactions and time independent reactions (Callreus 2006; Aronson & Ferner 
2003). Time independent reactions can take place at any point during the treatment regimen 
independent of the length of the course. This often happens when the concentration of the 
drug is altered at the site of action i.e. digoxin toxicity occurs when elimination of the drug is 
reduced due to renal impairment (Aronson & Ferner 2003).  
Time dependent reactions can be classified into six subtypes: 
1) Rapid reactions occur when the drug is administered too quickly, for instance the rapid 
injection of vancomycin has been known to cause red man syndrome (Sivagnanam & Deleu 
2003).    
2) First dose reactions will take place after the first dose of a drug in the treatment regimen. 
An example of this includes anaphylaxis with penicillin treatment (Drain & Volcheck 2001) or 
hypotension following first dose of angiotensin converting enzyme inhibitors (ACEi) in 
hypertensive patients (Vitovec & Spinar 2000).  
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3) Early reactions take place within the first few doses of treatment and usually cease with 
continued dosing when the individual has developed a tolerance. For instance nitrate 
induced headaches generally plateau after repeated doses (Wall et al. 1996). 
4) Intermediate reactions generally occur after a some delay, however if the reaction has not 
taken place within a certain period of time then there is a low risk of the reaction taking place 
at all (Aronson & Ferner 2003). An example would be neutropenia with the prodrug 
carbimazole (Bux et al. 2000). 
5) Late reactions seldom occur at the beginning of the treatment regimen but the risk of a 
reaction increases upon continuing exposure to the drug. For example Cushings Syndrome 
with continued glucocorticoid therapy (Sharma & Nieman 2011). This subtype also includes 
the withdrawal reactions experienced upon cessation of the drug treatment such as the 
headaches dizziness and nausea that can be experienced upon opiate withdrawal. 
6) Delayed reactions can be observed a long period of time after exposure to the drug, even 
upon drug withdrawal prior to a reaction taking place. Teratogenetic reactions that were 
associated with thalidomide treatment in pregnant women is an obvious example (Kim & 
Scialli 2011). 
1.3.3. Susceptibility 
 
The third section of the DoTS paradigm takes into account the various factors that could  
affect an individual’s susceptibility to a reaction. These include genetics, age, sex 
physiological state, exogenous drugs or foods and other disease states (Aronson & Ferner 
2003; Callreus 2006). This is summarised in Table 1.2. 
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Susceptibility Variable Example 
Genetics Patients positive for HLA-B*57:01 are 
more susceptible to hypersensitivity 
reactions with abacavir. 
Age Increased susceptibility to adverse 
reactions in older patients with renal 
failure which is more prevalent in 65<. 
Sex Increased risk of cutaneous reactions 
among females. 
Physiological State Anti-epileptic drugs can be excreted 
faster in pregnant women resulting in 
increased seizures. 
Exogenous Factors The consumption of grapefruit juice can 
adversely affect the bioavailabilty of 
numerous drugs that are metabolised 
via CYP3A4. 
Disease Hepatic cirrhosis affects morphine 
metabolism. 
 
 
 
 
Table 1.2. Factors influencing an individual’s susceptibility to an adverse drug reaction. 
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1.4. Drug induced hypersensitivity reactions 
 
Drug induced hypersensitivity reactions are ADRs that are observed in susceptible individuals 
after exposure to certain drugs (Alfirevic & Pirmohamed 2010). Hypersensitivity reactions 
are type B reactions which can often be severe and in some cases life threatening (Sukasem 
2014). As previously mentioned these reactions are not detected during drug discovery or 
clinical trials and generally only come to light during post marketing surveillance when 
exposed to susceptible individuals. This often results in the affected patient being prescribed 
alternate therapies which may have a reduced efficacy as well as being more expensive, 
which has a negative impact from both a patients and a healthcare professionals point of 
view (Alfirevic & Pirmohamed 2010).  
Many hypersensitivity reactions are immunologically mediated (Phillips & Mallal 2011) and 
can often present symptoms including skin rash, anaphylaxis, gastrointestinal (GI) 
disturbances and severe cutaneous reactions including SJS and TEN (Phillips & Mallal 2011; 
Sukasem 2014). Hypersensitivity reactions can be classified into two groups; immune 
mediated reactions and non-immune mediated reactions.  
Immune mediated reactions were classified into four main categories by Gell and Coombs 
(1963), ranging from Type I-IV.  
Type I reactions are immediate type reactions that are produced by drug/antigen specific IgE 
antibodies and can manifest as angioedema, anaphylaxis and bronchoconstriction (Sukasem 
2014). 
Type II reactions referred to as cytotoxic mechanism reactions are caused by IgG and IgM 
cytotoxic events which can lead to cellular destruction and detachment affecting target cells 
such as erythrocytes, leukocytes and platelets (Pichler 2007). This can lead to haemolytic 
anaemia and thrombocytopenia.    
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Type III reactions are mediated by IgG and IgM and depend on the formation of immune 
complexes, which may take place during drug treatment, giving rise to an immune response 
(Pichler 2007). This can manifest as small vessel vasculitis and serum sickness. 
Type IV reactions are known as delayed hypersensitivity reactions and are mediated via T-
cells. SJS and TEN are prime examples of type IV hypersensitivity reactions, however based 
on the subgroups of T-lymphocytes involved and the cytokine expression profile, this group 
of reactions has been divided into an additional four subsets (IVa-IVd) (Sukasem 2014). The 
further (a-d) classification of these reactions is dependent on the respective involvement of 
monocytes (IVa), eosinophils (IVb), cytotoxic T-cells (IVc) and neutrophils (IVd) (Adam et al. 
2011).  
1.5. Clinical manifestations 
 
The skin is the most common site of hypersensitivity reactions to drugs,  due to it being a 
highly immunologically privileged site. Therefore it is a prime target for reactions mediated 
by the immune system as well as the fact that rashes present on the skin, even mild, are 
visible to the patient and are therefore more likely to be reported when compared with other 
organs where mild reactions may go unnoticed (Uetrecht & Naisbitt 2013). Maculopapular 
eruptions are the most common ADRs observed in the skin. Often reported as drug rashes 
or eruptions they account for 90% of cutaneous ADRs (Hunziker et al. 1997) . These reactions 
start on the trunk, upper extremities and increasingly become more widespread. This usually 
takes place 4-14 days following initiation of treatment with a drug and may still be apparent 
for 1-2 days following termination of therapy (Roujeau 2005).  
Drug reaction with eosinophilia and systemic syndrome (DRESS) is a much rarer drug induced 
hypersensitivity reaction characterised by severe eruption, fever and rash, along with at least 
one symptom affecting other organs including lymphadenopathy, hepatitis, nephritis, 
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pneumonitis, carditis, thyroiditis and haematological anomalies such as thrombocytopenia 
and leukopenia. This reaction is reported to occur in between 1:1000 and 1:10000 patients 
with exposures to culprit drugs including anticonvulsants (lamotrigine, phenytoin and 
carbamazepine), antimicrobials (flucloxacillin, ampicillin, dapsone, sulfamethoxazole) and 
antivirals (abacavir and nevirapine) (Spriet & Banks 2015).  Symptoms develop in 2-6 weeks 
post first use, which is typically later than other reactions and have been reported to be most 
frequent in people of African descent. Subsequent re-exposure can evoke a reaction in a 
much shorter period of time (24 hours) (Roujeau 2005; Verma et al. 2013).  Abnormalities in 
the liver are apparent in up to 70% of patients expressing symptoms of DRESS, which is 
usually characterised by a clear increase in serum alanine aminotransferase levels often 
resulting in hepatitis directly associated with the 20% mortality rate of DRESS (Shiohara et 
al. 2006). DRESS reactions to drugs have been shown to be regulated by the cellular actions 
of eosinophils mediated via the secretion of IL-5 from T-cells, which was demonstrated to be 
elevated in patients with DRESS (Choquet-Kastylevsky et al. 1998). Viral reactivation is 
associated with the more severe symptoms of DRESS and is often used as a diagnostic tool 
(Pritchett et al. 2012). Human herpes virus-6 (HHV-6) is detected in a majority of patients 
with severe DRESS symptoms. Indeed, an increased HHV-6 DNA has been detected in the 
serum of fatal cases of DRESS associated with renal failure (Descamps et al. 2003). The 
presence of cytomegalovirus (CMV) and Epstein Barr virus (EBV) have also been shown to 
participate in some cases of DRESS with drugs including allopurinol and phenytoi n (Aihara et 
al. 2001; Descamps et al. 2003).  
SJS and TEN are severe adverse cutaneous reactions which primarily affect the skin and 
mucosal membranes. TEN is the most severe of the cutaneous reactions yielding a mortality 
rate of approximately 30% while SJS is a milder form of the same reaction. TEN has an 
incidence of 0.4-1.2 cases per million persons per year while SJS is slightly higher at 1-2 cases 
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per million persons per year (Rzany et al. 1996). The presentation of SJS is identified by the 
presence of small blistering emerging on purple macules. Widespread lesions are also 
apparent and usually predominate on the trunk. The spread of these blisters can result in 
separation of the epidermis from the dermis and overall detachment in <10% of the bodily 
surface area (Roujeau 2005; Uetrecht & Naisbitt 2013). The same lesions are characteristic 
of TEN but with a higher prevalence of blisters resulting in overall detachment of large 
epidermal sheets on >30% of the bodily surface area. Cases where the detachment lies 
between 10 and 30% are referred to as overlap SJS-TEN (Bastuji-Garin et al. 1993). Various 
mucosal sites including the mouth, genitals, eyes and intestines are implicated in both SJS 
and TEN which can result in blindness.  
The pathogenesis of SJS/TEN is thought to be immune mediated due to the fact that re -
challenge with culprit drugs can result in swift reappearance of symptoms (Harr & French 
2010). SJS/TEN lesions demonstrate keratinocyte apoptosis followed by necrosis, which is a 
marker of epidermal detachment. Blister fluid analysis reveals the presence of cytotoxic 
lymphocytes suggesting a MHC Class I-restricted CD8+ T-cell-mediated reaction is involved 
(Le Cleach et al. 2000). Keratinocyte apoptosis appears to be regulated via the death ligand 
FasL and its associated receptor Fas, which keratinocytes demonstrate exceptional sensitivity 
to and is shown to be enhanced in the presence of the proinflammatory cytokine IFN-γ, 
present in the skin during TEN (Abe et al. 2003). Blister fluid cells also express high levels of 
granulysin mRNA, which when administered in mice has been shown to mimic SJS/TEN (Harr 
& French 2010). Indeed, granulysin levels are found to be elevated in serum from blister fluid 
from ADRs compared to the low expression taken in absence of blistering ADR suggesting an 
imperative role for granulysin in SJS/TEN (Chung et al. 2008).  
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1.6. In-vitro diagnostic tests for delayed hypersensitivity reactions 
 
The fundamental aim of the diagnosis of a drug allergy is to firstly confirm that the symptoms 
presented correlate with a drug hypersensitivity reaction but also to identify the culprit 
therapeutic for the reaction experienced.  To identify the drug in question in vivo tests such 
as skin and drug provocation may be utilised. A variety of skin tests are readily available for 
clinical use including patch, prick and intracutaneous tests, however all are accompanied 
with problems (Porebski et al. 2011). Skin tests have low sensitivity and often yield negative 
results in patients, even if a history of DHR is known, and are also invasive in nature (Romano 
et al. 2004; Bousquet et al. 2008; Padial et al. 2008; Aberer et al. 2003) . While drug 
provocation tests can be useful in diagnosis, they are not well tolerated by patients due to 
the potential to further elicit a recurrence of severe reactions (Romano et al. 2004; Aberer 
et al. 2003) and the fact that they can only be performed after an appropriate period of time 
when the symptoms of the initial reaction have subsided (Porebski et al. 2011).   
In vitro tests provide a much safer alternative as they avoid invasiveness of the skin tests and 
the risks of severe reactions that accompany the provocation tests. In vitro tests also provide 
a greater insight into the mechanisms involved in hypersensitivity reactions while allowing 
for the evaluation of many immune responses from multiple therapeutics concurrently 
(Porebski et al. 2011).  The standard in vitro tests used as diagnostic tools include the 
lymphocyte transformation test (LTT), enzyme linked immunospot (ELIspot) assay and others 
including the use of flow cytometry to detect markers on cells along with intracellular 
cytokine synthesis.  
These tests are not without limitations; firstly, they are not useful in detecting class II and III 
reactions (Porebski et al. 2011). Secondly, they are dependent on the access to and ethical 
approval of patient peripheral blood mononuclear cells (PBMCs) and the relevant  
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infrastructure to both study and cryopreserve these cells. A researcher must also be 
appropriately trained to isolate PBMCs from patient samples and incorporate them into the 
aforementioned assays, most of which require sterile techniques. However, as many of these 
limitations also exist with the skin and drug provocation assays, these in vitro techniques still 
represent a safer alternative. 
1.6.1. Lymphocyte transformation test (LTT) 
 
The LTT, also referred to as the lymphocyte proliferation or stimulation test, is a commonly 
used in vitro test for the diagnosis of T-cell responses specific to a drug (Nyfeler & Pichler 
1997; Pichler & Tilch 2004). Use of this diagnostic assay involves the isolation of PBMCs from 
hypersensitive patients in response to treatment with the drug in question. PBMCs are re-
challenged with the specific drug and proliferation of T-cells is measured via 3H-thymidine 
uptake in dividing cells during DNA synthesis. A heightened proliferative response in the 
presence of the assumed allergenic drug is taken as a marker of drug specific T-cell activation. 
Proliferation is expressed as a stimulation index (SI) and an SI value of ≥2 is considered 
positive. Such proliferative responses are not observed in PBMCs isolated from drug naïve 
individuals, indicating that said proliferation is indeed a sign of prior sensitization and 
subsequent activation of memory cells. Luque et al demonstrated that the LTT assay is an 
effective screening tool for the diagnosis of both immediate and delayed hypersensitivity 
reactions to beta lactam drugs (Luque et al. 2001). The LTT assay is useful for a variety of 
groups of therapeutics including antibiotics (beta-lactams, sulfonamides), antiepileptics 
(lamotrigine, carbamazepine, phenytoin), antituberculosus drugs (rifampicin, isoniazide) and 
antihypersensitives (enalapril) among others (Pichler & Tilch 2004). Therapeutics known to 
cause hypersensitivity reactions via the hapten model (section 1.9.1), and PI model (section 
1.9.2) have been shown to produce positive results in the LTT.  
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The readout stage of this assay can be adjusted to measure other markers of T-cell activation. 
This includes the measurement of both the synthesis and release of cytokines including IL-5, 
IL-10 and IFN-γ (Merk 2005). Furthermore, the measurement of CD69 expression can serve 
as a marker of T-cell activation (Simms & Ellis 1996). The sensitivity of the LTT is thought to 
range between 56% to 78% while its specificity ranges from 85% to 93% (Elzagallaai & Rieder 
2015; Nyfeler & Pichler 1997). There are various factors that are known to influence the 
ability of the LTT assay at identifying drug hypersensitivity. These include the timing of the 
test following the initial reaction in the patient, the clinical manifestation of the reaction, the 
nature of the drug involved in the reaction, the test procedure itself specifically with the lack 
of standardization to the procedure and the read out system employed by the researcher 
(Elzagallaai et al. 2009).  
The LTT assay requires experience by a researcher with knowledge of cellular techniques and 
also the relevant infrastructure to allow the assays to be carried out correctly. The use of 
radioactive thymidine at the readout stage is one obvious drawback due to the use of 
radioactive material. While a positive LTT is a valued contributor to drug allergy di agnosis, 
the sensitivity of the assay is still limited and more importantly a negative LTT does not rule 
out a drug hypersensitivity reaction in the patient (Pichler & Tilch 2004). 
1.6.2. Flow cytometry 
 
Flow cytometry is a widely used technique for the analysis of the expression of cell surface 
markers and intracellular molecules. It allows for the multiparametric analysis of an assorted 
population of cells concurrently, making it an effective high throughput diagnostic tool. 
Activated T-cells display unique surface markers not observed in naïve T-cells. This includes 
receptor proteins, costimulatory molecules, chemokine receptors and MHC class II molecules 
(Shipkova & Wieland 2012). The upregulation of these surface markers is a commonly used 
hallmark for T-cell activation. The upregulation and surface expression of the early antigen 
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activation receptor protein CD69 has been demonstrated to occur rapidly following 
activation of T-cells and displays a distinct difference from baseline values (Porebski et al. 
2011). It has been known to be a useful readout of T-cell activation in response to 
therapeutics including amoxicillin, carbamazepine (Beeler et al. 2008) and abacavir (Yerly et 
al. 2017). Other cell surface markers of T-cell activation include CD25 (IL-2 receptor), CD71 
(transferrin receptor) and HLA-DR (MHC Class II) (Shipkova & Wieland 2012; Caruso et al. 
1997). Flow cytometry may also be used to measure the proliferative responses of T-cells to 
a particular antigen. This is carried out using the carboxyfluorescin diacetate succinimidyl 
ester (CFSE) assay. CFSE permeates the cellular membrane and interacts with the amino 
groups of the intracellular proteins forming a stable covalent bond. Each cellular division 
results in a halving of the CFSE fluorescence allowing lymphocyte proliferation to be 
measured via flow cytometry (Quah et al. 2007; Faulkner et al. 2012; Gibson et al. 2014). 
1.6.3. ELISA 
 
Enzyme-linked immunosorbent assay (ELISA) is a diagnostic tool that allows for the detection 
and measurement of substances including peptides, proteins and cytokines, the latter of 
which can be quantified as a measure of T-cell activity. This assay involves the use of 
monoclonal antibodies which bind to the surface of wells in a 96-well plate. The addition of 
supernatant from a given sample will cause cytokines to bind to the capture antibodies. 
Unbound cytokines are removed by washing and a detection antibody is added, specific for 
the cytokine in question, followed by enzyme horseradish peroxidase, substrate solution 
tetramethylbenzidine (TMB) and finally H2SO4 stop solution. The resultant colour change can 
be measured and compared against a baseline value as a marker of T-cell activation. Many 
studies have used the ELISA assay as a method for various cytokines and effector molecules, 
for measuring of T-cell activation in response to various antigens (Salehi et al. 2016; Zhao et 
al. 2017; Toksoy et al. 2017). However, this assay is limited due to its inability to measure 
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cytokine secretion at the single cell level along with its low sensitivity when compared with 
the ELIspot assay, discussed below (Cox et al. 2006; Czerkinsky et al. 1988).   
1.6.4. ELIspot assay 
 
Enzyme-linked immunospot (ELIspot) assay is a fast, quantitative assay that allows for the 
quantification of T-cell activation via the detection and subsequent measurement of 
secreted cytokines or effector molecules such as the granzymes and perforin. This provides 
an insight into the biological function of the cells as well as the mechanistic properties of the 
antigens. First described in 1988 the ELIspot assay employs the use of epitope -specific 
monoclonal antibodies for the detection of individual cytokine secreting cells (Czerkinsky et 
al. 1988). Monoclonal or polyclonal antibodies, which are speci fic for each cytokine, are 
coated onto a white ELIspot plate, T-cells are then added to the plate and co-incubated in 
the presence of a particular antigen. During the incubation period, the T-cells secrete 
cytokines that are captured by the antibody coated on the plate. Cells are then removed via 
washing, and a detection antibody is added and, following subsequent washing, the 
strepdavidin conjugate is added followed later by BCIP/NBT substrate. The precipitation of 
this substrate manifests as spots at the sites of cytokine secretion, which can be quantified 
as a measure of T-cell activity (Cox et al. 2006; Lehmann & Zhang 2012). The most utilized 
ELIspot assay is for the detection of IFN-γ secretion as a primary readout for the activation 
of CD4+ and/or CD8+ T-cells (Rasmussen et al. 2013; Naisbitt et al. 2015; Monshi et al. 2013). 
However, this assay may be adjusted to distinguish between the various subsets of T-cells 
via the detection of the multitude of cytokines they are known to secrete (Fujihashi et al., 
1993; Wang et al., 1994; Bell et al., 2013). This includes Th1 helper cells which secrete 
cytokines IL-2, IFN-γ and TNF-α, Th2 cells which secrete IL-4, IL-5, IL-10 and IL-13, or Th17 
cells which secrete IL-17 (Fujihashi et al. 1993; Hiro et al. 1994; Faulkner et al. 2016). The use 
of the ELIspot assay displays numerous advantages including its rapidness, wide range of 
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cytokines available for detection and ability to address questions on the mechanistic profile 
of the antigen in question at the same time. The ELIspot assay has been shown to have a 
sensitivity of around 200 times greater than the ELISA assay (Tanguay & Killion 1994). The 
main limitation of the ELIspot assay is cost, mainly due to the fact that only single cytokines 
can be detected in each well, meaning individual antibodies for each cytokine must be 
purchased, however this limitation is also apparent with the ELISA assay.  
 
 
 
 
 
 
Figure 1.1. Schematic of the ELIspot assay used for the detection of cytokine secretion in 
response to an antigen. 
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1.6.5. Luminex 
 
Multiplex assays such as luminex allow for the simultaneous recognition and measurement 
of multiple secreted proteins including cytokines and effector molecules. This assay employs 
a similar principle to that of the ELISA and ELIspot assays. Beads which have been pre -coated 
with a capture antibody specific to the analyte of interest are coated onto a plate allowing 
for the capture of the secreted analyte. Detection antibodies are then added which bind to 
the secreted antigen and finally a conjugated strepdavidin is added allowing for the  
quantification of multiple cytokine secretions via dual laser flow-based detection (Khalifian 
et al. 2015).  
1.6.6. T-cell cloning  
 
T-cell cloning is a well-established effective procedure for the detection of antigen specificity 
in T-cells in vitro. It allows for the expansion of the drug-specific population of T-cells which 
often represents only a small subset of the overall T-cell population, thereby overcoming the 
issue of low cell numbers. Expansion of the antigen-specific T-cell population allows for 
further analysis of the T-lymphocytes including mechanistic studies, analysis of protein 
surface expression and characterisation on the cellular phenotypes and effector functions. 
This process represents a mainstay for studying the antigen-specific T-cell functions and has 
been shown to be imperative in understanding the cellular pathophysiology of reactions 
associated with exposure to drugs such as carbamazepine (Lichtenfels et al. 2014),  
flucloxacillin (Monshi et al. 2013), dapsone (Alzahrani et al. 2017) and abacavir (Bell et al., 
2013; Adam et al., 2014; Naisbitt et al., 2015).   
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1.7. The immune system 
 
The immune system comprises an interactive network of lymphoid organs, cells and 
cytokines for the protection against organisms that the host is exposed to throughout its life. 
The primary objective of the immune system is to control and eliminate these microorganism 
and toxins. This relies on the complex detection of structural features present on a pathogen 
or toxin to distinguish from cells belonging to the host, this is essential for the host to 
eliminate a foreign pathogen without injuring its own tissues (Parkin & Cohen 2001).  The 
immune system can be classified into two parts. Innate, non-specific, immune system which 
contributes an immediate response to an antigen with the adaptive immune system 
complementing and ultimately driving the immune response (Medzhitov & Janeway 1997). 
1.7.1. Cellular components of the innate immune system 
 
The innate immune system encompasses the first line of defence for the host against 
invading pathogens during infection playing a critical role in the primary recognition and 
successive initiation of a proinflammatory response to these pathogens. As well as 
composing of physical and chemical barriers to infection, this system relies on the 
recognition of conserved structures present on pathogens known as pathogen associated 
molecular patterns (PAMPs) via recognition receptors encoded within the germ line (Akira et 
al. 2006). The response primarily initiated by the innate immune system is regarded as non-
specific, unlike adaptive immunity, and takes place via phagocytotic cells and antigen 
presenting cells including dendritic cells, macrophages and granulocytes.  
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1.7.1.2. Mast Cells 
 
Mast cells are granulocytes that originate from myeloid stem cells and are primarily found in 
the skin and mucosal tissues during homeostasis. These cells play an important role in many 
allergic reactions and inflammatory responses. Mast cells originate in the bone marrow 
where their expansion is mediated by the binding of stem cell factor to its receptor and a 
number of cytokines including IL-3, IL-4, IL-9 and IL-10. They are characterised by the 
presence of organelles in the cytoplasm, which contain inflammatory mediators known as 
leukotrienes, histamine and cytokines. During an allergic reaction, IgE (released from B-cells) 
will attach to the mast cells covering the cells plasma membrane. Following binding to the 
mast cell receptor, the antigen binding segment of IgE is able to interact with and bind the 
antigen (Mekori & Metcalfe 2000). Further exposure to the same antigen results in cross 
linking of the cellular bound IgE and consequently induces the release of histamine and 
cytokines including GM-CSF, IL-8, IL-9 and TNF-α, resulting in allergic inflammation (Mekori 
& Metcalfe 2000; Chaplin 2010). Mast cells have been shown to play an imperative role in 
diseases such as asthma, ear infection and pulmonary fibrosis (Amin 2012; Bradding et al. 
2006) as well as more recently being demonstrated to be important in allergic immune 
reactions such as anaphylaxis (Galli & Tsai 2013).  
1.7.1.3. Macrophages 
 
Macrophages are white blood cells that are responsible for engulfing and digesting foreign 
substances including cellular debris, microbes and other pathogens in a process known as 
phagocytosis, playing a critical role in both the innate and adaptive immune responses. They 
are produced via the differentiation of monocytes and are known to express cellular proteins 
CD14, CD40, CD11b, CD64 and CD68 (Khazen et al. 2005). The process of phagocytosis is 
initiated via the attachment of PAMPs to the pathogen recognition receptors (PRRs) present 
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on the macrophages. This results in the engulfment of the pathogen which then fuses with 
the lysosome. Once engulfed the pathogen is degraded via reactive oxidative species, nitric 
oxide and lysosomal enzymes (Aderem & Underhill 1999). 
As previously stated, macrophages also have a role in adaptive immunity by acting as antigen 
presenting cells. Following the ingestion of a pathogen the macrophage will display an 
antigen on the cellular surface through attachment to the cellular membrane on an MHC 
Class II molecule. This antigen is then presented to Th1 helper cells resulting in the 
proliferation of these cells and the production of pro-inflammatory cytokines (Unanue 1984).  
1.7.1.4. Neutrophils 
 
Neutrophils are white blood cells belonging to the granulocyte family due to their multi-
lobed nuclei. They are the most abundant in the granulocyte family and the most abundant 
of the leukocytes accounting for around 70% and form the first line of defence against 
pathogens including protozoa, fungal and bacterial particles. These cells are known to be one 
of the major factors in acute inflammation, due to being one of the first classes of leukocyte 
recruited to the site of inflammation (Kolaczkowska & Kubes 2013). They undergo a process 
known as chemotaxis which allows them to migrate towards the site of inflammation. This 
process involves the use of cellular receptors by neutrophils to detect the chemical 
concentrations of IL-8, which has been shown to play a pivotal role in this process, to relocate 
to the site of inflammation (Bickel 1993; Baggiolini & Clark-Lewis 1992). Upon encountering 
a pathogen a neutrophil will engulf it via phagocytosis and once encapsulated the pathogen 
is destroyed using reactive oxidative species and antibacterial proteins including cathepsins 
and lysozymes (Segal 2005). 
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1.7.1.4. Basophils 
 
Basophils are the least common granulocytes, accounting for less than 1% of leukocytes. 
Activation of basophils, via binding of IgE to the FcεRI receptor, initiates the process of 
degranulation leading to the secretion of histamine, heparin, proteolytic enzymes, GM-CSF 
as well as cytokines including IL-4 and IL-13 causing a pro-inflammatory response (Parkin & 
Cohen 2001) . These cells are known to be involved in allergic reactions including asthma, 
atopic dermatitis and anaphylaxis (Siracusa et al. 2013). 
1.7.1.5. Eosinophils 
 
Eosinophils are granulocytes that comprise between 1-6% of leukocytes. They originate from 
stem cells in a process known as hematopoiesis in the bone marrow and relocate to the blood 
(Donohugh 1996). Once in circulation eosinophils are recruited to sites of inflammation in 
tissues in a process mediated by eotaxins and IL-5 (Jacobsen et al. 2012). Activation of 
eosinophils leads to the production of cytotoxic cationic granule proteins, reactive oxidative 
species and cytokines including IFN-Ƴ, IL-2, IL-4, IL-12, IL-5, IL-9 and IL-13 (Stone et al. 2011).  
1.7.1.6. Dendritic cells 
 
Dendritic cells (DCs) are professional antigen presenting cells that serve as sentinels of the 
immune system. They are formed from various cell lineages and are expressed in small 
numbers in most tissues throughout the body including skin, nose, lungs and stomach 
(Banchereau & Steinman 1998). They originate from hematopoietic bone marrow progenitor 
cells which develop into immature DCs. These immature cells are characterised by their high 
endocytic activity and low T-cell activation potential. Immature DCs constantly explore their 
immediate environment for pathogens that are mainly of viral or bacterial origin. This is 
achieved via the expression of PRRs such as toll like receptors (TLRs). These TLRs recognise 
specific chemical entities that are present on pathogens (Mellman 2013; Dalod et al. 2014). 
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Following exposure to danger signals including TLR ligands and proinflammatory signals such 
as LPS, TNF-α, or DAMPs such as HMGB1 or heat shock proteins, the process of maturation 
in immature DCs is initiated. During this process, the endocytotic ability of the cells is 
downregulated while the lysosomes and antigen processing components of the cell are 
activated, upregulating the peptide-MHC production also resulting in higher expression of 
costimulatory molecules such as CCR7, CCR5 and CCR1 and increased secretion of IL-12 
(Rescigno et al. 1998; Han et al. 2009). Once matured DCs migrate to the T-cell affluent 
regions of the lymph nodes and initiate antigen specific memory or naïve  T-cell responses. 
DCs capture and take up microbial antigens from the external environment and passage 
these antigens to naïve T-cells, which are present at low levels in the blood and migrate to 
the lymph nodes (Banchereau & Steinman 1998). DCs marshal the presence of pathogens to 
the adaptive immune system, which triggers a series of antigen-specific responses. This is 
achieved via the coordination of proteolytic apparatus present in the endosomal -lysosomal 
system, the cytosol and the endoplasmic reticulum (Cella et al. 1997). This helps to break 
down the pathogen derived proteins resulting in antigenic peptides which are processed and 
presented by MHC molecules. However, this presentation is not adequate to initiate a T-cell 
response on its own. For this, co-stimulation is required and it is provided mainly by CD40, 
CD80 and CD86 as well as other molecules. These are expressed on the antigen presenting 
cell surface and interact with ligands CD28 and CD40L (Mellman 2013; Hubo et al. 2013).  
Activation of naïve T-cells requires various signals from DCs. Signal I is regulated by MHC in 
complex with a peptide that has been processed from antigens and is recognised by specific 
T-cell receptors. Signal II, the costimulatory signal, is non-antigen specific but the presence 
of this signal is imperative for complete T-cell activation to occur (Kalinski 2009). It is mainly 
provided by the initiation of CD28 on the T-cell via ligation with CD80 and CD86 molecules 
on the DC. A third signal exists by the way of soluble factors such as the cytokines IL-12, IL-
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15, IL-6 and TNF-α which also play a role in the activation and proliferation of naïve T-cells.  
A combination of these signals define the T-cell differentiation process (Kapsenberg 2003).  
1.7.1.7. Natural killer cells 
 
Natural killer cells are cytotoxic lymphocytes that play a critical role in the innate immune 
system, mainly against intracellular viruses and bacteria. They are defined by their ability to 
kill infected cells upon development without further differentiation and make up between 
5-15% of mononuclear cells in the blood. Their development occurs mainly in the bone 
marrow from hematopoietic stem cells differentiating into lymphoid progenitors which 
further differentiate into NK-T progenitors (Leischner et al. 2015). Natural killer cells can be 
identified via the expression of CD56 and CD16, which plays a role in the recognition of 
antibody-coated cells, and the absence of the T-cell marker CD3 (Caligiuri 2008). The function 
of NK cells is to eliminate infected cells, including virally infected and tumorigenic cells, and 
produce the proinflammatory cytokine IFN-γ, activating macrophages to destroy 
phagocytosed microbes. NK cells are equipped with cytotoxic proteins stored within 
secretory lysosomes. The major cytotoxic proteins contained within these secretory 
lysosomes in NK cells are the granzymes and perforin (Kägi et al. 1994). Recognition of a 
target cell induces secretory lysosome exocytosis and the release of the cells cytotoxic 
contents. Perforin works to mediate the entry of granzymes into the cytoplasm of the target 
cell, once inside they cleave a number of intracellular targets including caspases, causing cell 
death via apoptosis, eliminating the stores of infected cells (Voskoboinik et al. 2015; Korey 
R. Demers, Morgans A. Reuter 2013). 
NK cells are able to differentiate between infected and healthy cells via the interplay 
between signals generated from activating and inhibitory receptors. Activating NK cell 
receptors include CD16, NKG2D and the short-tailed members of the killer immunoglobulin 
like receptors (KIRs). These signal via the association with DAP10 allowing for Pi3-kinase 
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activation or DAP-12 containing immunotyrosine based activation motifs (ITAM) (Lanier 
2008). Stimulation of these motifs leads to the downstream phosphorylation of signalling 
substrates. Inhibitory NK receptors contain long tail members of the KIR family along with 
LAIR-1 and KLRG-1 which signal via the cytoplasmic immunotyrosine based inhibitory motifs 
(ITIM) (Lanier 2008). Signalling from inhibitory receptors stimulates phosphatases to inhibit 
protein kinases. Interaction between NK cells and other cellular components involves a 
complex interplay between the signals originating from activating and inhibitory receptors 
(Pegram et al. 2011). Stimulation of the activating receptors induces the cellular killing profile 
of NK cells, while activation of inhibitory receptors impedes NK cell function preventing 
cellular destruction.      
1.7.2. The adaptive immune system 
 
The adaptive immune system, also known as the acquired immune system or more rarely 
the specific immune system, is a subset of the entire immune system that consists of highly 
specialised cells which are responsible for the destruction of invading pathogens and the 
toxic products they generate. Unlike innate immunity, the adaptive immune responses are 
specific to individual pathogens (Chaplin 2010). This feature is due to the antigen-specific 
receptors that are displayed on the surface of lymphocytes in the adaptive immune system. 
This differs from the innate immune system in that pathogen-specific receptors are already 
encoded in the germline of innate immune cells.  
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1.7.2.1. Cellular components 
 
Adaptive immune responses are undertaken by white blood cells known as lymphocytes. 
These responses can be classified as antibody-mediated responses and cell-mediated 
responses, which are carried out via B-cells and T-cells respectively. Both of these classes of 
cells originate from the same hematopoietic stem cells and prior to their activation are 
morphologically identical.  
1.7.2.2. B-Cells 
 
B-cells and their associated antibodies are critical components of humoral immunity which 
serves to protect against a plethora of pathogens. They are identifiable via their specific 
expression of CD19 and differentiate into either long-lived memory cells or effector plasma 
cells to protect against pathogens via the secretion of antibodies. B-cells develop from 
hematopoietic stem cells within the bone marrow and are present in peripheral lymphoids. 
The humoral immune response is triggered via the binding of antigens to IgM and IgD on 
naïve B-cells. This activation leads to the proliferation and subsequent differentiation of 
these cells to yield antibody secreting plasma cells and memory B-cells. A marker of B-cell 
activation is the production of antibodies apart from IgM and IgD in a process known as 
isotype switching. As a humoral response mounts, the activated B-cells secrete IgE antibodies 
which bind to antigens with high affinity. IgG is the major antibody found in the blood and 
extracellular fluid, it plays an important role in the control of infection in various tissues. They 
have been detected in cases of drug hypersensitivity to therapeutics including piperacillin 
(Clark & Dalmasso 1982; Amali et al. 2017). 
1.7.2.3. T-lymphocytes 
 
T-cells are activated by the presence of a foreign antigen to then proliferate and differentiate 
into effector T-cells. These can be classified into two distinct categories; helper T-cells (CD4+) 
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and cytotoxic T-cells (CD8+). These cells are the products of hematopoietic stem cell 
differentiation and relocate to the thymus from the bone marrow via the bloodstream. Once 
in the thymus these cells expand to produce a subset of cells known as thymocytes. Initially 
these cells do not express receptors for CD4 or CD8 and are therefore classified as double 
negative. These double negative cells undergo a process of TCR-β chain rearrangement to 
generate cells which are positive for both CD4 and CD8, defined as double positive cells. Next 
these double positive cells undertake a process of TCR-α chain rearrangement which results 
in the generation of CD4 or CD8 single positive cells which migrate from the thymus into 
circulation (Overgaard et al. 2015).  
1.7.2.4. Cytotoxic T-cells  
 
Cytotoxic (CD8+) T-cells are crucial for the immune defence mechanisms against intracellular 
pathogens including viruses and bacteria. CD8+ T-cells destroy the infected cell before 
microbes are able to proliferate and infect neighbouring cells. The infection of cells by 
intracellular pathogens results in the breakdown of foreign proteins through antigen 
processing. This leads to peptide fragments being presented to the T-cell receptor of CD8+ T-
cells via MHC class I.  
Naïve CD8+ T-cells only need a short exposure to antigenic peptide displayed by MHC to 
become activated and induce cellular division. Once activated CD8+ cells initiate a process of 
programmed differentiation resulting in them becoming effector cytotoxic T-cells. These 
cells secrete the proinflammatory cytokines IFN-γ and TNF-α and effector molecules 
including granzymes, FasL, and perforin (Bell et al., 2013).   
Cytotoxic T-cells secrete the pore forming protein perforin, which undergoes polymerisation 
with the plasma membrane of the target cells resulting in the formation of transmembrane 
channels. The formation of these pores allows the granzymes, contained within the cytotoxic 
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T-cell, to enter the infected cell. Once inside these granzymes cleave the intracellular 
proteins, halting viral protein production which results in cellular death via apoptosis 
(Voskoboinik et al. 2015; Korey R. Demers, Morgans A. Reuter 2013). 
Cellular killing can also be initiated by CD8+ T-cells via the FasL pathway which is upregulated 
by CD8+ T-cells post activation. The interaction between FasL expressed on the cellular 
surface of the CD8+ T-cell and the cell surface death receptor Fas, which is commonly 
expressed on target cells, results in the formation of the intracellular death signalling 
complex (DISC) (Kischkel et al. 1995; Rouvier et al. 1993).  Activation of DISC results in the 
upregulation of cellular caspase signalling eventually leading to cell death via apoptosis (Yang 
et al. 2008).  
The role of CD8+ T-cells has been implicated in a the hypersensitivity reactions to variety of 
drugs including carbamazepine (Ko et al. 2011; Lichtenfels et al. 2014), nevirapine (Keane et 
al. 2014) and abacavir (Chessman et al., 2008; Bell et al., 2013; Naisbitt et al., 2015) which 
will be discussed in more detail later.  
1.7.2.5. T-helper cells 
 
CD4+ T-helper cells play a role in a variety of immune functions, including the activation of 
the innate immune system, B-cells, cytotoxic T-cells, non-immune cells and the suppression 
of immune mediated reactions. CD4+ T-cells play an important role in immunological memory 
T-cell responses and consequently a reduction in their cellular numbers increases the  hosts 
susceptibility to a number of infectious diseases. The initial step of differentiation of naïve T-
cells is the antigenic stimulation which occurs as a result of the interactions of the TCR of 
CD4 with the antigenic peptide MHC II complex presented by antigen presenting cells. This 
induces a network of downstream signalling pathways which will eventually result in naïve 
cell proliferation and subsequent differentiation into effector, memory or regulatory T-cells 
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(Zhu et al. 2010). This process is dependent on many factors including the presence of 
particular cytokines within the cellular environment, the types of APCs present as well as 
costimulatory molecules (Luckheeram et al. 2012). The distinct populations of differentiated 
CD4+ T-cells can be divided into two major groups Th1 and Th2 (Mosmann et al. 1986), while 
newer subclasses have been identified in recent years  (Weaver 2009; Eyerich et al. 2009).  
1.7.2.6. Th1 and Th2 helper cells 
 
Th1 and Th2 cells can be characterised by the cytokines secreted in response to stimulation 
but also via the expression of cell surface markers. Th1 cells are considered to be 
proinflammatory and produce IFN-γ as a primary cytokine as well as lymphotoxin, IL-2 and in 
some cases TNF-α. Conversely Th2 cells are considered to be anti -inflammatory and are 
characterised by their secretion of IL-4, IL-5 and IL-13, coupled with their inability to produce 
IFN-γ and lymphotoxin (Zhu et al. 2010).  
The cytokines IL-12 and IFN-γ are pivotal for the instigation of downstream signalling 
pathways involved in the production of Th1 cells. IL-12, produced by APCs following their 
activation, is able to activate natural killer cells subsequently leading to the generation of 
IFN-γ (Trinchieri et al. 2003). The differentiation of Th1 cells is dependent on various 
transcription factors working in coordination with each other. The main transcription factor 
involved in this process is T-bet, a member of the T-box family of transcription factors, which 
is induced in naïve CD4+T-cells in response to both an antigen and IFN-γ (Kanhere et al. 2012). 
IFN-γ is also shown to promote activation of the transcription factor STAT1 which in turn 
promotes further expression of T-bet and the suppression of Th2 and Th17 cells, as well as 
further IFN-γ secretion (Luckheeram et al. 2012). This creates a positive feedback loop where 
IFN-γ secretion will result in further IFN-γ secretion downstream. Th1 responses are known 
to take place in retaliation to bacterial and viral infection.  
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Th2 cellular differentiation contrasts greatly from Th1 in that the cytokines IL-2 and IL-4 are 
required for the initiation of the pathway to generate these cells. IL-4 is produced by mast 
cells or eosinophils in response to helminths. Secretion of IL-4 results in the upregulation of 
the transcription factors STAT6 (Trinchieri et al. 2003) and GATA-binding protein GATA-3, the 
major regulating factor in the generation of Th2 cells (Kanhere et al. 2012). GATA3 is 
upregulated by STAT6 in response to IL-4 generation subsequently resulting in further IL-4 
secretion which leads to an amplification of the Th2 response and subsequent inhibition of 
Th1 and 17 development.  
Two further subgroups of T-helper cells have been recently discovered, these being Th17 and 
Th22 cells. They are characterised by their secretion of IL-17 and IL-22 respectively (Chen & 
O’Shea 2008; Eyerich et al. 2009). 
The Th17 subset plays a key role in the killing of extracellular bacteria and fungi via the 
recruitment of neutrophils and the induction of inflammation. The differentiation of Th17 
cells is mediated by the proinflammatory cytokines IL-1 and IL-6, which are secreted by 
dendritic cells in response to the presence of bacterial particles, along with IL-21 and IL-23. 
IL-1, IL-6 and IL-21 are thought to mediate the early stages of Th17 differentiation while IL-
23 may be involved in promoting proliferation and overall maintenance of differentiated 
Th17 cells (Estelle et al. 2006). The key regulator of this process is the retinoic acid receptor 
related orphan receptor gamma-T (RORƳT). The anti-inflammatory cytokine TGF-β also plays 
a pivotal role in this differentiation process. When secreted in the presence of IL-6, TGF-β 
causes an enhancement of the transcription factor STAT3 via the inhibition of suppressor of 
cytokine signalling 3 (SOCS3), a negative regulator of the STAT3 signalling pathway (Veldhoen 
et al. 2006; Manel et al. 2008). This inhibition results in the further activation of RORƳT 
producing secretion of IL-17 and in some cases IL-22. Secreted IL-17 is primarily involved in 
the recruitment of neutrophils, thereby producing an overall inflammatory response. IL-22 
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however is produced in epithelial tissues and functions primarily to regulate the integrity of 
the epithelial barriers via the induction of repair mechanisms. However, IL-22 may also play 
a role in the inflammatory response by way of chemokine production promoting the 
migration of immune cells. 
While IL-22 secretion is associated with Th17 cell activation in response to bacterial and 
fungal infection, a subset of CD4+ T-cells is known to exist, which indeed secrete IL-22, but 
not IL-17 (Fujita 2013). IL-22 demonstrates both proinflammatory and anti-inflammatory 
characteristics. Th22 cells originate from the stimulation of naïve T-cells in the presence of 
IL-6 and TNF-α in a process dependent on the aryl hydrocarbon receptor (AHR) (Bouchery et 
al. 2014). While immune cells are capable of IL-22 secretion, its receptor is restricted to non-
hematopoietic cells such as epithelial cells, with high expression found in the skin, liver, 
intestine and kidneys. IL-22 is known to be involved in a variety of inflammatory skin diseases 
including psoriasis (Boniface et al. 2007), atopic dermatitis (Nograles et al. 2010) and contact 
dermatitis (Larsen et al. 2009) as well as recently being shown to play a key role in the 
hypersensitivity reactions to the β-lactam drug piperacillin (Sullivan et al. 2016).   
Regulatory T-cells (Tregs) are a subset of CD4+ T-cells characterised by their expression of 
CTLA4, CD25 and FoxP3 which function in the suppression of the immune system following 
an immune response as well as playing a role in the maintenance of tolerance to self -antigens 
(Rudensky 2011). The development of Tregs is dependent on FoxP3 which is a member of 
the forkhead family of transcription factors and Treg cells are known to secrete the cytokines 
IL-10 and TGF-β which have a marked inhibitory effect on the proliferation and functions of 
T-cells thereby acting to control the immune response (Vignali et al. 2008). Tregs act to 
supress the immune response via the secretion of these inhibitory cytokines or via 
upregulation of the cell surface receptor CTLA4, a negative mediator of T-cell activation.  
Dysregulation of Treg cell function may result in a variety of autoimmune diseases including 
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type 1 diabetes, multiple sclerosis and psoriasis many of which are mediated by Th1 
responses (Vojdani & Erde 2006). Impaired Treg function and number will result in a loss of 
the suppression abilities of the immune system which can lead to overstimulation of CD4+ 
effector T-cells resulting in an unregulated overproduction of proinflammatory cytokines 
which have autoimmune effects (Rudensky 2011).  
Further subsets of CD4+ T-helper cells also exist including Th9 and follicular helper T-cells 
(Tfh). Their cytokine secreting profiles along with the key mediators in their cellular 
differentiation from naïve T-cells are shown in Figure 1.2.  
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Figure 1.2. Maturation of naïve T-cells into T-helper cell subsets. The differentiation of naïve 
T-cells into multiple subsets of T-helper cells with the governing transcription factor for each 
primary pathway indicated, along with the primary cytokines secreted by each T-helper subset. 
T-bet (T-box transcription factor), GATA-3 (Anti-GABA transporter 3), RORƳT (Retinoic acid 
receptor related orphan receptor gamma T), AHR (aryl hydrocarbon receptor, PU.1 
(macrophage transcription factor), Bcl-6 (B-cell lymphoma 6), FoxP3 (forkhead box P3). 
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1.8. Antigenic processing and presentation 
 
Antigen processing is a vital immunogenic procedure which is pivotal for the initiation of an 
immune response in T-cells. This mechanism exists on cell types including mononuclear 
phagocytes, B-cells and non-phagocytotic cells such as dendritic cells (Chesnut & Grey 1985). 
The pathways of antigen processing convert antigenic proteins that are either present in the 
cytosol or those that have been internalized from the extracellular environment into peptide 
fragments. These fragments are then loaded onto MHC molecules and subsequently 
presented to T-cells. Two general pathways exist for antigen processing.  
Class I MHC pathway: MHC class I molecules primarily present antigen which have been 
manufactured within the antigen presenting cell. Such intracellular antigens are mainly of 
viral or bacterial origin whereby a virus enters the cell and escapes into the cytosol. Antigens 
may also be derived from microbes, internalized via phagosomes, which are capable 
damaging the phagocytic membrane forming pores allowing exit into the cytosol (Neefjes et 
al. 2011). These proteins undergo a process of digestion to yield peptides via proteolysis 
which takes place in large multiprotein enzyme complexes known as proteasomes (Leone et 
al. 2013). These newly generated peptides are transported into the cellular endoplasmic 
reticulum (ER) via a specialised transporter protein known as the transporter associated with 
antigenic presentation (TAP). This transporter is found in the membrane of the ER and is 
responsible for mediating the transport of peptides from the cytosol into the ER in an ATP 
dependent process (Blum et al. 2013). Within the ER, the TAP associates with the protein 
tapasin which has strong affinity for newly formed MHC class I molecules. Peptides that enter 
the ER via TAP along with peptides synthesized within the ER are cleaved to the correct size 
to allow binding to the MHC via the ER-resident amino peptidase (ERAP) (Leone et al. 2013). 
This allows for the binding of the peptide to the MHC class I which is bonded to TAP via 
tapasin (Blum et al. 2013). Once the peptide is bound the MHC it loses its affinity for tapasin 
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allowing it to escape the ER for cell surface presentation. The stable MHC class I molecules 
then move to the cell surface via the golgi apparatus via the formation of exocytic vesicles. 
Peptide bound MHC class I is then expressed on the surface of the antigen presenting cell for 
subsequent interaction with CD8+ T-cells (Harding & Unanue 1990; Neefjes et al. 2011).  
Class II MHC pathway: MHC class II antigen processing involves the manufacture of peptides 
from antigens that have been internalized via endocytosis. This processing pathway is only 
carried out by specialist APCs such as dendritic cells and macrophages. The e xtracellular 
antigen binds to the APC and is internalized via endocytosis, this is carried out via the 
expression on cell surface receptors that can recognise various microbial structures (Roche 
& Furuta 2015). Following internalization, the protein antigen is enveloped by vesicles known 
as endosomes. These proteins are cleaved enzymatically within endosomes and lysosomes 
by proteases such as cathepsins, producing peptides capable of binding to the MHC cleft 
(Villadangos et al. 1999). MHC class II molecules are generated within the ER via the 
correlation of individual α and β chains through binding of an invariant chain trimer which 
blocks the peptide binding site making it impossible for peptides to bind MHC class II within 
the ER (Broeke et al. 2013). The MHC is then transported to the cell surface via endosomal 
vesicles. Once inside the endosome the invariant chain is proteolytically degraded, thereby 
freeing the peptide binding cleft for the antigenic peptides (Robinson & Delvig 2002; Roche 
& Furuta 2015). Peptide bound MHC class II is then expressed on the antigen presenting cell 
surface where it is recognised by CD4+ T-cells.  
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Figure 1.3. Antigen processing and presentation. Class I: Intracellular antigens are 
degraded in the proteasome into peptides containing around 9 amino acids. They are then 
transported into the endoplasmic reticulum by the transporter associated with antigen 
presentation where they bind to MHC class I molecules. Finally the MHC bound peptide is 
trafficked to the golgi apparatus where it is loaded into a vesicle and trafficked to the cell  
surface for recognition by T-cells. Class II: Extracellular antigens are ingested by 
phagocytosis and processed by endosomal enzymes. The class MHC II molecules are 
transported to the golgi then subsequently to the phagolysosome to allow for peptide 
loading. This MHC-peptide complex is then transported to the cell  surface for display to T-
cells.  
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1.9. Mechanisms of hypersensitivity reactions 
1.9.1. Hapten hypothesis 
 
The inception of the hapten hypothesis dates back to the 1930’s to studies conducted by 
Landsteiner and Jacobs using chemically reactive compounds with a small molecular weight 
such as dinitrofluorobenzene (DNFB). They were able to sensitize guinea pigs to this 
compound and speculated that protein conjugation may be involved the observed immune 
response (Landsteiner & Jacobs 1936). Similarly, the hapten hypothesis proposes that small 
molecules such as drugs do not have immunogenic properties on their own and to initiate an 
immune response they must act as haptens. A hapten is defined as a small chemically 
reactive molecule (MW <1000 D) which is capable of undergoing a stable covalent binding 
process to a larger protein or peptide altering the side chain of the bound residue (Adam et 
al. 2011; Pavlos et al. 2015).   
These haptenated proteins are processed by the antigen presenting cell, a process which 
results in the display of haptenized peptides by MHC class I or II molecules. This is recognised 
by T-cells as a foreign antigen and initiates a de novo immune response (Adam et al. 2011; 
Llano & Brander 2012). Most environmental haptens act as cutaneous allergens producing 
an allergic contact dermatitis (ACD) reaction on the skin. The most common haptens include 
urushiol, nickel, oxazolone, phosphorylcholine, p-phenylene diamine (Erkes & Selvan 2014). 
The immunogenicity of each hapten is dependent on many properties including how rapidly 
the hapten can bind, how quickly it can penetrate the skin and other factors such as 
electrophilicity, hydrophobicity and bioavailabi lity (Erkes & Selvan 2014; Chipinda et al. 
2011). A prime example of a hapten like drug is the beta lactam penicillin which is known to 
covalently bind to the lysine groups within cellular and serum proteins (Pichler 2002; 
Padovan et al. 1997).  
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Haptens may induce an immune response via stimulation of both the innate and adaptive 
immune system. Innate responses occur following the covalent binding of the hapten to the 
cells proteins which subsequently emit a danger signal thereby activating immune system 
components such as the upregulation of costimulatory CD40 (Sanderson et al. 2007). These 
hapten protein complexes may also be presented to T-cells by MHC as a hapten modified 
peptide which will trigger a complete immune response (Naisbitt et al. 2000; Pichler 2007). 
However, most drugs are not capable of undergoing haptenation with a cellular protein on 
their own and require bioactivation via metabolism to become protein reactive (Williams et 
al. 2000; Castrejon et al. 2010). This is termed the prohapten concept and it highlights the 
fact that while many drugs are not chemically reactive themselves, they are able to be 
metabolized into reactive intermediates capable of eliciting an immune-mediated response 
(Castrejon et al. 2010) (Naisbitt et al. 2000; Pichler 2002). Therefore prohaptens are not 
protein reactive unless they have been metabolized to the electrophillic state (Erkes & Selvan 
2014). A prime example of this is the antibiotic sulfamethoxazole (SMX) which becomes 
reactive via intracellular metabolism via CYP2C9 in the liver to sulfamethoxazole-
hydroxylamine (SMX-NHOH) which can be converted to nitroso-sulfamethoxazole (SMX-NO) 
(Cribb & Spielberg 1992). SMX-NO is capable of binding covalently to cysteine residues on 
proteins and if the level of binding exceeds a certain threshold may cause toxicity. However 
it can also produce a neo-antigenic signal for specific T-cells eliciting an immune response 
(Sanderson et al. 2007).  
1.9.2. Pharmacological interaction model 
 
The ability of small drugs to evoke a T-cell response without covalently binding to a larger 
protein is in direct contrast with the hapten/prohapten model. This has led to the proposition 
of the pharmacological interaction (PI) model (Pichler 2002). This proposes that chemically 
inert drugs, which are incapable of binding covalently to proteins or peptides, can interact 
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directly with and bind to MHC molecules and/or the T-cell receptor (TCR) reversibly and in a 
non-covalent manner without the involvement of the antigen processing and presentation 
(Llano & Brander 2012; Pavlos et al. 2015; Adam et al. 2011; Pichler 2008).   
Indeed it has been demonstrated with drugs such as carbamazepine and some of its 
metabolites that removal of the antigen processing pathway via aldehyde fixation maintains 
the ability to induce T-lymphocyte proliferation (Wu et al. 2006). As well as carbamazepine, 
drugs such as SMX, lidocaine and mepivacain have been shown to activate T-cells via this 
pathway (M P Zanni, von Greyerz, Schnyder, Wendland, et al. 1998; Zanni et al. 1999; 
Schnyder et al. 1997). Furthermore, T-cells which are activated via this mechaism are shown 
to respond raipdly to drug stimulation by way of increased calcium influx and T-cell 
downregulation when coincubated with these drugs, something which would take far longer 
if acting via a hapten mechanism (Zanni et al. 1998). Although it is now well established that 
drugs activate certain T-cells via a direct MHC-TCR binding interaction, the site and nature of 
the binding has not been defined. It is possible that drugs could interact primarily with the 
MHC molecules, MHC binding peptide or the TCR.  
1.9.3. Altered peptide repertoire model 
 
Neither the hapten or PI concept have ever been accepted as a full explanation of abacavir 
hypersensitivity syndrome in HLA-B*57:01 positive individuals. Abacavir undergoes 
extensive oxidative metabolism to generate a number of isomeric carboxylic acids, three of 
which are formed in the cytosol of APCs. The formation of these carboxylates takes place 
through a two-step oxidation process via a reactive aldehyde intermediate (Bell et al., 2013). 
This reactive aldehyde binds to proteins to form conjugates, demonstrated in vitro using 
human serum albumin (HSA) and glutathione S-transferase Pi (GSTP) (Meng et al. 2014). 
However, this aldehyde or its protein conjugates have not been shown to activate T-cells 
(unpublished data). Furthermore no haptenated peptides by abacavir have ever been 
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detected, compounded by the fact that abacavir has been shown to elute unbound from 
peptides at the MHC (Illing et al. 2012). As the interactions of abacavir with HLA-B*57:01 
take place in a non-covalent manner via van der waals forces, the PI model can be accepted 
as a model for activation of some abacavir clones. Indeed, it has been shown that abacavir 
can induce responses in T-cell clones in a period of minutes, suggesting direct interaction 
with surface MHCs (Adam et al. 2012). However, glutaraldehyde fixation of APCs significantly 
reduces the number of antigen specific T-cells when compared to unfixed APCs. It was also 
demonstrated that a significant reduction in abacavir presentation was apparent in the 
mutant cell line 721.220 which expresses HLA-B*57:01 but is deficient in tapasin, something 
not observed in 220.hTsn which is not deficient in tapasin (Chessman et al. 2008). In the MHC 
class I antigen presentation pathway endogenous peptide, ligands are synthesised in the 
cytoplasm by the process of proteolysis and subsequently imported into the endoplasmic 
reticulum by the transporter associated with antigen presentation (TAP), where the peptide 
loading is enhanced by the chaperone tapasin (Chessman et al. 2008). The loss of either TAP 
or tapasin results in impaired peptide loading and a loss of antigen presentation; however, 
the addition of exogenous peptide ligands restores the immune response, demonstrating 
that abacavir hypersensitivity reactions are dependent on the antigen presentation 
pathways, something which drugs interacting via the PI mechanism are known to bypass 
(Chessman et al. 2008).  Indeed, T-cells have been shown to be activated by abacavir via two 
independent pathways (Bell et al., 2013). Approximately 50% of abacavir-specific CD8+ T-cell 
clones were activated in the absence of APCs. While other abacavir clones required APCs and 
furthermore incubation of abacavir T-cell clones with APCs pulsed overnight with the drug 
was sufficient to induce a T-cell response in some clones (Bell et al., 2013). Therefore, a 
number of clones from HLA-B*57:01+ donors are activated via a different mechanism. In 
2012 Illing et al demonstrated that incubation of antigen presenting cells with abacavir will 
gives rise to an alteration of the peptide repertoire that is presented to T-cells by HLA-
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B*57:01. Using mass spectrometry, it was found that treatment with abacavir favoured 
peptides with small chain C-terminal amino acids including isoleucine and leucine, instead of 
the larger chain amino acids phenylalanine and tryptophan commonly detected in untreated 
cells. This was observed only at the C-terminal of the peptide and not been seen with any 
closely related alleles including HLA-B*57:03 and HLA-B*58:01. This incepted the hypothesis 
that abacavir modifies the conformation of the antigen binding cleft of HLA-B*57:01 reducing 
its size and allowing for the accommodation of smaller chain amino acids (Illing et al. 2012; 
Norcross et al. 2012; Ostrov et al. 2012). These altered peptides are subsequently presented 
to T-cells, which perceive them to be foreign. It is hypothesized that these altered peptide 
sequences are responsible for the activation of certain CD8+ T-cells in abacavir hypersensitive 
patients. As mentioned earlier, abacavir can also induce T-cell activation via direct binding 
with surface MHCs. These responses can take place in minutes therefore not allowing 
sufficient time for loading of a new peptide onto HLA-B*57:01 (Adam et al. 2012). Therefore, 
it is likely that direct binding of abacavir can alter the conformation of the existing bound 
peptide, mimicking that of a native peptide to a closely related allele, in a manner similar to 
allo-reactivity often observed in organ transplant rejection (Adam et al. 2014). 
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Figure 1.4. Mechanisms of drug/metabolite specific T-cell activation. a) Hapten model. A 
small molecule (drug or metabolite) binds covalently to a larger protein or peptide, these 
haptenated proteins are processed by the APC resulting in the display of haptenated peptides 
to T-cells. b) Pharmacological interaction model. Drugs can interact directly and bind with the 
TCR and some HLA-molecules without the need for antigen processing. c) Altered peptide 
repertoire model. The bound drug alters the shape and chemistry of the antigen binding cleft, 
leading to an accommodation of a range of new self-peptides not previously exposed to 
peptides. 
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1.9.4. The Danger Model 
 
The danger model was first proposed in 1994 by Polly Matzinger. This model is built as a 
critique of the self vs non-self-model first proposed by Burnet in 1962. According to the self 
vs non-self-model, all foreign units (i.e. non-self) will be subjected to an immune response, 
while no response will be targeted against the hosts own entities (i.e. se lf). Contrary to this 
theory, the danger model proposes that cellular self -elements can initiate an immune 
response if they pose a threat such as cellular stress and autografts, while non-self-entities 
may be tolerated if they pose no danger to the host (Matzinger 1994; Matzinger 2002). 
According to this model the immune system gives more attention to potential danger signals 
than the presence of a foreign particle. This may indeed explain why exposure to a plethora 
of non-self-entities fails to evoke an immune response in the absence of cellular damage. 
Furthermore, this model may also explain how endogenous molecules can initiate immune 
mediated reactions (Li & Uetrecht 2010). Danger signals consist of molecules or molecular 
frameworks that are secreted by cells undergoing cellular stress or death. This causes the 
activation of APCs, normally in the resting state, which provide costimulatory signals even in 
the absence of a foreign antigen (Gallucci & Matzinger 2001).   
It is thought that three immune signals are required for the induction of a complete immune 
response, but at least two are necessary for immune activation (Curtsinger et al. 1999). Signal 
1 comprises the interaction between the MHC peptide complex and the TCR. Signal 2 
represents the interactions between the co-stimulatory molecules expressed on the antigen 
presenting cell and the TCR along with the presence of the pro-inflammatory cytokines such 
as IL-2, TNF-α and IFN-γ which can induce the upregulation of co-stimulatory molecule 
expression. The presence of signal 1 without 2 is thought to lead to tolerance (Pirmohamed 
et al. 2002). Signal 2 is regulated via the release of exogenous PAMPs such as viral RNA, LPS 
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and peptidoglycan as well as endogenous DAMPs released from dead or damaged cells 
including heat shock proteins, IFN-α and IL-1β (Pradeu & Cooper 2012).   
Signal 3 is derived from polarising cytokines that can interact directly on T-cells leading to 
Th1 or Th2 responses. Therefore, a drug could theoretically act as signal 1 via providing the 
source of the antigen and signals 2 and 3 by evoking cellular damage, thereby inducing the 
production of the aforementioned endogenous danger signals. Furthermore, some drugs 
have been known to cause damage to APCs such as DCs along with provoking necrotic cell 
death which combined with antigenic determinants may evoke T-cell activation 
(Pirmohamed et al. 2002; Curtsinger et al. 1999; Park et al. 2001). 
Danger signalling has been detected with several drugs known to cause hypersensitivity 
reactions. This includes SMX and its metabolite SMX-NO which upregulate expression of the 
co-stimulatory molecule CD40 through covalent modification of intracellular proteins 
(Sanderson et al. 2007). Amoxicillin was shown to propel dendritic cells from hypersensitive 
patients to a mature phenotype, thereby inducing T-cell proliferation in a similar fashion to 
danger signals such as LPS (Rodriguez-Pena et al. 2006).   
Abacavir was shown to evoke the redistribution of HSP70 in PBMCs isolated from abacavir 
hypersensitive patients when compared to naïve. Furthermore, the blocking of HSP70 itself 
and its cellular surface receptors CD14 and TLR2 was shown to completely blunt the observed 
redistribution of HSP70 (Martin et al. 2007). Abacavir has also been demonstrated to evoke 
the secretion of endogenous DAMPs such as IL-1β in inflammasomes that have been primed 
with exogenous PAMPs such as LPS in vitro (Toksoy et al. 2017). Inflammasome activation is 
a two-step procedure that first involves priming via stimulation of a TLR. It has been 
previously demonstrated that TLR8 can be activated by the HIV-1 virus leading to subsequent 
release of IL-1β (Guo et al. 2014). This incepts the theory that the presence of HIV-1 may 
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prime inflammasomes via TLR8 stimulation and the IL-1β release may be stimulated by 
treatment with abacavir (Toksoy et al. 2017).  
1.10. Major Histocompatibility Complex  
 
Major Histocompatibility Complex (MHC) class I and II proteins are essential components of 
the innate and adaptive immune system. Both proteins play a key role in the capture and 
subsequent presentation of peptides, on the surface of the antigen presenting cell, thereby 
allowing for their recognition by T-cells. 
The human MHC locus is found on the short arm of chromosome 6 at the 6p21.3 position. 
Chromosome 6 is approximately 150-180Mb in size, with the MHC locus comprising of 
around 4Mb (genomic data). In humans, the MHC class I and II genes are known as Human 
Leukocyte Antigen (HLA) class I and II genes respectively. 
HLA genes are closely linked with the MHC being inherited as a HLA haplotype from each 
parent by means of mendelian genetics. Strong linkage equilibrium exists between the 
antigens from different HLA loci present on a HLA haplotype.  
The HLA system displays extreme polymorphism in humans, being the most polymorphic 
region in the genome. Variations in the amino acid residues at numerous locations 
throughout the HLA lead to subtle alterations in the shape of the peptide binding groove, 
thereby having a direct influence on the specificity of peptides bound to the HLA molecule.  
MHC class I is present on all nucleated cells and can theoretically be expressed on all cell 
types except red blood cells (Hewitt 2003). Class I MHC includes HLA-A, HLA-B and HLA-C loci 
with bound peptides presented on the cellular surface of the antigen presenting cell for 
recognition by cytotoxic CD8+ T-cells. Class I MHCs are heterodimers of a single heavy chain 
integrated membrane protein and a β2-microglobulin soluble protein. The extracellular 
component of the heavy chain is comprised of three domains; the α1, α2 and α3, while β2m 
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comprises the fourth domain. Of these domains, the α1 and α2 constitute the peptide 
binding groove on the upper region of the class I molecule while α3 carries the 
transmembrane domain (Wieczorek et al. 2017). While not being membrane bound, β2-
microglobulin, plays a key role in the transport of newly synthesised MHC molecules to the 
cellular surface after peptide loading (Harding & Unanue 1990). The binding groove of MHC 
class I is closed at each end by a conserved tyrosine residues present in the structure. This 
tends to limit the length of peptide which can typically bind to the MHC to those of between 
8 and 10 amino acids; however, it has been demonstrated in some instances that peptides 
are capable of protruding from the groove at the N-terminal region which can allow for 
accommodation of longer peptide sequences (Pymm et al. 2017). The C-terminus of these 
peptides typically resides in the F-pocket of the MHC (Illing et al. 2012).   
Class II MHCs are expressed on professional antigen presenting cells such as macrophages, 
B-cells and especially dendritic cells. Class II MHCs are encoded by HLA-DR, HLA-DQ and HLA-
DP loci, with bound peptides presented on the cellular surface for the recognition by CD4+ 
effector cells (Neefjes et al. 2011). While being structurally similar to class I, class II MHCs are 
composed of two separate membrane bound chains, α and β, to form the peptide binding 
groove. Class II MHCs therefore adopt a more open structure of the binding groove allowing 
for the accommodation of peptides between 13 and 25 amino acids in length with the N -
terminus of these peptides typically residing in the P1 pocket of the MHC (Münz 2016).  
The peptide binding groove incorporates peptides via the formation of hydrogen bonds 
between the side chains of the MHC and residues of the peptide. Also, interactions between 
the anchor residues of the peptide (P2, 5, 6 and Ω (C-terminal peptide) in MHC class I and P1, 
4 and 9 in MHC class II) and specific binding grooves within the MHC molecule are important 
for the binding of the peptide (Wieczorek et al. 2017).  
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Class III MHC molecules include secreted proteins that display immune functions such as heat 
shock proteins and cytokines (TNF-α). Class III MHC does not exhibit the same function as 
class I and II but is located between them on the short arm of chromosome 6.  
1.11. HLA-Nomenclature  
 
The genes that encode the HLA-alleles are highly polymorphic and are situated on the short 
arm of chromosome 6 which contains more than 200 protein-encoding genes, many of which 
are related to the immune system.  
The first HLA-antibody and antigen was discovered by Dausset via the observation of in vitro 
agglutination in serum taken from an agranulocytic individual when mixed with bone marrow 
from another individual (Dausset et al. 1952). HLA-A and B antigens were subsequently 
identified, followed by the discovery of the HLA-C loci in 1970 (Thorsby et al. 1970) and then 
class II alleles in 1978 (Albert et al. 1978). Serological techniques were originally used for the 
detection of HLA polymorphisms. This was achieved by the identification of epitopes present 
Figure 1.5. Class I and II MHC structure. 
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on HLA molecules that evoked an antibody response (Tait 2011). The use of the 
aforementioned leukocyte agglutination and microlymphocytoxicity assays were employed 
to investigate this (Terasaki & McLelland 1964).  
The advancement of gene sequencing techniques led to the development of assays that 
identified the full polymorphism of HLA-genes, something that serological techniques were 
limited in doing. This has allowed for the inception of a new method of nomenclature of HLA-
alleles (Tait 2011; Torres & Moraes 2011). The new nomenclature involves a letter 
corresponding to the locus to which the allele is situated. The letter is succeeded by an asterix 
which indicates the use of sequencing techniques to identify the allele.  
Each allele has a unique number corresponding to up to four sets of numbers that are divided 
by colons. The numbers preceding the first colon describe the type of allele which matches 
the serological antigen associated with an allotype. The next set of numbers following the 
colon describes the subtypes with numbers being assigned in the order to which DNA 
sequences have been determined. Alleles that are unique from others only by silent 
nucleotide substitutions within the coding sequence are discriminated by a third set of digits. 
A fourth set of numbers is assigned to alleles which differ only by sequence polymorphisms 
in the non-coding regions. Finally, a discretionary suffix may accompany the allele number in 
the form of a letter which is added to specify the alleles expression status (Marsh et al. 2010).  
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The list of suffixes is outlined below: 
N= null allele 
L= Low cell surface expression 
S= Secreted allele but not present on the cell surface 
C= Assigned to alleles that produce proteins present in cytoplasm but not on cell surface  
A= Aberrant expression, where there is some doubt about protein expression 
Q= Questionable expression 
However, as of 2010 the suffix’s A and C were no longer used to classify alleles (Torres & 
Moraes 2011). 
 
 
 
 
Figure 1.6. Nomenclature of HLA-alleles. 
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1.12. HLA-associations with adverse drug reactions 
 
Many T-cell mediated ADRs have been associated with the carriage of HLA alleles in 
susceptible individuals to a variety of culprit drugs (Table 1.3). These HLA associations can 
include both class I and II allleles, with notable examples described below. 
 
 
 
 
Culprit Drug Adverse Drug 
Reaction 
HLA-association Ethnicity Reference 
Abacavir  HSS HLA-B*57:01 Caucasian (Mallal et al. 2002) 
Carbamazepine SJS/TEN 
 
 
 
SJS/TEN, MPE 
HLA-B*15:02 
 
HLA-A*31:01 
Han Chinese 
 
Japanese 
European 
(Chung et al. 2004) 
(Ozeki et al. 2011) 
(McCormack et al. 
2011) 
Allopurinol SJS/TEN, DRESS HLA-B*58:01 Han Chinese (Hung et al. 2005) 
Flucloxacillin DILI HLA-B*57:01 Caucasian (Daly et al. 2009) 
Dapsone HSS HLA-B*13:01 Chinese (Zhang et al. 2013) 
Lamotrigine SJS/TEN 
HSS 
HLA-B*15:02 
HLA-A*31:01 
Han Chinese 
Caucasian 
(Man et al. 2007) 
(McCormack et al. 
2012) 
Phenytoin SJS/TEN HLA-B*15:02 Han Chinese (Man et al. 2007) 
Amoxicillin-
Clavulanate  
DILI HLA-DRB1*15:01 
HLA-DQB1*06:02 
Caucasian (Lucena et al. 
2011) 
Lumiracoxlib  DILI HLA-DRB1*15:01 Caucasian (Singer et al. 2010) 
Ticlopidine  DILI HLA-A*33:03 Japanese (Hirata et al. 2008) 
Nevirapine  DRESS HLA-DRB1*01:01 
 
HLA-C*04:01                      
Hispanic, 
African 
Malawian 
(Martin et al. 
2005) 
(Carr et al. 2013) 
Table 1.3. Examples of HLA restricted adverse drug reactions.  
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1.12.1. Carbamazepine 
 
Carbamazepine is a sodium channel blocking agent commonly prescribed in the treatment 
of epilepsy and nerve pain such as trigeminal neuralgia. SJS and its associated disease TEN 
are implicated in some individuals undergoing treatment with this anticonvulsant. Chung et 
al 2004 conducted a case control study in patients with carbamazepine induced SJS (44 
patients in total), with 5 patients overlapping with TEN. These patients were compared 
against 101 controls who had been taking carbamazepine for at least 3 months with no 
adverse events (CBZ-tolerant). Genotyping for HLA alleles A, B and C along with DRB1 was 
carried out and it was found that the allele HLA-B*15:02 was present in all 44 of the 
individuals with CBZ-SJS. This allele was only present on 3 of the individuals from the CBZ-
tolerant group of the study yielding an odds ratio, the measure of association between 
exposure and outcome, of 2504 (Chung et al. 2004). A follow up study by the same group 
confirmed the association between the risk allele HLA-B*15:02 and SJS/TEN reactions 
induced by carbamazepine; however, the induction of milder skin reactions such as 
macropapular eruption was found not to be associated with HLA-B*15:02 (Hung et al. 2006). 
Further studies also confirmed these findings indicating a strong association between the 
observed reactions and the carriage of this risk allele in the Han Chinese population 
(Locharernkul et al. 2008; Man et al. 2007). Indeed, prospective genotyping measures for the 
HLA-B*15:02 risk allele are now employed in Han Chinese populations prior to the 
prescription of carbamazepine and those testing positive are provided with alternative 
therapeutics such as lamotrigine (Phillips & Mallal 2011; Chen et al. 2011). However, studies 
on patients of European descent with carbamazepine induced SJS demonstrated no apparent 
association with HLA-B:15:02, once such suggestion for this may be the prevalence of 
another allele which may be protective of these reactions (Alfirevic et al. 2006). The 
prevalence of the HLA-B*15:02 risk allele within the Caucasian population is relatively low 
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(1-2%) when compared with the Han Chinese population (8%), suggesting that other alleles 
may be involved in the regulation of SJS/TEN reactions induced by carbamazepine.  
Ozeki et al 2011 conducted a large GWAS within the Japanese population which indicated 
the presence of SNP’s associated with carbamazepine induced ADRs. These SNP’s were found 
to be situated on chromosome 6p21.33 including the HLA-A locus. Subsequent genotyping 
of single HLA-A alleles identified the presence of HLA-A*31:01 in around 60% of individuals 
that displayed carbamazepine-induced adverse drug reactions. This demonstrated HLA-
A*31:01 as a risk factor for adverse drug reactions induced by carbamazepine yielding a 
sensitivity and specificity of 60% and 87.5% respectively (Ozeki et al. 2011). The association 
of adverse drug reactions, including maculopapular exanthema (MPE) and in some cases 
SJS/TEN, with carbamazepine and the carriage of HLA-A*31:01 in the Caucasian population 
has also been demonstrated (McCormack et al. 2011; Gidal 2011).  
While the SJS/TEN reactions induced by carbamazepine in patients carrying the HLA-B*15:02 
allele appears to be exclusive to Japanese populations, the association between ADRs and 
the HLA-A*31:01 allele has been observed in both Asian and European populations. 
However, the association between this allele and the observed ADRs is much weaker than 
that of HLA-B*15:02 which yields a sensitivity value of close to 100% (Kaniwa & Saito 2013). 
In a systematic review of published genotyping data, Yip et al in 2012 demonstrated an odds 
ratio of 113.4 for HLA-B*15:02 and carbamazepine induced SJS/TEN. These findings 
corresponded to a number needed to treat (NNT), the average number of patients wo 
needed to be treated to prevent one additional adverse outcome, value of 461 with regard 
to prospective genotyping for HLA-B*15:02 (Yip et al. 2012). Conversely the carriage of HLA-
A*31:01 displayed significant association with various manifestations of carbamazepine 
hypersensitivity in multiple ethnicities providing an odds ratio of 9.5. This translates to a NNT 
value of between 47 and 67 patients, indicating a much lower number of individuals required 
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to treat in order to prevent one case of hypersensitivity (Yip et al. 2012). These findings 
suggested an effective use of HLA genotyping for the avoi dance of carbamazepine 
hypersensitivity. Indeed, prospective genotyping for HLA-B*15:02 is now commonly 
undertaken in the Asian populations, however to date genotyping for HLA-A*31:01 has not 
yet been employed prior to carbamazepine therapy.  
CD8+ T-cells isolated from carbamazepine induced SJS/TEN patients proliferate and secrete 
cytokines following in vitro activation with carbamazepine. Furthermore, the TCR Vβ-11IGSY 
was identified to be prevalent in 84% of patients with SJS/TEN, while being absent in all 
tolerant patients. It was also shown that PBMCs primed from healthy volunteer’s positive for 
the HLA-B*15:02 and TCR Vβ-11IGSY were able to display cytotoxicity in the presence of 
carbamazepine. These cytotoxic responses could subsequently be diminished via the 
addition of anti-TCR-Vβ-11 antibody indicating a pivotal role for the TCR in carbamazepine 
induced SJS/TEN (Ko et al. 2011) . It was next shown that CD8+ T-cell responses induced by 
carbamazepine were independent of antigen processing machinery and involved a direct 
interaction of the drug with the HLA-B molecule (Wei, Chung, et al. 2012). Lichtenfels et al 
isolated T-cell clones from patients positive for the HLA-A*31:01, with indicative symptoms 
such as MPE. Subsequent phenotyping of these clones demonstrated the presence of both 
CD4+ and CD8+ T-cell clones, both of which evoked a cytotoxic effector function (Lichtenfels 
et al. 2014). While activation of CD8+ T-cell clones was wholly dependent on the HLA-A*31:01 
allele, shown by the blunting of the proliferative response in the presence of MHC Class I 
block, CD4+ responses were only diminished in the presence of MHC Class II block. These 
findings led to the subsequent discovery of the involvement of a class II allele DRB1*04:04 in 
the CD4+ mediated T-cell response. Indeed, strong linkage disequilibrium exists between 
DRB1*04:04 and HLA-A*31:01 indicating that a common haplotype may be an important 
factor in the multiclonal response to carbamazepine observed in Caucasians (Lichtenfels et 
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al. 2014).   While the HLA-A*31:01 allele has strong association with SJS/TEN in Japanese 
populations, such association is weak in Europeans.  Conversely, the expression of HLA-
A*31:01 in European populations has a strong association with the milder but still 
problematic reactions MPE and DRESS, not commonly observed in Japanese populations 
(Ozeki et al. 2011; McCormack et al. 2011). As mentioned previously, the class II allele 
DRB1*04:04 forms a common haplotype with HLA-A*31:01 in Caucasians. CD4+ mediated T-
cell reactions to carbamazepine were restricted to the DRB1*04:04 allele, suggesting that in 
the Caucasian population CD4+ T-cell responses form the primary response  to 
carbamazepine, hence the preferential manifestations of MPE and DRESS (Lichtenfels et al. 
2014). Such common haplotype with HLA-DRB1*04:04 is not as frequent in Japanese 
populations, suggesting that responses to carbamazepine in HLA-A*31:01 individuals are 
primarily mediated by CD8+ T-cells, hence the manifestation of much more serious reactions 
i.e. SJS/TEN (Ozeki et al. 2011). Indeed, this suggests that the ethnicity of the individual 
seems to be pivotal for the manifestation of the cutaneous reactions to carbamazepine.  
1.12.2. Allopurinol 
 
Allopurinol is a xanthine oxidase inhibitor used for the treatment of hyperuricemia related 
diseases including gout, Lesch-Nyham syndrome and recurrent kidney stones (Wortmann 
2002) . However, it is one of the most frequent causes of adverse drug reactions, contributing 
to approximately 5% of Severe Cutaneous Adverse Reactions (SCARs) (Roujeau et al. 1995; 
Hung et al. 2005). In 2005 Hung et al using genetic marker studies demonstrated the 
relationship between the observed reactions to allopurinol and the prevalence of the HLA-
B*58:01 allele in the Han Chinese population.  This allele was detected in 100% of patients 
exhibiting allopurinol induced SCARs but only in a small percentage of allopurinol tolerant 
patients (15%) (Hung et al. 2005). This association was subsequently detected to a more 
modest degree, in various other populations including Thailand, Japan, South Korea, 
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Australia and Europe (Lonjou et al. 2008; Tassaneeyakul et al. 2009; Kaniwa et al. 2008), 
indicating HLA-B*58:01 to be an effective marker for the adverse reactions. More recently, 
a study was undertaken to assess the validity of prospective screening for the HLA-B*58:01 
allele prior to treatment in Taiwanese individuals displaying need for allopurinol therapy, 
that had not been previously exposed to the drug (Ko et al. 2015). From this it was identified 
that no patient who had tested negative for HLA-B*58:01 exhibited any symptoms of SCARs, 
leading to the conclusion that prospective genotyping for HLA-B*58:01 was capable of 
reducing the incidence of allopurinol induced SCARs in the Taiwanese population (Ko et al. 
2015). The prevalence of the HLA-B*58:01 in the Asian populations is around 15-18% but 
much lower in Europeans accounting for 1-2% (Plumpton et al. 2017), therefore prospective 
genotyping for HLA-B*58:01 may prove to be a cost effective means in Asian countries, 
already demonstrated in Korea (Park, et al., 2015) and Thailand (Saokaew et al. 2014), but 
due to the low prevalence in European populations it is unlikely that this method would be 
a cost effective procedure currently (Plumpton et al. 2017). Allopurinol is rapidly metabolized 
to oxypurinol in vivo with a plasma half-life of 1-2 hours, suggesting oxypurinol to be 
implicated in the induction of SCARs (Yun et al. 2013). Indeed, LTT results from allopurinol 
allergic patients demonstrate dose dependent T-cell activation in response to oxypurinol, 
but not allopurinol (Yun et al. 2013). Furthermore, T-cell lines generated to allopurinol and 
oxypurinol reacted immediately to the addition of either drug in an antigen processing 
independent manner.  Docking studies suggested oxypurinol to bind HLA-B*58:01 with a 
higher affinity than allopurinol, suggesting oxypurinol is primary sensitizer in allopurinol 
allergic patients (Yun et al. 2014). Currently, the U.S Food and Drug administration (FDA) 
does not advise HLA-B*58:01 genotyping for allopurinol therapy; however, as the cost of 
effective genotyping continues to reduce, this may become a useful practice in the future.  
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1.12.3. Flucloxacillin 
 
Flucloxacillin is a beta-lactam antibiotic belonging to the penicillin class, which is commonly 
used to treat a broad range of gram-positive bacterial infections such as skin and tissue 
infections, respiratory and urinary tract infections and diseases such as meningitis (Wing et 
al. 2017). Despite being generally well tolerated, flucloxacillin is associated with cholestatic 
liver injury affecting new users of the drug at a rate of 8.5 per 100,000 (Andrews & Daly 2008; 
Russmann et al. 2005).  This can occur via interference with the bile flow through inhibition 
of bile formation and transport both into and out of hepatocytes as well as affecting the 
normal function of the bile ducts (Padda et al. 2012). 5’hydroxymethylflucloxacillin is the 
main active metabolite of flucloxacillin which is generated via the hydroxylation of the 5-
methyl group of the isoxazole ring, achieved via the actions of the CYP3A4 enzyme (Thijssen 
1979). Flucloxacillin does not display direct cytotoxicity on hepatocytes or biliary epithelial 
cells. However, conditioned media from cultured hepatocytes that were  preincubated with 
flucloxacillin initiated a significant increase in lactate dehydrogenase, often released during 
tissue damage, in the biliary epithelial cells. Furthermore, this observed response was lost 
following inhibition of CYP3A4 metabolism and enhanced following CYP3A4 induction 
(Lakehal et al. 2001). Much like the parent drug, the flucloxacillin metabolites did not display 
direct toxicity. While these findings accounted for the mechanism of flucloxacillin injury, they 
did not explain why such reactions were found only in a small number of individuals.  
In 2009 Daly et al conducted a GWAS study using over 800,000 markers in 51 cases of 
flucloxacillin-induced DILI. This study identified the association between flucloxacillin liver 
injury and the carriage of the HLA-B*57:01 allele, also heavily associated in hypersensitivity 
reactions to the antiretroviral drug abacavir (Daly et al. 2009; Mallal et al. 2002). Association 
with this allele implicates a role of T-cells in the adverse reaction. Indeed, flucloxacillin 
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specific T-cell responses were detected in PBMCs isolated from DILI patients via the ELIspot 
assay (Maria & Victorino 1997).  
Monshi et al demonstrated the flucloxacillin-specific PBMC responses from patients with 
flucloxacillin-induced liver injury by way of IFN-γ secretion, with no such activation observed 
in tolerant individuals or drug naïve patients. Responsive T-cell clones obtained to patients 
were identified as CD4+ and CD8+. Furthermore, mass spectrometric analysis of albumin 
obtained from flucloxacillin-treated cell cultures revealed the presence of irreversibly bound 
haptens generated via the direct adduction of flucloxacillin. The CD8+ responses were 
processing dependent and HLA-B*57:01 restricted. This indicates the role of the hapten 
model as a paradigm for T-cell mediated reactions to flucloxacillin.  A strong correlation 
between the strength of flucloxacillin binding and the level of the proliferative response 
observed provides further supporting evidence (Monshi et al. 2013).  
However, it was later identified that flucloxacillin was able to stimulate CD8+ T-cells in two 
individual manners (Wuillemin et al. 2013). Indeed, T-cell clones generated to flucloxacillin 
from HLA-B*57:01+ and HLA-B*57:01- drug naïve individuals were found to follow two 
distinct patterns of activation. It was found that the hapten mechanism of activation was 
observed primarily in HLA-B*57:01- individuals, while T-cells from those positive for the risk 
allele responded in a mechanism more consistent with the PI model. This was confirmed via 
the identification of immediate reactions and the presence of labile binding, which was easily 
removed by washing. Furthermore, these responses had no dependence on the antigen 
processing, suggesting direct interaction (Wuillemin et al. 2013). Activation via the hapten 
mechanism in this study was not restricted to HLA-B*57:01, as flucloxacillin pulsed APC 
responses were only observed in HLA-B*57:01- individuals. Given the presence of multiple 
binding sites on a protein, it is unlikely that the hapten mechanism will be restricted to a 
single allele based on the fact that after processing a plethora of potential drug bound 
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peptides would be generated, with the ability to be loaded onto many different HLA-alleles 
(Wuillemin et al. 2013). A recent study by Yaseen et al identified preferential activation of 
flucloxacillin via a hapten mechanism in T-cells generated from DILI patients positive for HLA-
B*57:01. This was confirmed using APC pulsing assays, where T-cell clones were activated 
only by pulsed autologous HLA-B*57:01 APCs (Yaseen et al. 2015). Conversely, responses to 
soluble flucloxacillin were observed across a number of HLA-allele mismatched APCs. This 
suggests that HLA-B*57:01 patient responses to flucloxacillin are mediated via the hapten 
mechanism while T-cells generated from healthy donors are activated with the parent drug 
in an antigen processing independent mechanism, i.e. PI (Yaseen et al. 2015). This indicates 
the role of multiple mechanisms in driving T-cell activity towards flucloxacillin.   
1.13. Abacavir 
 
Abacavir ((1S,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-
methanol) is an antiretroviral prodrug used for the treatment of the Human 
Immunodeficiency Virus (HIV). It belongs to the nucleoside reverse transcriptase inhibitor 
(NRTI) class of antiretroviral’s, the other being non-nucleoside reverse transcriptase 
inhibitors (NNRTI’s), with HIV treatment being most effective when abacavir is used in 
conjunction with other anti-retroviral agents such as lamivudine and zinovudine (Hervey & 
Perry 2000). The chemical formula of abacavir is C14H18N6O and the chemical structure 
consists of a cyclopentenyl moiety, a 2-amino purine moiety and a cyclopropyl moiety as 
shown in Figure 1.7. 
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1.13.1. Mechanism of action 
 
Abacavir is a carbocyclic nucleoside analogue which is metabolised into a 2’-deoxyguanosine 
nucleoside analogue. It is broken down in an anabolic process through a pathway not 
involving enzymes known to phosphorylate other NRTI drugs (Hervey & Perry 2000). In the 
primary metabolic pathway, abacavir is metabolised to abacavir 5’-monophosphate via the 
action of the stereospecific enzyme adenosine phosphotransferase (Barbarino et al. 2014; 
Faletto et al. 1997). This is followed by a deamination process to form carbovir 
5’monophosphate via the action of an unknown cytosolic enzyme. It then undergoes further 
rounds of phosphorylation by cellular kinases to generate first carbovir di -phosphate and 
finally carbovir tri-phosphate (Barbarino et al. 2014; Hervey & Perry 2000; Faletto et al. 
1997). 
Carbovir monophosphate may be generated via another minor metabolic pathway (minor 
pathway) which accounts for less than 2% of the generated metabolite. In this pathway 
abacavir is converted to 6-amino carbovir, which can then be phosphorylated via adenosine 
Figure 1.7. Chemical structure of abacavir  
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phosphotransferase generating 6-amino carbovir monophosphate. Next, via the action of 
adenosine monophosphate deaminase, it is converted to carbovir monophosphate. The 
minor metabolised product 6-amino carbovir can be deaminated to generate the metabolite 
carbovir and next via the action of AMP deaminase and 5’ -nucleoside inosine 
phosphotransferase respectively the generated metabolites are converted to carbovir 
monophosphate, which are subsequently phosphorylated to yield carbovir triphosphate 
(Faletto et al. 1997) (Figure 1.8).  
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HIV is a single stranded RNA virus which undergoes the process of reverse transcription to 
generate double stranded viral DNA. This process is dependent on the enzyme reverse 
transcriptase, specific to HIV. The viral DNA is then integrated into the host’s genome and, 
via mechanisms using the host’s machinery, used to produce viral offspring.  
As previously mentioned, abacavir is metabolised to carbovir triphosphate, which then 
competes with the endogenous nucleotide 2’deoxyguanosine triphosphate (dGTP) for 
integration into the nucleic acid chain at the active site (Hervey & Perry 2000). Carbovir 
triphosphate lacks the 3’-OH structure which is required for the 5’ to 3’ phosphodiester 
linkage. When incorporated into the viral DNA strand, carbovir triphosphate inhibits the 
addition of new bases which in turn blocks further strand elongation, leading to a premature 
halt in viral DNA synthesis resulting in chain termination, thereby resulting in a cessation of 
viral replication (Martin & Kroetz 2013).  
Abacavir is rapidly absorbed following oral administration and demonstrates around an 83% 
bioavailability. On average following a 300mg dose twice a day abacavir’s plasma 
concentration (Cmax) ranges from 0.64 to 4.38 mg/L which is usually reached around 40 
minutes to 1 hour after ingestion. The area under the concentration time curve (AUC 0-12 
hours) after a single oral dose of 300mg in a fasted individual is on average 6.02 ± 1.73 
mg/L/hr, although it should be noted that food does not significantly alter the absorption of 
abacavir.   
The volume of distribution of abacavir is 0.86 ± 0.15 L/kg following an intravenous 
administration. The protein binding of the drug is approximately 50% and is not dependent 
on concentration. The clearance is determined as 0.8 ± 0.24 L/hr/kg which was 
representative of an HIV infected adult receiving a single IV dose of 150mg.   
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Abacavir is metabolised by enzymes in the liver including alcohol dehydrogenase and 
possesses a mean elimination half-life of 1.54 ± 0.63 hours This hepatic metabolism 
generates a reactive aldehyde, which readily isomerizes to be converted to carboxylic acids 
(Walsh et al. 2002). The reactive aldehyde is capable of adduction reactions with the N-
terminal valine of haemoglobin via a Schiff base formation (McDowell et al., 1999; Walsh, 
Reese and Thurmond, 2002; Charneira et al., 2011; Bell et al., 2013; Meng et al., 2014). 
Approximately 1.2% is excreted in the urine as abacavir, while 30% is excreted as the 
5’carboxylic acid metabolite and a further 36% as the 5’guanosine metabolite. Furthermore 
16% of the dose is excreted in the faeces and 15% is excreted in the urine as unknown 
metabolites.     
1.13.2. Abacavir-induced hypersensitivity 
 
Hypersensitivity reactions to abacavir are CD8+ T-cell mediated and take place in 5-8% of 
patients treated with the drug (Lucas et al. 2015). This syndrome is restricted to those who 
are positive for the HLA-B*57:01 allele which consequently has led to the inception of 
prospective genotyping of patients for this risk allele prior to abacavir prescription (Mallal et 
al, 2008). 
These hypersensitivity reactions generally occur within the first 6 weeks of commencing 
treatment with abacavir with a median time to onset being 11 days (Mallal et al. 2008), 
(Hetherington et al. 2001). Symptoms include fever, rash, GI and respiratory symptoms as 
well as constitutional symptoms such as weight loss, all of which become more severe with 
continued dosing. Of these symptoms the most frequently reported were a combination of 
fever, rash and fatigue as well as GI symptoms such as nausea, vomiting and diarrhoea, while 
respiratory symptoms such as pharyngitis and coughs were much less common (Symonds et 
al. 2002). Following onset of such symptoms the cessation and discontinuation of abacavir 
therapy is imperative, leading to a reversal of symptoms (Mallal et al. 2008).  Any subsequent 
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rechallenge following a HSR with abacavir is contraindicated and can produce far more 
serious reactions such as hypotension within a few hours which can be life threatening 
(Mallal et al. 2008; Hetherington et al. 2001; Mallal et al. 2002).  
Such symptoms of abacavir hypersensitivity can be difficult to detect as they are non-specific 
and often indistinguishable from symptoms of infections, reactions to other drugs and 
symptoms of inflammatory disease (Mallal et al. 2008).   
In 2002 Mallal et al conducted a study using MHC region typing in 200 HIV patients that had 
been exposed to abacavir. Of these 200 patients, abacavir hypersensitivity was identified in 
18 patients while 167 patients had gone 6 weeks or more of abacavir treatment without 
developing any symptoms of hypersensitivity, this group was defined as abacavir tolerant. 
From the 18 abacavir hypersensitive patients, 14 tested positive for the HLA-B*57:01 allele 
(78%) which was also present in 4 of the 167 abacavir tolerant patients (2%) (Mallal et al. 
2002). From this they concluded that the withholding of abacavir in patients positive for this 
allele would diminish the frequency of hypersensitivity reactions (Mallal et al. 2002). These 
finding were mirrored in a 2002 retrospective, case control study conducted by Hetherington 
et al. HLA-B*57:01 was present in 39 of the 84 abacavir hypersensitive patients (46%) and 4 
of the 113 control patients (4%) (Hetherington et al. 2002). This group concluded that the 
retrospective genotyping should not be used to diagnose a hypersensitivity reaction due to 
the dangers of rechallenging with abacavir but instead recommended the potential of 
prospective genotyping (Hetherington et al. 2002). 
The PREDICT-1 study conducted by Hughes et al in 2008 was a fully powered, randomized, 
blinded, prospective study designed to assess the clinical relevance of HLA-B*57:01 
screening, with a view to reducing hypersensitivity reactions to abacavir in HIV -positive 
patients.  Subjects were randomised into an abacavir containing treatment regime with or 
without prospective screening for HLA-B*57:01. Those in the prospective screening group 
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who tested positive for this risk allele were excluded from the treatment regime, while close 
hypersensitivity monitoring was carried out in the non-screening group (Hughes et al. 2008). 
A reduction from 7.3% to 3.6% in clinically suspected abacavir hypersensitivity reactions was 
observed in the genetic screening group compared with the non-genetic screening group. 
This laid down a marker for the effectiveness of prospective genotyping for HLA -B*57:01 
prior to commencement of abacavir therapy (Hughes et al. 2008). This study was continued 
by Mallal et al who carried out a double blinded, prospective, randomized study which 
encompassed 1956 patients from 19 different countries, accounting for different ethnicities. 
Patients were randomly assigned to a prospective screening group with those who were HLA-
B*57:01 positive excluded from the trial and a standard of care treatment with abacavir 
group without the prospective genotyping (Mallal et al. 2008). Epicutaneous patch testing 
was performed for the purposes of clinically diagnosing a hypersensitivity reaction. 
Prospective screening eradicated hypersensitivity reactions to abacavir with 0% of the 
patients in the prospective group experiencing a hypersensitivity reaction while 2.7% of  
patients in the control group experienced a clinically diagnosed hypersensitivity reaction 
(Mallal et al. 2008). This yielded a negative predictive value of 100% and a positive predictive 
value of 47.9% (Mallal et al. 2008). This demonstrated the ability of prospective genotyping 
and other pharmacological tests to be used as a means of preventing adverse effects of a 
therapeutic.  
The cost effectiveness of prospective genotyping for the HLA-B*57:01 risk allele prior to 
commencing abacavir therapy has been demonstrated. Hughes et al conducted a study in 
2004 where patients with and without abacavir hypersensitivity were identified and 
genotyped for HLA-B*57:01. Alongside this a cost effectiveness analysis was undertaken to 
assess the cost of testing and the cost of treating abacavir hypersensitivity as well as the cost 
and selection of alternate treatment regimens (Hughes et al. 2004). In this study 46% of 
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patients who had suffered abacavir hypersensitivity were HLA-B*57:01 positive while 10% of 
patients in the control group were also positive for this allele. Furthermore the cost 
effectiveness model in the study demonstrated testing for HLA-B*57:01 to be of beneficence 
over not testing due to being less expensive than treating hypersensitivity reactions (Hughes 
et al. 2004). This was continued by Schackman et al using a simulated cohort of patients 
commencing HIV therapy with an aim to assessing the cost effectiveness of treatment with 
abacavir and tenofovir with prospective HLA-B*57:01 genotyping (Schackman et al. 2008). 
Testing for HLA-B*57:01 generated a cost effectiveness ratio of $36,700/QALY when 
compared with no testing. However prospective genotyping in tenofovir therapy actually 
increased the cost of therapy with no obvious improvements in the quality adjusted life 
expectancy and cost more than an abacavir treatment regime with prospective genotyping 
(Schackman et al. 2008). Therefore, it was concluded that prospective HLA-B*57:01 
genotyping is a cost-effective means of preventing hypersensitivity reactions to abacavir in 
patients. In July 2008 the FDA issued a boxed warning on abacavir and abacavir containing 
medications strongly advising patients to seek screening for HLA-B*57:01 allele prior to 
commencing abacavir therapy.    
The generation of responsive T-cell clones to abacavir in vitro from drug naïve healthy donors 
positive for the HLA-B*57:01 allele has been widely demonstrated (Chessman et al., 2008; 
Adam et al., 2012; Bell et al., 2013; Naisbitt et al., 2015). Furthermore responses in abacavir 
specific T-cell clones are not observed when co-incubated with antigen presenting cells 
expressing closely related alleles such as HLA-B*57:02 (114 Asp-Asn, 116 Ser-Tyr, 156 Leu-
Arg), HLA-B*57:03 (114 Asp-Asn, 116 Ser-Tyr) or HLA-B*58:01 (45 Met-Thr, 46 Ala-Glu, 97 
Val-Arg, 103 Val-Leu) indicating that abacavir binding is highly specific to HLA-B*57:01 with 
particular sensitivity in the F-pocket region of the allele namely residue Serine 116 (Ostrov 
et al. 2012; Illing et al. 2012; Chessman et al. 2008).  
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Unmodified abacavir binds to HLA-B*57:01 in a non-covalent manner across the bottom of 
the antigen binding cleft and protruding into the F-pocket where the carboxy terminal amino 
acid tryptophan usually anchors peptides bound to HLA-B*57:01 (Ostrov et al. 2012; Illing et 
al. 2012; Norcross et al. 2012). Abacavir binds specifically to HLA-B*57:01 and induces an 
alteration in the shape and chemistry of the antigen binding cleft consequently altering the 
repertoire of endogenous peptides that can bind to HLA-B*57:01 (Ostrov et al. 2012; Illing et 
al. 2012; Norcross et al. 2012). Using peptide elution studies Illing et al demonstrated a 
change in the repertoire of self-peptides in the presence of abacavir. C1R-B *57:01 cells 
comprise a fully functional B-cell line transfected to express HLA-B*57:01, which can act as 
professional APCs. These cells were treated in the presence and absence of abacavir and the 
peptides eluted from the antigen presenting cells were subsequently analysed via mass 
spectrometry. It was observed that up to 25% of the total peptides eluted from the HLA -
B*57:01 in the presence of abacavir were novel self-peptides not detected in abacavirs 
absence (Illing et al. 2012). The prevalence of larger amino acids phenylalanine and 
tryptophan was severely diminished at the PΩ position (C-terminus) of the peptide 
corresponding to the F-pocket region of the MHC. The decrease in these amino acids was 
replaced with a significant increase in the smaller side chain amino acids leucine and 
isoleucine at the same position, while an increase in valine prevalence was also observed 
however the change was not significant in this study. This mass shift in amino acid prevalence 
was only observed in the PΩ position and nowhere else on the peptide chain (Illing et al. 
2012). Furthermore, these findings were not mirrored in closely related alleles of HLA-
B*57:01 including HLA-B*57:03 or HLA-B*58:01, nor were there any differences in the 
prevalence of the small side chain amino acids at the P2 (B-pocket) position between 
abacavir-treated and untreated cells (Illing et al. 2012).  
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Norcross et al demonstrated the alteration of self-peptides from the typical peptides 
containing C-terminal tryptophan, phenylalanine and tyrosine residues common to treated 
and untreated samples alike. However, peptides observed only in abacavir-treated cells 
displayed a far higher prevalence of the smaller amino acids isoleucine and leucine at the C-
terminal position. Furthermore, two synthesized peptides containing C-terminal isoleucine 
and leucine residues demonstrated strong affinity binding interactions within HLA-B*57:01 
in the presence of abacavir. Importantly, similar observations were not detected with 
flucloxacillin bound to HLA-B*57:01 (Norcross et al. 2012). 
The binding affinity of peptides was also tested by Ostrov et al using positional scanning 
combinatorial peptide libraries in both the presence and absence of abacavir. Again, in the 
absence of abacavir a stronger preference for binding HLA-B*57:01 was shown in peptides 
with C-terminal tryptophan and phenylalanine. However, in the presence of abacavir an 
increased affinity was detected in de novo peptides containing C-terminal smaller chain 
amino acid residues valine, alanine and isoleucine all of which displayed an increase in 
prevalence of between 5 and 8 fold compared to untreated cells (Ostrov et al. 2012). 
Individual synthesized peptides with respective C-terminal valine (pep-V) and tryptophan 
(pep-W) were generated. HLA binding studies demonstrated that pep-V required abacavir in 
a dose dependent manner in order to bind to HLA-B*57:01 with sufficient affinity while no 
significant binding effect of abacavir was observed for pep-W binding (Ostrov et al. 2012).  
As previously mentioned, abacavir consists of a cyclopentenyl moiety, a 2-amino purine 
moiety and a cyclopropyl moiety. It has been demonstrated that the cyclopropyl moiety of 
abacavir plays a key role in the interactions with HLA-B*57:01. This moiety extends towards 
and protrudes into the F-pocket, leading to interactions that reduce the size of the MHC 
peptide binding cleft accounting for the preference of smaller chain amino acids such as 
leucine and isoleucine (Illing et al. 2012).  These findings are consistent with previous studies 
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where it was shown that endogenous peptides extracted from HLA-B*57:01 cells treated 
with abacavir contained alternate peptide sequences compared to untreated cells, which 
were shown to be predominantly leucine and isoleucine. Taken together these studies 
provide a strong case for abacavir interactions within HLA-B*57:01 demonstrating a possible 
unique manner of T-cell activation relying on the presentation of altered self-peptides to T-
cells. Patients are generally tolerant to these peptides as they are never exposed to them in 
the context of HLA-B*57:01. However, presentation of these altered self-peptides by HLA-
B*57:01 can be mistaken for a foreign entity by CD8+ T-cells, leading to an immune reaction 
(Ostrov et al. 2012; Norcross et al. 2012; Illing et al. 2012; Llano & Brander 2012) . It is also 
possible that T-cells may be activated by presentation of an existing HLA-B*57:01 binding 
peptide, but in an altered conformation (Figure 1.9)  (Illing et al. 2013).  
Despite the 100% NPV with abacavir hypersensitivity reactions, only 55% of individuals that 
are positive for HLA-B*57:01 will develop a hypersensitivity reaction upon exposure to 
abacavir (Lucas et al. 2015; Mallal et al. 2008). Indeed, abacavir-specific T-cells are detectable 
in the circulating blood of HLA-B*57:01 donors who have never been exposed to the drug 
(Adam et al. 2012; Schnyder et al. 2013). Using patch testing, Schnyder et al 2013, 
demonstrated only patients with previous confirmed hypersensitivity reactions to abacavir 
produced skin reactions on exposure to abacavir, while those without prior abacavir 
exposure, both HIV patients and healthy donors, yielded negative tests (Schnyder et al. 
2013). These findings suggest previous abacavir hypersensitivity to be a pre-requisite for a 
skin reaction to the drug. Furthermore, the onset of hypersensitivity reaction symptoms has 
been shown in some cases to occur as early as 36 hours post first exposure to the drug, 
compared to the typical onset time of around 3-6 weeks. This has led to the proposition that 
abacavir may activate memory T-cells present from a previous immunogenic episode via 
cross reactivity. This specifies that HLA-B*57:01 restricted CD8+ memory T-cells previously 
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primed to a pathogen specific epitope may cross recognise a self -peptide that has been 
presented by HLA-B*57:01 in the presence of abacavir, thereby initiating a rapid immune 
response (Lucas et al. 2015). This mirrors the model of heterologous immunity’s role in graft  
and transplant rejection caused by cross reactivity between viral specific memory T-cells and 
mismatched HLA molecules (Amir et al. 2010). 
Indeed, it has been recently demonstrated that structural similarity between viral peptides 
and self-peptides presented by HLA-B*57:01 in the presence of abacavir exists (Yerly et al. 
2017). In this study, the crystal structure of the abacavir self -peptide VTTDIQVKV was 
complexed to abacavir and HLA-B*57:01. The authors detected solvent accessible side chains 
protruding for recognition by T-cells. This self-peptide corresponded to the human 
transcription elongation factor SPT5 isoform A 976-984 which has previously been shown to 
stimulate T-cells from patients with abacavir hypersensitivity syndrome (Yerly et al. 2017). 
Using BLAST search three more peptides were identified with a sequence homology to SPT5a 
of between 40 and 80%. These three peptides corresponded to the HIV -1 virus or the HSV1 
or 1/2 virus. TCR transfected jurakat cells were treated with these viral peptides and peptide 
VTQQAQVRL and T-cell activation was observed in the absence of abacavir. This peptide 
sequence corresponded to the Human Simplex Virus 1/2 and when complexed within HLA-
B*57:01 demonstrated a similar binding conformation to peptide VTTDIQVKV, indicating 
similar interactions with T-cells. However the T-cell response with this peptide was only 
observed in transfectants expressing one particular TCR (BeS-B7) indicating tha  these cross 
reactive memory responses may be exclusive to a small sub population of CD8+ T-cells (Yerly 
et al. 2017).  
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Figure 1.9. Formation of HLA-B*57:01 abacavir-peptide complexes possessing 
immunogenic properties. Adapted from Illing et al 2013. 
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1.14. Aims and objectives of thesis 
 
Despite it being well established that hypersensitivity reactions observed to abacavir are 
exclusive to the carriage of the MHC class I allele HLA-B*57:01 (Mallal et al. 2008), the 
underlying mechanisms of abacavir hypersensitivity reactions remain unclear. Indeed, Illing 
et al  and others have demonstrated the shift in the prevalence of peptides presented to T-
cells in the presence of abacavir (Illing et al. 2012; Ostrov et al. 2012; Norcross et al. 2012). 
Prospective genotyping is employed for the carriage of HLA-B*57:01 in patients prior to 
treatment with abacavir, with those positive for the risk allele excluded from abacavir 
therapy. It has been demonstrated that modification to the 6-aminocyclopropyl moiety of 
abacavir is capable of diminishing the unwanted T-cell activation observed with abacavir, 
while retaining the antiviral activity of the compound (Naisbitt et al. 2015). 
Thus, the aims of this thesis were 
• To investigate the further modifications to the 6-amino cyclopropyl moiety of 
abacavir on T-cell responses and the antiviral potency of the compound. 
• Using a panel of abacavir analogues as molecular probes, explore the binding and 
interactions of the compounds within HLA-B*57:01 and its relationship with T-cell 
activity. 
• To investigate the effects of the abacavir substituted analogues on the peptide 
repertoire displayed on the antigen presenting cell surface. 
• To evaluate if the unique self-peptides eluted from HLA-B*57:01 in the presence of 
abacavir are capable of stimulating a T-cell response in the presence and absence 
of the drug.  
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2.1 Introduction 
 
Abacavir is a prodrug which when converted to its metabolite carbovir inhibits viral chain 
replication via halting the reverse transcription of the viral RNA. However, exposure to this 
potent antiviral therapeutic is accompanied by the risk of severe hypersensitivity reactions 
observed exclusively in individuals carrying the risk allele HLA-B*57:01 (Mallal et al. 2002; 
Martin et al. 2004; Mallal et al. 2008). Due to the high prevalence of this risk allele, primarily 
in the Caucasian population, and the 100% NPV, genetic screening for HLA-B*57:01 is 
routinely carried out in HIV patients prior to the commencement of abacavir therapy, with 
those testing positive HLA-B*57:01 prescribed an alternate therapy regimen (Mallal et al. 
2008).  
Abacavir is known to cause the secretion of proinflammatory cytokines including IFN-γ and 
TNF-α from immune cells. While these responses have been detected in PBMCs from 
abacavir hypersensitive patients (Almeida et al. 2008) it is difficult to detect this response 
using PBMCS from drug naïve individuals exposed to abacavir in vitro. This is mainly due to 
the large pool of cells encompassed by PBMCs in healthy donors all of which have different 
characteristics, making it difficult to obtain a distinctive result which can be individually 
attributed to a defined cell population.  
For this reason, the generation of abacavir-induced T-cell lines from healthy donor PBMCs 
followed by cloning provides an effective mechanism to generate functional T-cells 
responsive to abacavir, for mechanistic studies, without the additional complication of 
handling the HIV virus. The procedure of T-cell cloning is carried out using a technique known 
as serial dilution which is a relatively simple and cost-effective process, utilising T-cells 
primary growth factor IL-2, with the only notable draw back being the time consumption of 
the procedure.  
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Drug specific T-cells have been generated to a plethora of therapeutics known to be 
associated with adverse reactions including carbamazepine (Wu et al. 2006; Lichtenfels et al. 
2014), lamotrigine (Naisbitt et al. 2003), sulfamethoxazole (Castrejon et al. 2010), dapsone 
and dapsone nitroso (Alzahrani et al. 2017) , flucloxacillin and amoxicillin (Yaseen et al. 2015) 
among others.  
In the case of abacavir, the generation of drug specific T-cell clones has been widely 
demonstrated (Chessman et al., 2008; Bell et al., 2013; Adam et al., 2014; Naisbitt et al., 
2015). All responsive clones generated to abacavir identify as CD8+ accounting for the Th1 
response commonly observed, which are characterised by the secretion of the 
proinflammatory cytokines such as IFN-γ. Utilisation of studies with T-cell clones allows for 
the quick and concise analysis of T-cell characteristics including phenotype, cytokine 
secretion and mechanistic studies such as the ability to be activated by abacavir in the 
presence and absence of antigen presenting cells.  
Abacavir is hypothesised to interact with HLA-B*57:01 by way of non-covalent binding. 
Abacavir can bind directly to MHC peptide complexes to activate T-cells via a PI mechanism  
(Adam et al., 2012; Bell et al., 2013). However, abacavir also induces a change in the shape 
and chemistry of the peptide binding groove, namely in the F-pocket region. Such change 
results in the accommodation of altered self-peptides, with a new repertoire carrying smaller 
chain anchors at the C-terminal region for presentation to T-cells. These abacavir induced 
self-peptides are perceived as foreign by T-cells, presumably also resulting in a CD8+ 
mediated immune response (Illing et al. 2012; Norcross et al. 2012; Ostrov et al. 2012).  
In this chapter, we explore the ability to generate abacavir-responsive T-cells from a panel 
of healthy, drug naïve donor’s positive for HLA-B*57:01. Some of the generated T-cell clones 
were then further analysed for cellular phenotype and mechanistic studies to examine the 
reactivity of the clones along with underlying mechanism of activation by abacavir.  
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2.2 Aims 
 
The aim of this chapter is to generate abacavir-specific T-cell clones from healthy drug- naïve 
donors positive for the HLA-B*57:01 risk allele. These generated clones will be subjected to 
further functional analysis for their cellular phenotype, mechanisms of T-cell activation and 
cytokines secretion properties. 
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2.3 Methods 
 
2.3.1 Materials 
 
Abacavir was received as a gift from GlaxoSmithKline (GSK). Human AB serum and foetal 
bovine serum were obtained from Innovative Research Class A (Michigan, USA) and 
Invitrogen (Paisley, UK) respectively. Interleukin-2 (IL-2) was purchased from Peprotech 
(London, UK). Multisort bead separation kits were supplied by Miltenyi Biotec (Surrey, UK). 
Antibodies for staining were purchased from BD Biosciences (Oxford, UK). ELIspot kits 
including the coating and detection antibodies, strepdavidan alkaline phosphate conjugate 
and BCIP/NBT substrates were purchased from Mabtech (Stockholm, Sweden). Other 
reagents were purchased from Sigma-Aldrich (Dorset-UK) unless otherwise stated. 
2.3.2 Cell culture medium 
 
Cell culture medium for T-cells (R9) is composed of RPMI supplemented with 10% human AB 
serum, HEPES (25mM), penicillin (1000 U/mL), streptomycin (0.1mg/mL), L-glutamine (2mM) 
and transferrin (25µg/mL).   
EBV transformed B-cells were cultured in F1 medium composed of RPMI supplemented with 
10% foetal bovine serum, HEPES (25mM), penicillin (1000 U/mL), streptomycin (0.1mg/mL) 
and L-glutamine (2mM). 
2.3.3. Isolation of peripheral blood mononuclear cells (PBMCs) 
 
PBMCs were isolated from blood collected in heparinised vacuette 9mL tubes. The blood 
(25mL) was slowly layered on top of 25mL of lymphoprep and centrifuged at 2000 rpm at 
25OC with acceleration set to 4 and the brake set to 0.  The buffy coat layer was transferred 
to a fresh 50mL tube using a Pasteur pipette. The PBMCs were washed a further two times 
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using HBSS to remove any remaining lymphoprep solution and the pellet was resuspended 
in 30mL of R9 medium.   
The PBMC suspension (10µL) was diluted in an equal volume of trypan blue and cells were 
counted using a Neubauer haemocytometer under a Leica DME microscope (Leica 
Microsystems, Milton Keynes). Cell viability was measured by trypan blue exclusion and the 
percentage viability of the cells was assessed as follows: percentage viability = viable number 
of cells/ total number of cells x 100. 
 
 
 
 
 
 
 
Figure 2.1 Isolation of PBMCs from whole blood patient samples via density centrifugation. 
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2.3.4 EBV generation 
 
Epstein-Barr virus transformed B-cell lines (EBVs) were produced from the PBMCs of cohort 
donors. Virus producing B95.8 cells were centrifuged at 1500 rpm for 10 minutes and 9mL of 
the supernatant was aspirated and filtered over donor PBMCs (5x106). Cyclosporin A (CSA) 
(1µg/mL) was added and cells were incubated overnight (37OC; 5% CO2). Cells were then 
centrifuged and resuspended in F1 medium + CSA and transferred to a 24 well plate to a 
maximum of 2mL. These were incubated for 3 weeks being fed with F1 medium + CSA 
(1µg/mL) twice a week to prevent growth of non-immortalised EBV infected B-cells. Once 
sufficient growth of EBVs had taken place, cells were transferred to a 25mL flask and fed 
twice a week with F1 media alone. These cells were used as a ready supply of immortalised 
autologous antigen presenting cells. 
2.3.5 Generation of abacavir-responsive T-cells. 
 
HLA-B*57:01 positive donors were selected from our cell cohort containing PBMCs from 
1200 genotyped healthy donors. The cohort derives largely from the Liverpool student 
population; thus it is extremely unlikely that any donor has been exposed to abacavir. Ethical 
approval for the study was obtained from the local research ethics committee and each 
donor underwent a consenting process prior to blood donation. For studies in this thesis, a 
total of five donors were utilized. Donors 1-4 were used for the generations of abacavir-
specific T-cell clones, while donor 5 was used for the naïve T-cell priming assay, described in 
chapter 4. PBMCs from each donor were incubated in the presence of abacavir (35µM) in R9 
medium for a period of 14 days. On days 6 and 9 cells were fed with R9 medium containing 
IL-2 to preserve the abacavir driven expansion of T-cells. On day 14, CD8+ T-cells were 
positively selected using MultiSort kits (Miltenyi Biotec, Surrey UK) and T-cell clones were 
generated via means of serial dilution. 
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CD8+ T-cells were seeded at a concentration of 0.3/1/3 cells/ well (96 well U-bottomed plate) 
and stimulated with allogenic PBMC feeder cells (5x104/well) and the mitogen 
phytohaemagglutin (PHA; 5µg/mL) in R9 medium containing IL-2 (2µL/mL). Cells were fed 
every 2 days with R9 medium containing IL-2 (2µL/mL) and well growing clones were 
transferred to a new 96 well plate and expanded across 4 wells. On day 14 clones were 
restimulated and further expanded for a further 28 days.  
 
 
2.3.6. Testing clones for antigen specificity 
 
Approximately four weeks after beginning the serial dilutions abacavir-specificity was 
measured by assessing cell proliferation in the presence of the drug. Abacavir induced 
proliferation was measured by culturing T-cell clones (5x104/50µL) with irradiated 
autologous EBVs (1x104/50µL) in the presence and absence of an optimal concentration of 
abacavir (35µM). Following 48-hour incubation, tritiated thymidine (0.5µCi) was added and 
proliferation was assessed 16 hours later via scintillation counting. The proliferative response 
of T-cell clones is expressed as counts per minute (cpm). A stimulation index is obtained by 
dividing the average cpm of the drug treated wells by the average of the control wells. T-cell 
Table 2.1. HLA-allele typing of five healthy drug naïve donors. Yellow denotes positive expression of the HLA-
B*57:01 risk allele for hypersensitivity reactions to abacavir.  
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clones with a proliferative stimulation index of 2 or greater were picked and expanded by 
mitogen restimulation in cell culture media containing irradiated allogenic PBMCs (5x105 
cells/well), IL-2 (5µL/mL) and PHA (10µg/mL) for further analysis. 
2.3.7. Confirmation of antigen specificity via ELIspot Assay 
 
ELIspot plates were activated with 15µL of 35% EtOH and washed 5 times with dH2O. The 
plates were then coated with 100µL/well of interferon gamma capture (IFN-γ) antibody 
(15µg/mL) and incubated overnight at 4OC. The following day, wells were washed 5 times 
with sterile PBS and then blocked with 250µL of R9 medium at room temperature for a period 
of 30 minutes to prevent non-specific binding. Drug specific T-cell clones (5x104/50µL) were 
added to each well along with autologous EBVs (1x104/ 50µL). Cells were then cultured in 
the presence or absence of abacavir (35µM, 100µL) for a period of 48 hours at 37OC; 5% CO2. 
Following a 48 hour incubation period, cells were discarded and the plates were washed 5 
times with 250µL PBS. Biotin labelled detection antibody was diluted 1µg/mL in PBS 
containing 0.5% FBS and 100µL/well was added to the plate, which was then incubated for 2 
hours at room temperature. Following this incubaton period the detection antibody was 
discarded and the plate washed with PBS (250µL/well). Streptavidin-ALP diluted to 1µg/mL 
in PBS containing 0.5% FBS was added to the plate at 100µL/well and the plate was incubated 
at room temperature for 1 hour. Next, wells were again washed with PBS and 100 µL of 
filtered BCIP/NBT substrate was added to each well for a period of 20 minutes in the dark at 
room temperature. Wells were then washed under running cold water to stop the reaction 
and the plate was left to dry overnight then counted using an AID ELIspot reader (Cadama 
Medical, Stourbridge, UK).  
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2.3.8. CD4/CD8 cellular phenotyping via flow cytometry 
 
Flow cytometry was used to investigate the cell surface phenotype and function of T-cell 
clones. This was primarily used to assess if T-cells expressed CD4 or CD8 markers. T-cells 
(50µL) were transferred to a FACs tube and 1.5µL of CD4 (FITC) and CD8 (PE) antibody was 
added to each tube and incubated at 4OC for 20 minutes in the dark. Following incubation, 
500µL of FACs buffer was added to each tube and cells were centrifuged at 1500rpm, 4OC for 
a period of 5 minutes. Supernatant was then discarded and cells were resuspended in 200µL 
FACs buffer. Phenotyping on clones was performed using BD FACSCanto II flow cytometer 
(CD4-FITC) and (CD8-PE).  
2.3.9. Dose and antigen presenting cell dependency of abacavir-specific CD8+ T-cell 
clones. 
 
The dependence on antigen presenting cells for activation of abacavir-specific CD8+ T-cell 
clones was analysed by conducting dose response assays to abacavir in the presence and 
absence of autologous EBVs. Abacavir-specific CD8+ T-cell clones were incubated in the 
presence of abacavir at concentrations of 0-35µM in the presence and absence of autologous 
APCs for a period of 48 hours (37OC; 5% CO2). Activation of T-cells was quantified using the 
IFN-γ ELIspot assay. 
2.3.10 Abacavir Pulsing of APCs 
Autologous EBVs (functioning as APCs) were pulsed with abacavir (35µM) (37OC; 5% CO2) for 
a period of 1, 4 and 16 hours to assess processing dependency and kinetics. Following 
incubation, EBVs were washed three times in R9 medium. The cells were then irradiated and 
cultured with T-cell clones (5x104/ 50µL). No further drug was added and T-cell responses 
were measured using IFN-γ ELIspot as described in section 2.3.7. Soluble abacavir (35µM) 
was used as a positive control. 
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2.3.11 Analysis of cytokine secretion from abacavir-specific CD8+ T-cell clones. 
 
The cytokine secretive profiles of abacavir clones was assessed using the ELIspot assay for 
various cytokines including; IFN-γ, IL-5, IL-10, IL-13, IL-17, IL-22 and effector molecules 
granzyme B, perforin and FasL. T-cell clones were incubated (5x104/ 50µL) with autologous 
APCs (1x104/ 50µL) in the presence and absence of abacavir (35µM). Cytokine secretion was 
measured using the respective detection antibodies according to the manufacturer’s 
instructions and plates were counted using AID-ELIspot reader.  
2.3.12. TCRVβ analysis of T-cell responsive clones. 
 
TCR Vβ expression analysis of individual T-cell clones was conducted using IOTest® beta mark 
(Beckman Coulter, Indianapolis, USA). This test allows for the multi-parametic analysis of TCR 
Vβ expression in human T-cells via the use of FITC and PE conjugated antibodies. . Each 
antibody was capable of detecting three individual TCR Vβ (FITC, PE, FITC/PE), meaning the 
TCR Vβ detection kit could detect a total of twenty four TCRs.  A total of eight tubes was 
required per clone tested. Cellular suspension (50µL) was transferred to each tube and TCR 
Vβ antibodies (A-H) (5µL) were added individually to the respective eight tubes. Cells were 
incubated in the presence of the antibodies for 20 minutes in the dark at room temperature. 
Next, cells were washed and resuspended in 200µL of FACs buffer before being analysed 
using BD FACSCanto II flow cytometer.  
2.3.13 Statistical analysis. 
 
For comparison between control and test values in proliferation assays the Mann-Whitney 
test was used. 
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2.4. Results 
 
2.4.1 Generation of abacavir-specific T-cell clones 
 
From a total of 2279 clones tested across the four donors utilized (donors 1-4), 101 were 
found to proliferate in the presence of abacavir yielding a stimulation index (SI) value of 2 or 
greater. A varied number of responsive clones was found across the four donors in this study 
with the percentage of responsive clones ranging from as low as 0.4% in donor 2 to 12.5% in 
donor 4 (Table 2.2). Figures 2.2-2.4 show the proliferative response in all clones incubated in 
the presence of abacavir across the four donors.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Antigen specificity of T-cell clones to abacavir (Donor 1, HLA-0617 and Donor  
2, HLA-0957, both genotyped as HLA-B*57:01 positive. T-cell  clones (5x10
4
/50µL) were 
co-incubated with autologous APCs (1x10
4
/ 50µL) in the presence and absence of abacavir 
(35µM) in a U-bottomed 96 well microplate. Cells were incubated for 48h (37
o
C; 5% CO
2
). 
Tritiated thymidine was then added for an additional 16h incubation. T-cell  proliferation 
was assessed using scintil lation counting. Clones with a stimulati on index (SI) of 2 or 
greater were considered positive and were expanded for further study. 
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Figure 2.3. Antigen specificity of T-cell clones to abacavir (Donor 3, HVN-158 and Donor 4, HLA-0622, both 
genotyped as HLA-B*57:01 positive. T-cell  clones (5x10
4
/50µL) were co-incubated with autologous APCs 
(1x10
4
/ 50µL) in the presence and absence of abacavir (35µM) in a U-bottomed 96 well microplate. Cells 
were incubated for 48h (37
o
C; 5% CO
2
). Tritiated thymidine was then added for an additional 16h incubation. 
T-cell  proliferation was assessed using scintillation counting. Clones with a stimulation index (SI) of 2 or 
greater were considered positive and were expanded for further study. 
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Figure 2.4. T-cell response of abacavir-specific clones. Average proliferative response of T-cell  clones 
incubated from four HLA-B*57:01 donors with abacavir (35µM). Cell culture media (Control) was used 
as a negative control. Data shown as mean of all  responsive clones vs control ± SEM. * P<0.05, ** 
P<0.01, *** P<0.001.  
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m
Table 2.2. Responsive clones generated from four HLA-B*57:01 positive donors.  
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2.4.2 Confirmation of antigen specificity of abacavir-specific T-cell clones 
 
Clones which generated a proliferative response corresponding to an SI of 2 or greater were 
subjected to mitogen driven expansion for a period of 2 weeks to allow for cellular growth. 
Following this restimulation period clones were further tested to confirm their antigen 
specificity to abacavir. Due to its enhanced sensitivity over the proliferation assay for CD8+ 
T-cell clones, the secretion of IFN-γ was used as a readout for this stage by utilisation of the 
ELIspot assay as described in section 2.3.7. Following incubation of abacavir with clones and 
EBVs for 48 hours, the ELIspot plate was developed via the separate additions of detection 
antibody and streptavidin conjugate followed by BCIP/NBT substrate. The precipitation of 
the substrate manifests as spots at the sites of IFN-γ secretion, allowing for the quantification 
of T-cell activity. Lack of observed IFN-γ secretion in a particular T-cell clone at the second 
test indicates a false positive result was obtained at the proliferation readout stage or that 
the clone has lost antigen specificity to abacavir. All clones failing to produce a cytokine 
secretive response were subsequently destroyed. From the 101 clones obtained to abacavir 
at the first testing stage, 52 displayed distinct IFN-γ secretion in the presence of abacavir at 
the 2nd testing stage. Figures 2.5-2.8 show the IFN-γ secretion from abacavir T-cell clones 
incubated in the presence and absence of the drug. All responsive T-cell clones were 
maintained in cell culture and used for further experiments. 
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Clone ID Ø ABC 
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Clone ID Ø ABC 
Figure 2.5. Confirmation of antigen specificity of T-cell clones from Donor 1 (HLA-0617). a) 
ELIspot well images from a panel of representative clones tested for secretion of IFN-Ƴ.  b) 
Secretion of IFN-γ from all  T-cell  clones to Donor 1. Grey bars denote cells incubated with R9 
medium and black bars denote cells incubated with abacavir for 48h. ELIspot plates were 
coated with human IFN-γ antibody and incubated at 4
o
C overnight. T-cell  clones (5x10
4
/ 50µL) 
were co-incubated with APCs (1x10
4
/ 50µL) in the presence and absence of abacavir (35µM) 
for 48h (37
O
C; 5% CO
2
). The ELIspot plate was then developed according to the manufactures 
protocol and counted using ELIspot AID reader. 
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TCC 40 
TCC 41 
TCC 42 
TCC 43 
Clone ID Ø ABC 
Figure 2.6. Confirmation of antigen specificity of T-cell clones from Donor 2 (HLA-0957). a) 
ELIspot well images from a panel of representative clones tested for secretion of IFN-γ.  b) 
Secretion of IFN-γ from all T-cell clones to Donor 2. Grey bars denote cells incubated with R9 
medium and black bars denote cells incubated with abacavir for 48h. ELIspot plates were 
coated with human IFN-γ antibody and incubated at 4
o
C overnight. T-cell  clones (5x10
4
/ 50µL) 
were co-incubated with APCs (1x10
4
/ 50µL) in the presence and absence of abacavir (35µM) 
for 48h (37°C; 5% CO
2
). The ELIspot plate was then developed according to the manufacturers 
protocol and counted using ELIspot AID reader. 
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TCC 110 
Clone 
ID
Ø ABC Clone 
ID
Ø ABC 
Figure 2.7. Confirmation of antigen specificity of T-cell clones from Donor 3 (HVN-158). a) ELIspot 
well images from a panel of representative clones tested for secretion of IFN-γ.  b) Secretion of IFN-γ 
from all  T-cell  clones to Donor 3. Grey bars denote cells incubated with R9 medium and black bars 
denote cells incubated with abacavir for 48h. ELIspot plates were coated with human IFN-γ antibody 
and incubated at 4
o
C overnight. T-cell  clones (5x10
4
/ 50µL) were co-incubated with APCs (1x10
4
/ 
50µL) in the presence and absence of abacavir (35µM) for 48h (37
O
C; 5% CO
2
). The ELIspot plate was 
then developed according to the manufacturers protocol and counted using ELIspot AID reader. 
2nd Test Donor 3 
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Figure 2.8. Confirmation of antigen specificity of T-cell clones from Donor 4 (HLA-0622). a) ELIspot 
well images from a panel of representative clones tested for secretion of IFN-γ.  b) Secretion of IFN-
γ from all T-cell clones to Donor 4. Grey bars denote cells incubated with R9 medium and black bars 
denote cells incubated with abacavir for 48h. ELIspot plates were coated with human IFN-γ 
antibody and incubated at 4
o
C overnight. T-cell  clones (5x10
4
/ 50µL) were co-incubated with APCs 
(1x10
4
/ 50µL) in the presence and absence of abacavir (35µM) for 48h (37
O
C; 5% CO
2
). The ELIspot 
plate was then developed according to the manufacturers protocol and counted using ELIspot AID 
reader. 
2nd Test Donor 4 
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2.4.3 T-cell phenotyping 
 
Abacavir-responsive T-cell clones were analysed for surface receptor expression of CD4 and 
CD8. T-cell clones (50µL) were co-incubated with CD4-FITC and CD8-PE antibodies then 
analysed via flow cytometry using BD FACSCanto II flow cytometer. All abacavir-responsive 
T-cell clones generated from the four HLA-B*57:01 positive donors were phenotyped as CD8 
(Figure 2.9 shows the representative analysis for donor 1 CD4/CD8 phenotyping).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9. Cell phenotyping for expression of CD4 and CD8 on the surface of abacavir -specific 
T-cell clones. Cells (50µL) were stained with antibodies CD4-FITC and CD8-PE and incubated for 
20 minutes at 4°C. Cells were then washed and flow cytometry used to analyse cellular 
phenotype (BD FACSCANTO II) 
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2.4.4 Dose-and antigen presenting cell-dependency for activation of abacavir-specific 
CD8+ T-cell clones 
 
The activation of abacavir-specific CD8+ T-cell clones was assessed in the presence and 
absence of APCs using IFN-γ secretion as a primary readout. A total of nine abacavir clones 
from the HLA-B*57:01 positive donors were selected and tested at concentrations of 
abacavir ranging up to 35µM. Cytokine secretion was observed in abacavir-specific T-cell 
clones in both the presence and absence of APCs. The T-cell activation of nine representative 
abacavir clones tested is shown in Figures 2.10-2.12. It was observed that in the case of some 
clones (TCC 27) minimal difference exists in T-cell activation between clones incubated in the 
presence of APCs and those incubated without APCs. In most of the clones tested, despite T-
cell activation occurring in the absence of APCs there is an enhanced activation observed in 
the presence of APCs. Some T-cell clones demonstrated no activation at all when incubated 
with abacavir in the absence of APCs (TCC 40 and 41) indicating the reliance on antigen 
processing and presentation for T-cell activation. It can also be observed that for most 
abacavir clones which are activated in the absence of APCs that as the concentration of the 
drug decreases the requirement of APCs for T-cell activation becomes apparent i.e. TCC 42 
ceases to respond in the absence of APCs at 0.9µM and TCC 63 at 1.25µM.  
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 Figure 2.10. Dose-and antigen-presenting cell dependency of abacavir responsive T-
cell clones. T-cell  clones were incubated +/- autologous APCs in the presence of 
abacavir (ABC 0-35µM) for 48 hours (37°C; 5% CO
2
). ELIspot plates were developed 
following manufacturer’s instructions and plates were read using AID ELIspot reader. 
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Figure 2.11. Antigen presenting cell 
dependence of abacavir responsive T-cell 
clones. T-cell  clones 40 and 41 were incubated 
+/- autologous APCs in the presence of 
abacavir (ABC 35µM) for 48 hours (37
O
C; 5% 
CO
2
). ELIspot plates were developed following 
manufacturer’s instructions and plates were 
read using AID ELIspot reader. 
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Figure 2.12. Antigen presenting cell dependence of abacavir responsive T-cell clones. T-cell  
clones 51 and 63 were incubated +/- autologous APCs in the presence of abacavir (ABC 0-
35µM) for 48 hours (37
O
C; 5% CO
2
). ELIspot plates were developed following manufacturer’s 
instructions and plates were read using AID ELIspot reader. 
APC 
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2.4.5 Activation of abacavir-specific clones with drug pulsed antigen presenting cells. 
 
Ten representative abacavir-specific T-cell clones were used to ascertain the principal 
pathway of T-cell activation employed by the clones. Autologous APCs were incubated with 
abacavir (35µM) for periods of 1 hour, 4 hours and 16 hours. Following incubation, the cells 
were washed three times and irradiated prior to co-incubation with T-cell clones (5x104/ 
50µL). The T-cell response was measured by IFN-γ secretion using the ELIspot assay. T-cell 
clones incubated with autologous APCs in the presence of soluble abacavir (35µM) were used 
as a positive control.  
All clones produced strong IFN-γ secretion in the presence of soluble abacavir at the optimal 
concentration of 35µM. With exception of clone 121, all abacavir-specific T-cell clones 
produced a response to drug pulsed APCs for a time period of 16 hours. Clones which evoked 
T-cell activation to the pulsed APCs are presumed to interact via the altered pe ptide 
repertoire mechanism while those which were pulse negative interact via the PI mechanism. 
However, many clones produced T-cell activation to APCs pulsed for the shorter time periods 
of 4 hours and 1 hour. This indicates the likely employment of both the altered peptide and 
PI mechanism as these time points are not sufficient for the antigen processing to take place 
fully, thereby suggesting direct interaction with surface MHC peptide complexes.  
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Figure 2.13. Activation of abacavir-specific T-cell clones with pulsed APCs. a) Representative well 
images from ELIspot of T-cell  clones incubated with APCs pulsed for 1h, 4h or 16h in the presence 
and absence of abacavir (35µM). b) Graphs displaying IFN-γ secretion from four of the ten 
representative clones pulsed for 1h, 4h and 16h. Ten representative abacavir responsive CD8
+
 T-
cell  clones from three HLA-B*57:01 donors were used. Autologous APCs were pulsed with abacavir 
(35µM) overnight (37
O
C; 5% CO
2
). The following day cells were washed three times to remove 
unbound drug and T-cell  clones (5x10
4
/ 50µL) were co-incubated with irradiated autologous APCs 
(1x10
4
/ 50µL). The T-cell  response was measured via IFN-γ secretion. APCs pulsed with R9 medium 
alone (mock pulsed) were used as a negative control and soluble abacavir (35µM) was used as a 
positive control.  
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2.4.6 Cytokine secretion panel of CD8+ abacavir-responsive T-cell clones 
 
The cytokine secretion profiles of abacavir-specific clones was assessed using ELIspot assay 
for various cytokines including; IFN-Ƴ, IL-5, IL-10, IL-13, IL-17, IL-22 and the effector 
molecules granzyme B, perforin and FasL. Six abacavir clones were selected and incubated 
(5x104/ 50µL) with autologous APCs (1x104/ 50µL) in the presence of abacavir (35µM). 
Cytokine secretion was measured using the respective detection antibodies according to the 
manufacturer’s instructions.  
Figure 2.14 shows the cytokine secretion profiles from the six abacavir-specific clones. 
Secretion of proinflammatory cytokines IFN-γ and IL-13 was observed across all six of the 
clones tested along with granzyme B. Secretion of IL-5 was observed in low levels in one of 
the clones. No secretion of the anti-inflammatory cytokine IL-10 was observed in any clones 
in response to abacavir. Similarly, no Th17 or Th22 cytokines were detected. Secretion of the 
effector molecules FasL and perforin was detected in some of the clones in response to 
abacavir stimulation but not others indicating the differing mechanisms of T-cell activation 
employed across the clones. 
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Figure 2.14. Abacavir-specific cytokine activity of CD8
+
 T-cell clones. ELIspot well images from six 
representative abacavir-responsive T-cell  clones incubated in the presence and absence of abacavir 
(37
O
C; 5% CO
2
). T-cell  activation was measured via the ELIspot assay for the respective cytokines. 
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2.4.7. TCRVβ analysis of T-cell responsive clones. 
 
To investigate the TCR expression of abacavir-specific T-cell clones, Vᵦ analysis was carried 
out on a panel of 29 abacavir responsive T-cell clones. As shown in figure 2.15 a varied TCR 
expression employed across the T-cell clones tested, with 24% of clones expressing a TCR Vβ 
undetectable by the TCR kit. This indicates the expression of a rare TCR out with the 85% 
encompassed by the antibodies.  
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a) 
b) 
Figure 2.15. Comparison of TCR Vβ expression across the abacavir-responsive T-
cell clones. a) Bar chart and b) Pie chart displaying the varied expression of TCR 
Vβ expression across abacavir-responsive T-cell clones. 
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2.5 Discussion 
 
Hypersensitivity reactions to abacavir are observed exclusively in individuals carrying the 
HLA-B*57:01 risk allele, this association yields a NPV of 100% and a PPV of 48-55% (Mallal et 
al. 2008). Abacavir-specific CD8+ T-cell responses can be assessed via the use of lymphocytes 
isolated from healthy drug naïve volunteers positive for HLA-B*57:01. It has been 
demonstrated in various studies that abacavir-responsive T-cell clones from healthy, drug 
naïve individuals can be generated (Bell et al., 2013; Adam et al., 2014; Naisbitt et al., 2015). 
Abacavir binds non-covalently with HLA-B*57:01 altering the shape and chemistry of the 
peptide binding groove, specifically in the F-pocket region. This leads to the accommodation 
of an altered repertoire of self-peptides displayed on the antigen presenting cells surface, 
specifically with smaller C-terminal anchors. It is hypothesised that the presentation of these 
altered peptides on the surface for recognition by T-cells evokes an immunological response 
due to their perception as foreign antigens by the T-cells (Illing et al. 2012; Ostrov et al. 2012; 
Norcross et al. 2012). Studies to ascertain the mechanisms of T-cell activation in response to 
abacavir can be carried out comparatively easily on abacavir clones relative to PBMCs, which 
encompass many cells of varying characteristics, making it difficult to attribute a function to 
a particular cell type.  
The aim of this chapter was to generate abacavir-responsive CD8+ T-cell clones from four 
HLA-B*57:01 positive healthy donors that had not been previously exposed to the drug, for 
use throughout this thesis. A panel of these responsive clones were subjected to further 
testing for cellular phenotype, dose-dependency along with antigen processing dependency 
and cytokine secretion profile.  
A total of 2279 clones tested for abacavir-specificity across the four donors, 101 were found 
to proliferate in response to abacavir on first testing. This yielded an overall percentage of 
responsive clones of 4.6%, which is lower than in previous studies (Naisbitt et al. 2015); 
                                                                                                       Chapter 2 
 
104 
 
however, this value is skewed by the exceptionally low number of clones generated from 
donor 2 (0.4%). As shown in Table 2.2, the percentage yield of responsive clones displayed 
considerable variation between donors with some yielding a responsive clone value of as 
high as 12% while others were lower (0.4-4.5%). It would be intriguing to find out whether 
this represents a difference in T-cell receptor precursor frequency. If so, this might influence 
susceptibility to abacavir hypersensitivity. Antigen specificity on first test responsive clones 
was confirmed via the use of IFN-γ secretion as a readout due to the superiority of the ELIspot 
assay over proliferation for CD8+ T-cell clones. All clones displaying a proliferation SI>2 were 
subjected to an ELIspot assay to analyse the secretion of the proinflammatory cytokine IFN-
γ as a test for antigen specificity in response to abacavir. All clones demonstrating a distinct 
increase in IFN-γ secretion when co-incubated with abacavir compared to control were 
maintained in cell culture while those displaying no significant difference between untreated 
and abacavir treated were identified as false positives and were removed from cell culture. 
From the 101 abacavir clones responsive on first testing, 52 were found to secrete IFN-γ in 
response to co-incubation with abacavir. All 52 of these T-cell clones were phenotyped as 
CD8+, consistent with all previous findings in abacavir-responsive T-cell clones (Chessman et 
al., 2008; Bell et al., 2013; Adam et al., 2014; Naisbitt et al., 2015).  
Dose-response analysis of selected abacavir clones indicated a variation in T-cell reactivity to 
decreasing concentrations of abacavir even in the presence of APCs. Some T-cell clones 
responded to abacavir at exceptionally low concentrations (<1µM) e.g. TCC 27, while others 
displayed limited activation at concentrations below the optimal (35µM), TCC 40. Similarly, 
the activation profile of T-cells in response to abacavir was varied across the different T-cells, 
which were shown to be activated both in the presence and absence of APCs (Figures 2.10-
2.12). Some T-cell clones displayed strong T-cell activation in both the presence and absence 
of APCs, even at low concentrations of abacavir. However other clones required abacavir and 
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professional APCs for activation. Of note, all clones express surface class I molecules. The 
dependence on professional antigen presenting cells for T-cell activation was observed in 
many abacavir clones as the concentration of the drug decreased. Despite activation of T-
cells in the absence of APCs in many clones the T-cell response was much lower than in the 
presence of APCs suggesting the ability of these clones to utilize both APC dependent and 
independent activation pathways in response to abacavir. Antigen presenting cell pulsing 
assays were employed to further assess the mechanism of T-cell activation within a panel of 
abacavir-responsive T-cell clones. Optimal pulsing time was 16h to allow for abacavir binding 
to endogenous HLA-B*57:01, protein processing and subsequent loading of the MHC binding 
peptides and finally their transport to the cellular surface. Pulsing assays yield negative 
results for drugs which activate cells via the PI mechanism (Martin P. Zanni et al. 1998; Pichler 
2002a; Pichler 2008; Wu et al. 2006). Thus, it is likely that pulse positive abacavir-specific 
clones are activated via the altered peptide repertoire concept. Some abacavir clones 
displayed a diminished response when 16-hour abacavir pulsed APCs were compared with 
co-incubation with soluble abacavir. Furthermore, a small number of clones produced a T-
cell response to APCs pulsed with abacavir for reduced periods of time (1 hour and 4 hours) 
indicating the self-presenting ability of these clones as well as direct interaction with surface 
MHC molecules (Adam et al., 2012; Bell et al., 2013). Collectively, these data demonstrate 
the capability of abacavir-responsive T-cell clones to utilize activation pathways which are 
both processing dependent and independent. Across the abacavir clones tested, the 
secretion of the proinflammatory cytokines IFN-γ and IL-13 along with granzyme B was 
detected at high levels in all clones, while no secretion of IL-10, IL-17 and IL-22 was detected. 
Secretion of IL-5 was observed in one abacavir clone at relatively low levels. Secretion of the 
effector molecule perforin and expression of FasL was varied across the abacavir-specific T-
cell clones tested. In two clones expression of FasL was accompanied by secretion of perforin, 
while in 2 other clones lack of FasL expression and perforin secretion was detected. However, 
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in clones 27 and 69 perforin secretion was detected at low levels but expression of FasL could 
not be observed, indicating the use of other mechanisms for perforin secretion. Consistent 
with previous findings the TCR Vβ repertoire across the abacavir-responsive T-cell clones 
tested displayed strong variation between the clones (Bell et al., 2013). Notably, a large 
percentage of abacavir-responsive T-cell clones (24%) expressed a rare TCR not included in 
the range detectable by the TCR Vβ antibody kit. The variability between abacavir clones 
suggests the existence of a heterologous population of abacavir-specific CD8+ T-cell with 
unique characteristics.   
The data presented in this chapter demonstrates that it is possible to generate abacavir-
specific CD8+ T-cell clones from healthy drug naïve volunteer’s positive for the HLA -B*57:01 
allele. These clones can be activated via two pathways that utilise the binding of abacavir to 
endogenous HLA-B*57:01 in an antigen processing dependent manner (Chessman et al. 
2008) and also via direct interaction with surface MHC molecules (Bell et al., 2013). Cytokine 
secretion data further demonstrates the variability in response observed in abacavir clones 
to stimulation by the drug. Taken together these data indicate the differing characteristics 
of T-cell clones generated from healthy donors by way of activation pathways and the 
responses observed to abacavir exposure. This illustrates the existence of a heterogenous 
pool of T-cells with varying characteristics, presenting important implications for drug safety 
analysis.  
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3.1 Introduction 
 
The association between the prevalence of HLA risk alleles and hypersensitivity reactions  to 
several different therapeutic agents has been widely documented. This includes severe 
cutaneous reactions such as SJS/TEN in patients expressing the HLA-B*15:02 allele with the 
anti-epileptic drug carbamazepine (Chung et al. 2004), as well as with the xanthine oxidase 
inhibitor allopurinol in patients expressing HLA-B*58:01 (Hung et al. 2005). However, the 
most widely recognised association between hypersensitivity reactions and the expression 
of HLA risk alleles are the reactions experienced exclusively in patients carrying HLA-B*57:01 
with the antiretroviral drug abacavir. These reactions yield a 100% NPV and a PPV of 48% 
with HLA-B*57:01 (Mallal et al. 2008; Mallal et al. 2002; Martin et al. 2004; Hetherington et 
al. 2002).   
Abacavir binds to HLA-B*57:01 in a non-covalent manner, the interactions within the peptide 
binding groove result in a reduction in the prevalence of larger C-terminal anchors such as 
tryptophan and phenylalanine, accompanied by an increase in the smaller C-terminal 
anchors such as valine, leucine and isoleucine (Illing et al. 2012; Ostrov et al. 2012; Norcross 
et al. 2012). These findings led to the inception of the hypothesis that the binding of abacavir 
to HLA-B*57:01 induces changes in the shape and chemistry of the F-pocket of the peptide 
binding groove, reducing its size, consequently altering the repertoire of peptides 
accommodated on the surface of the MHC molecules for presentation to T-cells. As these 
unique self-peptides are not observed in the absence of abacavir they are perceived as 
foreign by CD8+ T-cells, meaning an immune reaction is initiated (Ostrov et al. 2012; Illing et 
al. 2012).  
The generation of abacavir-specific CD8+ T-cell clones from drug naïve healthy donors 
positive for the HLA-B*57:01 allele has been widely demonstrated (Chessman et al., 2008; 
Adam et al., 2012; Bell et al., 2013; Naisbitt et al., 2015). Furthermore abacavir is 
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hypothesised to activate T-cell clones via two autonomous pathways where activation of the 
T-cells is dependent on the antigen processing and subsequent display of peptides by the 
MHC, and another where the drug is capable of interacting with the MHC T-cell receptor (Bell 
et al., 2013). The need for the antigen processing was demonstrated elegantly by Chessman 
et al, via the eradication of the class I restricted pathway in antigen presenting cells which 
was sufficient to abrogate T-cell responses to abacavir (Chessman et al. 2008). Bell et al 2013, 
demonstrated the need for the antigen processing pathways in the generation of an 
abacavir-specific response in T-cell clones. It was found that up to 50% of clones were 
activated by antigen presenting cells pulsed for 16 hours in the presence of abacavir, but not 
by APCs pulsed for 1 hour only. Additionally, abacavir was detected intracellularly in APCs 
pulsed for the 16 hour period, leading to the conclusion that abacavir is rapidly taken up and 
remains present in the APC for the whole 16 hours. Furthermore, these responses were 
abrogated following removal of the antigen processing pathways via glutaraldehyde fixation, 
indicating the imperative role for MHC processing and presentation (Chessman et al. 2008). 
However, this pathway accounts for approximately 50% of all abacavir-responsive CD8+ T-
cell clones, other clones were found to activate the proliferation of T-cell clones in the 
absence of antigen presenting cells or with glutaraldehyde fixed APC, indicating that abacavir 
may activate T-cell clones via a direct interaction with the surface MHC (Adam et al., 2012; 
Bell et al., 2013).  
The 6-amino cyclopropyl group of abacavir is imperative for the binding and interaction with 
HLA-B*57:01. The cyclopentyl and cyclopurine moieties nestle in the D and E pockets of HLA-
B*57:01 respectively, while the cyclopropyl moiety extends into the F-pocket of HLA-B*57:01 
inducing a conformational change in the peptide binding groove, reducing its size and 
thereby accounting for the preferred accommodation of the smaller chain amino acids 
mentioned earlier (Illing et al. 2012). This conformational change within the peptide binding 
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groove of HLA-B*57:01 may allow still for the binding of normal peptides observed in 
abacavirs absence, however the presence of abacavir within HLA-B*57:01 will result in the 
display of peptides in an altered conformation to the one in abacavirs absence, which can be 
sufficient to trigger a T-cell response (Illing et al. 2013). The metabolite of abacavir, carbovir, 
which lacks the cyclopropyl moiety (Figure 3.1) is known to be devoid of immune responses 
in CD8+ T-cells, indicating a specific role for the 6-amino cyclopropyl moiety interacting within 
the F-pocket of the HLA-B*57:01 (Chessman et al. 2008). 
 
 
Therefore, the theory that modifications to the cyclopropyl moiety of the compound could 
abolish the undesired T-cell activation observed with abacavir but retain the favoured 
antiviral activity was presented as a promising avenue for research.  
Indeed, this concept was explored by Naisbitt et al 2015 via the construction and synthesis 
of sixteen abacavir analogues, all of which contained substitutions at the 6-amino position 
of the compound, in place of the cyclopropyl group. From this sixteen, two analogues were 
identified that were devoid of T-cell activation when co-incubated with abacavir-responsive 
T-cell clones. Both analogues contained N-linked branched chains of three carbon atoms; 
analogue 15 (isopropyl) and analogue 16 (methyl-isopropyl). Additionally, both retained 
some antiviral activity as well as possessing reasonable in vitro cytotoxicity profiles.  
Figure 3.1. Chemical Structure of abacavir and its metabolite carbovir  
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Molecular modelling studies revealed unfavourable binding conformations of compounds 15 
and 16 within the F-pocket of HLA-B*57:01. Docking of these compounds within the antigen 
binding cleft resulted in the presence of unfavourable steric clashes between the functional 
groups of the analogues and the HLA-binding peptide, as well as amino acid residues within 
the F-pocket. The presence of these clashes indicate a hindrance in the binding capabilities 
of the two analogues within the F-pocket, meaning a change in the repertoire of self-peptides 
could not be induced resulting in a failure to activate T-cells (Naisbitt et al. 2015). Indeed, 
when docked into HLA-B*57:01 following the same procedure no such clashes were apparent 
between the cyclopropyl group of abacavir and the HLA-binding peptide or amino acid 
residues. This was also true for analogue 17 (propyl) which displayed clear activation of 
abacavir T-cell clones (Naisbitt et al. 2015). This study not only established the potential for 
generation of structural analogues of abacavir which can maintain antiviral activity and be 
deficient in the unwanted T-cell responses, but also gave a greater insight into the HLA-
B*57:01 binding characteristics of the compounds and the relationship between HLA-
B*57:01 binding and the activation of T-cells. 
Using this concept, another fourteen abacavir analogues were synthesised with further 
modifications to the 6-amino cyclopropyl moiety. These analogues were constructed around 
the azetidine ring group which has previously been demonstrated to maintain a favourable 
antiviral profile similar to abacavir (Daluge et al., 1997). These compounds were synthesised 
firstly to be examined as potential replacements for abacavir in a therapeutic setting based 
on their respective antiviral activity and T-cell activation profiles. Secondarily, these 
compounds were also utilized as molecular probes to explore the binding characteristics 
within HLA-B*57:01. Furthermore, peptide elution studies were carried out to investigate 
the effect of the 6-amino cyclopropyl group substitutions on the observed repertoire of 
peptides, given the obvious alterations seen with abacavir (Illing et al. 2012).   
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Using these procedures, we have developed a paradigm for the generation of safer antiviral 
agents by gaining a greater understanding into the interactions of compounds within HLA-
B*57:01 and its relationship with the repertoire of self-peptides presented on the surface of 
the antigen presenting cells for recognition by T-cells (Figure 3.2).  
 
Figure 3.2. Experimental design and structure of abacavir substituted analogues.  
Schematic representation of experimental procedure for design and use of abacavir 
analogues as molecular probes for greater understanding of the interactions within 
HLA-B*57:01. 
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3.2. Aims.  
 
In this chapter we aimed to develop a new series of abacavir analogues constructed around 
cyclic amine derivatives, namely the azetidine ring structure. These analogues were screened 
to investigate their T-cell activation capabilities, as well as their antiviral potency and safety 
profiles. Once a select number of promising analogues were identified, their interactions 
within HLA-B*57:01 was further examined via molecular modelling. Furthermore, the effect 
of these compounds on the repertoire of peptides presented to T-cells by HLA-B*57:01 was 
examined and compared to the peptide repertoires in untreated and abacavir treated cells. 
Finally, the safety of these promising analogues was confirmed via the generation of T-cell 
clones specific to the respective abacavir substituted analogues. Taken together, the studies 
in this chapter will help develop a tool for providing a greater understanding into the 
relationship between the T-cell activation profile and the binding interactions of the 
compounds within HLA-B*57:01. 
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3.3. Methods 
 
3.3.1. Materials 
 
Abacavir was received as a gift from GlaxoSmithKline (GSK). Human AB serum and foetal 
bovine serum (FBS) were obtained from Innovative Research (Michigan, USA) and Invitrogen 
(Paisley, UK), respectively. Interleukin-2 (IL-2) was purchased from Peprotech (London, UK). 
Multisort bead separation kits were supplied by Miltenyi Biotec (Surrey, UK). Antibodies for 
staining were purchased from BD Biosciences (Oxford, UK). ELIspot kits including the coating 
and detection antibodies, streptavidin alkaline phosphate conjugate and BCIP/NBT 
substrates were purchased from Mabtech (Stockholm, Sweden). Other reagents were 
purchased from Sigma-Aldrich (Dorset, UK) unless otherwise stated. 
3.3.2. Synthesis of abacavir substituted analogues 
 
The initial part of the project involved the synthesis of a stock sample of key intermediate 1 
(Figure 3.3.). Compound 1 (150.00 mg, 564.55 µmol, 1.00 eq), azetidine (2.00 eq) and N, N-
diisopropylethylamine (145.92 mg, 1.13 mmol, 2.00 eq) were taken up into a microwave tube 
in isopropyl alcohol (2.00 mL). The sealed tube was heated at 70 °C for 2 hours under 
microwave.  LCMS showed that the starting material was consumed completely. The mixture 
was concentrated in vacuum to yield the crude product. The crude product was then purified 
by prep TLC purification to yield the respective analogues as described in detail in Appendix 
section 1. Analogue synthesis was performed by Professor Paul O’Neill (Department of 
Chemistry at the University of Liverpool).  
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Figure 3.3. Abacavir analogues. a) Generalized procedure for the synthesis of the abacavir 
analogues A-N. b) Structure of abacavir with the 6-amino cyclopropyl functional group replaced 
with R. c) Functional groups of the abacavir analogues A-N and X. 
a) 
b) 
c) 
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3.3.3. Cell culture media. 
 
Cell culture medium for T-cells (R9) is composed of RPMI supplemented with 10% human AB 
serum, HEPES (25mM), penicillin (1000 U/mL), streptomycin (0.1mg/mL), L-glutamine (2mM) 
and transferrin (25µg/mL).   
EBV transformed B-cells were cultured in F1 medium composed of RPMI supplemented with 
10% foetal bovine serum, HEPES (25mM), penicillin (1000 U/mL), streptomycin (0.1mg/mL) 
and L-glutamine (2mM). 
3.3.4. Generation of abacavir-specific T-cell clones 
 
CD8+ T-cell cloning was carried out as described in detail in section 2.3.5. Briefly; PBMCs from 
HLA-B*57:01 positive donors were selected from an established HLA-typed healthy donor 
cohort. PBMCs from each donor were incubated in the presence of abacavir (35µM) in R9 
medium for a period of 14 days. On days 6 and 9 cells were fed with cell culture medium 
containing IL-2 (2µL/mL) to preserve the abacavir driven expansion of T-cells. On day 14, 
CD8+ T-cells were positively selected using MultiSort kits (Miltenyi Biotec, Surrey UK) and T-
cell clones were generated via serial dilution. CD8+ T-cells were seeded at a concentration of 
0.3/1/3 cells/ well (96 well U-bottomed plate) and stimulated with allogeneic PBMC feeder 
cells and PHA (5µg/mL) in R9 medium containing IL-2 (2µL/mL). Cells were fed every 2 days 
with R9 medium containing IL-2 (2µL/mL) and well growing clones were transferred to a new 
96 well plate and expanded across 4 wells. On day 14 clones were restimulated and further 
expanded for 28 days.  
3.3.5. Testing for drug antigen specificity 
 
Approximately four weeks after beginning the serial dilutions, abacavir-specificity was 
measured by assessing cell proliferation in the presence of the drug. Abacavir-induced 
                                                                                                       Chapter 3 
 
118 
 
proliferation was measured by culturing T-cell clones (5x104/50µL) with irradiated 
autologous EBVs (1x104/50µL) and abacavir (35µM) (total volume 200µL/96 well U-
bottomed plate). Following 48 hour incubation, tritiated thymidine (0.5µCi) was added to 
each well and proliferation was assessed 16 hours later via scintillation counting. The 
proliferative response of the T-cell clones was expressed as radioactive counts per minute 
(cpm). T-cell clones with a proliferative stimulation index (SI) of 2 or greater were picked and 
expanded by mitogen driven restimulation in R9 medium containing irradiated PBMCs (5x105 
cells/well), IL-2 (5µL/mL) and PHA (10µg/mL) for further analysis. 
The antigen specificity of the abacavir-responsive T-cell clones were confirmed by analysing 
IFN-γ secretion in response to abacavir using the ELIspot assay described in detail in section 
2.3.7. All clones displaying a significant increase in IFN-γ secretion in response to abacavir 
were maintained in cell culture for use in further experiments.  
3.3.6. Antiviral activity and cytotoxicity of abacavir analogues. 
 
3.3.6.1. Antiviral activity 
 
Human T-cell lymphotropic virus-I carrying human cell line (MT-4) cells are a human cell line 
with high sensitivity to the HIV-1 virus, making them ideal candidates for the analysis of 
antiviral activity (Gyuris et al. 1992). 
MT-4 cells were co-incubated with HIV-1 IIIB cells for a period of 1 hour. Following this 
incubation period, the infected cells were seeded in a 96 well plate containing serially diluted 
compounds (highest concentration 500µM; 8 concentrations, 4 fold serial dilutions in 
duplicate) and incubated for a period of 5 days with virus and cell controls as a comparator. 
Following incubation, cell viability was measured via luminescence using CellTiter-Glo 
reagent. The antiviral activity of the compounds was measured based on the protection of 
virus induced cytopathic effect at each concentration normalised by the virus control. 
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The antiviral activity of a compound was calculated as shown below: 
Activity (%) = (Raw datacompound-AverageVirus Control)/( AverageCell Control -AverageVirus Control)*100 
EC50 values were calculated according to dose response curves generated using GraphPad 
Prism software version 5.01. These experiments were conducted by the WuXi App Tech 
company in Shanghai. 
3.3.6.2. Cytotoxicity 
 
The cytotoxicity of the analogues was assessed using the same parameters as described in 
the antiviral testing, excluding the virus control.  
The compounds cellular toxicity was calculated as shown below: 
Viability (%) = (Raw datacompound)/( AverageCell Control)*100. 
CC50 values were calculated according to dose response curves generated using GraphPad 
Prism software version 5.01. 
3.3.7. Inhibition of T-cell and B-cell proliferation with abacavir analogues. 
 
To ascertain the direct effect of the analogues on cellular proliferation, the analogues and 
abacavir were cultured in the presence of EBV transformed B-cells or PBMCs at 
concentrations of 0-250µM. In the case of B-cells, the analogues were co-incubated for a 
period of 48 hours then tritiated thymidine was added directly to the cells for a further 16 
hours. Cells were then harvested onto a printed filter mat and radioactive incorporation was 
assessed via scintillation counting on a microBeta counter. In the case of PBMCs, cells were 
co-incubated with the compounds for a period of 72 hours before PHA (10µg/mL) was added 
to promote the proliferation of viable cells. Following a further 24-hour incubation, tritiated 
thymidine was added directly onto the cells for a further period of 16 hours. Cells were then 
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harvested and radioactive incorporation was measured as described above. IC50 values were 
calculated using SigmaPlot software 13.0. 
3.3.8. CD8+ T-cell activity of abacavir analogues 
 
To measure the effect of modifying the 6-amino cyclpropyl group of abacavir with regards to 
the activation of abacavir-specific T-cells, T-cell clones (5x104/50µL) were incubated with 
autologous EBVs (1x104/50µL) in the presence or absence of the abacavir analogues (10, 20, 
50µM) (total volume 200µL/96 well U-bottomed plate) for a period of 48 hours and IFN-γ 
secretion was assessed via ELIspot (described in detail in section 2.3.7). Abacavir was used 
as a positive control. The HLA-B*57:01 mediated CD8+ T-cell responses to the abacavir 
analogues was tested in six abacavir-responsive T-cell clones from four healthy drug naïve 
donors expressing the HLA-B*57:01 risk allele.  
3.3.9. HLA-B*57:01 molecular modelling 
 
Molecular modelling was carried out under the supervision of Dr Neil Berry in the 
Department of Chemistry at the University of Liverpool. Ligands were prepared for docking 
in Spartan’08 (wavefunction inc. Irvine, California, USA: 1991-2009). A native SMA ligand was 
exported from the protein data bank (PDB), code 3UPR (Ostrov et al. 2012). For each 
analogue, the cyclopropyl group of abacavir was replaced. Merk molecular force field 
minimization calculations were performed with all atoms frozen except newly added 
substitutions. For docking studies GOLD 5.1 (CCDC Software Limited, Cambridge, UK) was 
used to examine the potential binding poses of the abacavir analogues within the F-pocket 
of HLA-B*57:01. Figures of abacavir analogue binding conformations within HLA-B*57:01 
were produced using PYMOL software version 2.5.  
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3.3.10. MHC purification and peptide elution 
 
CIR.B*57:01 cells (Chessman et al. 2008) were grown to high confluency in the presence or 
absence of 35µM abacavir/analogue for a minimum of 4 days, prior to washing in PBS, 
pelleting and snap freezing in liquid nitrogen. Cell pellets of 4-5x108 cells were lysed by 
mechanical and detergent based lysis, the lysates cleared by ultracentrifugation, and MHC 
class I complexes isolated by immunoaffinity purification using solid-phase bound pan class 
I antibody w632 as described previously (Dudek et al. 2012). Complexes were dissociated 
using 10 % acetic acid and fractionated by Reversed Phase High Performance Liquid 
Chromatography (RP-HPLC) on a 4.6mm internal diameter x 100mm monolithic reversed-
phase C18 HPLC column (Chromolith SpeedROD; Merck Millipore) using an ÄKTAmicro HPLC 
(GE Healthcare) system. Peptides were loaded at 1mL/min onto the column in 98% Buffer A 
(0.1% trifluoroacetic acid) and 2% Buffer B (80% acetonitrile, 0.1% trifluoroacetic acid), and 
bound material eluted by running a gradient of buffer B at 2ml/min of 2-15% over 0.25 
minutes, 15-30% over 4 minutes, 30-40% over 8 minutes, 40-45% buffer B over 10 min, with 
collection of 500µL fractions. Fractions were vacuum concentrated and reconsti tuted in 0.1% 
formic acid. 
3.3.11. MS analysis 
 
Reconstituted fractions were analysed by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) via a data dependent acquisition strategy using a NanoUltra 
cHiPLC system (Eksigent) coupled to an SCIEX 5600+ TripleTOF mass spectrometer equipped 
with a Nanospray III ion source. Samples were loaded onto a pre-equilibrated cHiPLC trap 
column (3 µm, ChromXP C18CL, 120 Å, 0.5 mm x 200 µm), at 5µL/min in 0.1% formic acid, 
2% acetonitrile, and separated over a cHiPLC column (3 µm, ChromXP C18CL, 120 Å, 15 cm x 
75 µm) using a linear gradient of 2-35% Buffer B (80% acetonitrile, 0.1% formic acid)/Buffer 
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A(0.1% formic acid) over 75 minutes at a flow rate of 300nL/min. Data acquisition occurred 
with the following instrument parameters: ion spray voltage, 2,400 V; curtain gas, 30 l/min; 
ion source gas, 20 l/min; and interface heater temperature, 150 °C. MS/MS switch criteria 
selected the top 20 ions meeting the following criteria per cycle: m/z >200 amu, charge state 
of +2 to +5, intensity >40 counts per second. After two selections for fragmentation, ions 
were ignored for 30 seconds. For assignment MS/MS spectra were searched against the 
human proteome (UniProt/Swiss-Prot v2016_04) using ProteinPilot software (version 5.0, 
SCIEX). Peptide elution studies and analysis via mass spectrometry were carried out by Dr 
Patricia Illing in the Department of Biochemistry and Molecular Biology at Monash University 
in Melbourne Australia. 
3.3.12. Generation of CD8+ T-cell clones to a panel of abacavir substituted analogues 
 
Cloning to abacavir 6-amino substituted analogues was carried out using the same method 
described in section 3.3.4 for abacavir, with PBMCs being primed to respective analogues G, 
H, J and X with these compounds being used for first testing in place of abacavir. These 
compounds were selected based on their respective inductions of IFN-γ secretion in 
abacavir-responsive T-cell clones, with G and X representing non-activating analogues and H 
and J comprising activating analogues. 
3.3.13. Confirmation of antigen specificity and cross reactivity of CD8+ T-cell clones to 
abacavir analogues 
 
Clones specific to abacavir analogues were tested for IFN-γ secretion using ELIspot assay. 
Briefly; T-cell clones (5x104/well) along with autologous EBVs (1x104/well) were incubated in 
the presence or absence of respective analogues (35µM) with cell culture medium as a 
negative control for 48 hours (37OC; 5% CO2). Abacavir (35µM) was used to assess cross-
reactivity of T-cell clones and PHA (10µg/mL) was used as a positive control where required. 
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3.3.14. Statistical Analysis 
 
For comparison between control and test values in proliferation assays the Mann-Whitney 
test was used. Two-way ANOVA was used for comparison between abacavir and the 
analogue values.  
3.4. Results. 
3.4.1. Synthesis of abacavir analogues. 
 
Fourteen abacavir substituted analogues were synthesised in good yields and high analytical 
purity for both pharmacological and immunological experiments. NMR, LCMS and accurate 
mass and yield values are described in appendix section 2. Azetidine substituted analogues 
were classified by letters A-N. The isopropyl substituted analogue (Naisbitt et al. 2015) was 
reclassified as analogue X to be used as a comparator in assays. The relative structures are 
shown in Figure 3.3. 
3.4.2. Generation of abacavir-specific CD8+ T-cell clones 
 
T-cell clones specific to abacavir were generated using serial dilution assays. From a total of 
2279 clones tested across four HLA-B*57:01 positive donors, 101 were found to proliferate 
in the presence of abacavir on first testing, (Control , 1665 ± 188.5 cpm: abacavir 35µM, 6940 
± 729 cpm; P< 0.0001) (Section 2.4.1).  
Due to receiving the fourteen abacavir analogues in batches, at different times, a total of 15 
abacavir clones from the four HLA-B*57:01 positive donors were used. T-cell clones possess 
limited life in cell culture, often present issues when thawed and can lose antigen specificity 
over time, meaning a broad range of abacavir-responsive T-cell clones were used. Each 
analogue was tested to a total of six abacavir clones across the four healthy, drug naïve 
donors expressing HLA-B*57:01. All clones responsive in second test were phenotyped as 
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CD8+ (Section 2.4.3). The abacavir-responsive T-cell clones used for assays in this chapter are 
displayed in Table 3.1 with their corresponding donor. Results for T-cell specificity assays of 
these abacavir clones and subsequent phenotyping data is discussed in detail in section 2.4.  
 
 3.4.3. Antiviral activity of 6-amino substituted abacavir analogues 
 
The antiviral activity of the fourteen abacavir analogues was ascertained using cell viability 
assays carried out by the WuXi App Tech company in Shanghai. The antiviral activity of the 
analogues was measured on the basis that HIV kills MT-4 cells, thereby cellular survival was 
an indication of antiviral activity, presented as EC50. The cytotoxicity of the analogues in MT-
4 cells was also determined using the same process but without viral infection of the MT-4 
cells prior to incubation with the analogues, cytotoxicity values are presented as CC50.   
Consistent with previous findings, abacavir demonstrated potent antiviral properties (EC50 
2.05µM) and a relatively favourable cytotoxicity profile (CC50 42.4µM). Across the fourteen 
abacavir substituted analogues a diverse range of antiviral potency was observed with some 
analogues possessing antiviral potency to a similar degree as abacavir (D and H), while others 
* Clones generated to abacavir + natural  peptide 15, these clones demonstrated a strong response to abacavir 
and were incorporated into T-cell analogue assays. Second test data and phenotyping for these clones is found 
in chapter 5. 
 
Table 3.1 Panel of abacavir-responsive T-cell clones used for assays in this chapter 
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displayed no antiviral activity within the range of concentrations used ( E, F, I and N). 
Replacement of the cyclopropyl moiety of abacavir with an azetidine ring (D) maintains the 
antiviral profile of the compound (EC50 2.979µM). Furthermore, the addition of a fluoro 
group to the azetidine ring at the 3-position of the ring (H) retains the antiviral activity of the 
compound (EC50 2.456µM).  Also, both analogues D and H possessed more favourable 
cytotoxicity in MT-4 cells than abacavir. Antiviral activity (EC50), cytotoxicity (CC50) and SI 
(CC50/EC50) are presented in Table 3.2. Compounds with no antiviral activity or cytotoxcity 
are presented as >500µM.  
 
 
Compound 
ID 
Unit Antiviral activity 
(EC50) 
Cytotoxicity 
(CC50) 
SI 
(CC50/EC50) 
Abacavir µM 2.05 42.44 20.7 
Analogue A µM 16.68 >500 >29.98 
Analogue B µM 59.09 >500 >8.46 
Analogue C µM 30.08 263.2 8.75 
Analogue D µM 2.979 160 53.71 
Analogue E µM  >500                 >500 ND 
Analogue F µM >500 >500 ND 
Analogue G µM 38.55 >500 >12.97 
Analogue H µM 2.456 234.3 95.4 
Analogue I µM >500 >500 ND 
Analogue J µM 85.76 >500 >5.83 
Analogue K µM 33.59 467.7 13.92 
Analogue L µM 411.4 >500 >1.21 
Analogue M µM 33.67 343 ND 
Analogue N µM >500 >500 18.14 
Table 3.2. Antiviral activity and cytotoxicity values for 14 abacavir analogues (A-N) with abacavir as 
a comparator. Antiviral activity and cytotoxicity was measured in MT-4 cells and values are presented 
as EC50 and CC50 respectively.  
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3.4.4. Inhibition of T-cell and B-cell proliferation by abacavir and the abacavir 
substituted analogues. 
 
To assess cytotoxic profiles, abacavir and the fourteen substituted analogues were incubated 
with PBMCs and EBV transformed B-cells at concentrations of 0, 10, 25, 50, 75, 100 and 
250µM for periods of 72 and 48 hours, respectively. Proliferation was measured using 3H 
thymidine incorporation. Abacavir (PBMC 66.7µM IC50 EBV 102.3µM) inhibited proliferation 
of both T-cells and B-cells in a concentration dependent manner (Figure 3.5). Similar IC50 
values were found for analogues D (PBMC 61µM; EBV 220µM) and H (PBMC 71µM; EBV 
175µM) while all other analogues suppressed proliferation of T-cells and B-cells at much 
higher concentrations, with many failing to generate 50% inhibition of proliferation within 
the range of concentrations used (I, L and N).  
 
 
 
 
 
 
 
 
 
 
 
Table 3.3. Inhibition of T-cell and B-cell proliferation in PBMC’s and EBV transformed B-
cells respectively. Inhibition presented as IC50 in µM calculated using non-linear 
regression. Analogues which failed to react 50% inhibition within concentration range 
used presented as >250. 
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Figure 3.5. Inhibition of T-cell and B-cell proliferation in PBMC’s and EBV transformed B-cells respectively. 
Graphical representation of inhibition of a) PBMC proliferation and b) B-cell  proliferation in the presence of 
abacavir (ABC) and analogues A-N at concentrations of 0-250µM. 
a) 
b) 
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3.4.5. CD8+ T-cell activity of abacavir analogues. 
 
All abacavir substituted analogues (A-N) contained azetidine linked groups in place of the 6-
amino cyclopropyl moiety while analogue X (isopropyl amino) from a previous series of 
analogues (Naisbitt et al. 2015) was also incorporated into this assay as a comparator. To 
assess the effect of these substitutions on CD8+ T-cell activity, six abacavir clones from four 
HLA-B*57:01 positive donors were co-incubated with autologous APCs in the presence of 
these fifteen abacavir analogues for 48 hours. Little to no T-cell proliferation was observed 
in abacavir-specific clones co-incubated with ten of the substituted analogues. Slight 
activation was detected with analogue D at 50µM, with only analogue J inducing significant 
T-cell proliferation within the concentration range studied (Figure 3.6).  
 
 
Figure 3.6. T-cell  proliferation induced by co-incubation with abacavir analogues at 
concentrations of 10, 20 and 50µM. Abacavir (black) was used at the same concentrations as a 
comparator.  
                                                                                                       Chapter 3 
 
129 
 
Based on these findings, IFN-γ ELIspot was used to measure T-cell responses in abacavir 
clones due to its enhanced sensitivity over proliferation.  A varied response was observed 
across all fifteen abacavir analogues. The first five analogues (A-E), with the exception of B 
(azetidine methyl 3-ol) and E (azetidine isopropyl), evoked T-cell responses in the clones to 
some degree.  
The second five analogues (F-J) demonstrated a reduced T-cell activation profile in the T-cell 
clones compared to abacavir, except for analogue J (azetidine methoxy). Limited T-cell 
activity was observed in analogues F, G and I while J displayed a strong activation profile in 
the abacavir clones which was similar to the IFN-γ secretion levels observed for abacavir 
itself. Interestingly, analogue H (azetidine fluoro) induced no T-cell activity at concentrations 
of 10 and 20µM, however the higher concentration of 50µM resulted in a strong CD8+ T-cell 
response (Figure 3.7).  
Analogue K (cyclopropyl-fluoro azetidine) activated some T-cell clones while analogues L-N 
completely lacked any T-cell activity in all abacavir-responsive T-cell clones. In concordance 
with findings from Naisbitt et al 2015, analogue X, again did not evoke T-cell activation in all 
abacavir-specific CD8+ T-cell clones. 
Based on their respective structures, antiviral activity and T-cell activation profiles, these 
findings presented analogues D, G, H, J, M and X as candidates to take forward for further 
experiments. Analogues D and J represent the compounds with strong potential to induce 
cross-reactivity with abacavir-responsive T-cell clones, while M and X comprised those with 
no ability to activate abacavir specific T-cell clones. Analogue H was selected for further 
analysis based on the fact that T-cells were only activated by this analogue at higher 
concentrations. 
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Analogue X 
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3.4.6. Molecular modelling of abacavir analogues within HLA-B*57:01. 
 
We sought to assess the binding characteristics of the selected abacavi r analogues within the 
F-pocket of HLA-B*57:01 and this relationship with T-cell activation.  A molecular docking 
protocol was developed which replicated the crystal structure of the binding conformation 
of abacavir within the F-pocket of HLA-B*57:01. Using this protocol, the binding orientations 
of the analogues D, G, H, M and X were predicted within the F-pocket. Analogues were 
expected to bind in a similar fashion to abacavir with the cyclopurine moiety of the 
compound forming hydrogen bonds with the amino acid residues Asp-114, Ser-116 and Ile-
124. The conserved binding structure of abacavir suggests that modifications to the 
cyclopropyl moiety may produce steric clashes between the functional group of the 
compound and the HLA binding peptide, and in some cases residues of HLA-B*57:01.  
The binding pose employed by abacavir displays no overlapping in the atomic radii of the 
cyclopropyl group and that of the HLA-binding peptide, nor the Tyr-123 residue of HLA-
B*57:01. Clear protrusion of the cyclopropyl moiety of abacavir deep into the F-pocket region 
Figure 3.7. CD8
+
 T-cell activity of abacavir analogues. a) Mean IFN-γ secretion from six abacavir-
responsive T-cell clones incubated in the presence of the 14 abacavir analogues (solid l ine)  at 
concentrations of 0, 10, 20 and 50µM. Analogue X from Naisbitt et al was also tested against the six 
clones as a comparator. The mean abacavir response across six clones (dotted line) was used as a 
comparator. Comparison of abacavir and analogue values were analysed using Two Way ANOVA, * 
P<0.05, ** P<0.01, *** P<0.001. b) Eli-spot well images from 1 representative abacavir clone incubated 
in the presence of abacavir analogues A-N, analogue X and abacavir (ABC) as a comparator. 
X 
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is observed with no apparent steric clashes between the functional group and the HLA -
binding peptide, nor with residues within the F-pocket (Figure 3.8). This indicates a 
favourable binding pose of abacavir within HLA-B*57:01 to allow for strong interactions to 
induce a conformational change in the F-pocket that will result in the accommodation of 
altered self-peptides to be presented to T-cells. However, despite binding HLA-B*57:01 in a 
similar conformation to abacavir, the isopropyl functional group analogue X produces steric 
clashes with the Val-9 residue of the HLA-binding peptide as well as the Tyr-123 residue of 
HLA-B*57:01. This is demonstrated by the overlapping atomic radii of analogue X’s functional 
group and amino acid residues. The prevalence of such clashes demonstrates a hindrance in 
the binding of the compound within HLA-B*57:01, resulting in a lack of T-cell activity in 
abacavir clones (Figure 3.8). 
Analogues D and H, with the ability to induce T-cell activity, assume a favourable binding 
orientation within HLA-B*57:01 indicated by the absence of clashes between the respective 
functional groups and the amino acid residues of the peptide or within HLA -B*57:01. 
Analogue D in particular adopts a binding conformation very similar to that of abacavir, 
unsurprisingly eliciting T-cell activation (Figure 3.8). Analogue H however, binds within HLA-
B*57:01 in an altered manner to abacavir and analogue D with the guanosine portion of the 
compound inverted, suggesting this analogue to bind in an unconventional manner, which 
may explain why T-cells were activated by this analogue only at the higher concentrations.  
Conversely, the addition of a nitrile group at the 3-position of the azetidine ring (G), 
eradicated all T-cell responses observed in the ELIspot assay. When docked into HLA-B*57:01 
again a non-conventional binding conformation was observed, which, unlike with H, resulted 
in the presence of steric clashes between the azetidine ring and the Val -9 residue of the HLA-
binding peptide. Similarly, analogue M did not activate abacavir-specific T-cells in the ELIspot 
assay, while adopting a binding orientation in HLA-B*57:01 which resulted in the clashing 
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between the branched fluoride functional group and residues on the HLA-binding peptide 
(Figure 3.8). This is unsurprising based on previous results with branched chain functional 
groups within HLA-B*57:01. Collectively these data suggest that the binding conformations 
adopted by analogues which are known to evoke a T-cell response yield no unfavourable 
clashes within the peptide binding groove thereby allowing for the accommodation of 
altered self-peptides not observed in the absence of abacavir. The presence of such 
unfavourable steric clashes between the functional groups of the non-activating abacavir 
analogues and pep-V suggest that the binding of these analogues would hinder the 
presentation of this peptide. This would likely result in the presentation of other peptides or 
this peptide in an altered conformation. Both of these situations would yield the 
presentation of peptides distinct from those observed in the presence of abacavir, which 
may lead to the loss of cross-reactivity with abacavir-specific CD8+ T-cell clones.  
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Figure 3.8. Direct comparison of the CD8
+
 T-cell activity of abacavir substituted analogues and the 
binding orientations within the F-pocket of HLA-B*57:01. a) Crystal structure of HLA-B*57:01  
(PDB:3UPR) represented with the peptide, abacavir and analogue X coloured as pink, cyan and blue 
sticks respectively. i) Crystal structure binding orientation of abacavir. Stick representation of the 
peptide, pep-v (HSITYLLPV) shown in pink with the chemical structure of abacavir in cyan. Key amino 
acid residues which bind abacavir are shown as yellow sticks. All  non-polar hydrogen atoms removed. 
Key hydrogen bond interactions shown as black das hes. Spheres used to i l lustrate the atomic radii of 
the atoms in the cyclopropyl group of abacavir, peptide molecule and Tyr -123 amino acid. i i) Docking 
solution of analogue X (isopropyl) in the F-pocket of HLA-B*57:01. b) Docking solution of analogues i) 
D (azetidine), i i) G (azetidine-3-carbonitrile), i i i) H (azetidine-fluoro) and iv) M (azetidine-
trifluoromethyl) in the F-pocket of HLA-B*57:01. Stick representation of the peptide, pep-v (HSITYLLPV) 
shown in pink. Amino acid protein residues shown as yell ow sticks, with key hydrogen bond 
interactions shown as black dashes. All  non-polar hydrogen atoms removed. Spheres used to i l lustrate 
the atomic radii of the atoms in the functional group of the analogue, peptide and Tyr -123 amino acids. 
c) Representative ELIspot images from wells containing abacavir and analogues D, G, H, M and X.  
c) 
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3.4.7. Peptide elution from HLA-B*57:01 expressing APCs in the presence of a panel of 
abacavir analogues. 
 
To investigate the effect of the abacavir analogues on the peptide repertoire presented by 
HLA-B*57:01 to T-cells, peptide elution studies were carried out on C1R.B*57:01 cells 
incubated in the presence and absence of abacavir (35µM) or the abacavir analogues 
(35µM). Reconstituted peptide fractions were analysed by l iquid chromatography-tandem 
mass spectrometry (LC-MS/MS). Peptide fractions analysed from C1R.B*57:01 cells 
incubated with abacavir demonstrated a strong shift toward the prevalence of peptides 
containing the smaller chain amino acids, isoleucine and valine, at the P9 position.  Initially 
all peptides eluted from HLA-B*57:01 were analysed in the presence of the four substituted 
abacavir analogues (D, H, M and X) and the shift in prevalence of individual amino acids was 
compared to untreated and abacavir treated cells. Incubation with abacavir results in the 
significant enrichment of isoleucine and leucine at the C-terminal of the peptides. 
Furthermore, at the Ω-2 position a significant decrease in prevalence of arginine and lysine 
was observed. Both these amino acids are known to stabilise the interactions of the peptide 
with the Asp-114 amino acid, which in this case is blocked by the binding of abacavir. When 
analysed at the global level, taking all peptides into consideration, no apparent shift was 
observed in the prevalence of the smaller amino acids when cells were incubated with the 
abacavir analogues. We next analysed if any shift in amino acid prevalence was evident if 
peptides that were eluted in the absence of abacavir (untreated) were filtered out and 
removed from consideration. Upon removal of these peptides, a broad shift in some amino 
acids was observed in the presence of some of the analogues. In the presence of analogue 
X, an increase in 9-12 mer ligands terminating in amino acids methionine and alanine was 
observed, while little to no prevalence of amino acids isoleucine, leucine or valine was 
detected. Similarly, analogue M produced no apparent shift in the prevalence of the small 
chain amino acids at the C-terminal, displaying an overall similarity with the constitutive 
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ligands at the C-terminal position (untreated) (Figure 3.9). Conversely, the T-cell stimulating 
abacavir analogue D, when analysed in the absence of peptides prevalent in untreated cells, 
yielded an augmentation of isoleucine at the C-terminal of the peptide, although to a lesser 
extent than what was observed in abacavir treated cells along with increase in prevalence of 
methionine. Again, reduction of the amino acids arginine and lysine was observed at the Ω-
2 position indicating analogue D to possess a similar binding profile within HLA-B*57:01 to 
abacavir. Incubation with analogue H also generated an increase in the prevalence of C-
terminal isoleucine (Figure 3.9). Similar enrichment of isoleucine and methionine was 
observed in cells incubated with analogue H with the increase in isoleucine being less than 
the observed prevalence in the presence of abacavir, which may explain why analogue H only 
activated abacavir clones at higher concentrations. Indeed, the peptides eluted from HLA-
B*57:01 in the presence of analogues D and H demonstrate significant overlap with peptides 
detected in the presence of abacavir (Figure 3.9).  
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Figure 3.9. Comparison of amino acid prevalence in peptides eluted from HLA-B*57:01 in the presence of 
abacavir and analogues D, G, H, M and X .a) Length (i) and primary anchor characteristics (ii. Position 2, iii. 
C-terminal) of HLA-B*57:01 ligands isolated from CIR.B*57:01 grown in the absence of drug treatment, or in 
the presence of 35μM Abacavir (black) or analogues X (red), D (green), H (orange) or M (blue). Analyses are 
based on non-redundant peptide identifications (by sequence, modifications not considered) per data set 
made at a confidence greater than that for a 5% false discovery rate (FDR) and fi ltered for l igands of 
endogenous HLA molecules of parental CIR cells. Anchor residue preferences are shown for 9mers and are 
depicted as the proportion of peptides that possess specific amino acids at position 2 ( ii) and the C-terminus 
(iii). Data shown is the mean (+/- SD) of triplicate experiments for untreated and abacavir treated cells, 
duplicate experiments for analogue X, and single experiments for the remaining analogues. b) IceLogo for 
P1 to P3 and PΩ-2 to PΩ of 9-12mer peptides in the constitutive repertoire of HLA-B*57:01. c) Enrichment 
logo for 9-12mer HLA-B*57:01 ligands detected in the presence of abacavir in this study either i. unfiltered 
or ii. fi ltered for constitutive l igands (i.e. potential neo-epitopes). d), e), f) and g) show i. Icelogos for 9-
12mer HLA-B*57:01 ligands detected in the presence of analogues X, D, H and M, ii. Venn diagrams showing 
the numbers of potential neo-epitopes identified in both abacavir and analogue treatments and ii i . IceLogos 
for 9-12mer neo-epitopes identified. IceLogos were generated using Icelogo software (Colaert, N. et al. 
Nature Methods 6, 786-787 (2009)) util ising the human swiss -prot proteome as the reference set. Letter  
height corresponds to % difference in frequency of the amino acid compared to presence in the human 
proteome. 
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3.4.8. Generation of responsive CD8+ T-cell clones to a selection of abacavir analogues. 
3.4.8.1. Analogue G 
 
From a total of 568 clones tested to analogue G across 2 donors, 5 responsive clones were 
generated. As previously mentioned all clones generated from serial dilutions, following 
mitogen restimulation for a two-week period, were subjected to a second test by means of 
IFN-γ ELIspot to confirm their specificity to the drug in question. Clones generated to the 
analogues were tested in this way to the respective analogue (35µM), abacavir (35µM) (to 
assess the cross reactivity of the clones) and PHA (10µg/mL) (used as a positive control). 
Across the two HLA-B*57:01 positive donors a very small number of clones proliferated in 
response to stimulation by analogue G. Five clones from each donor with the highest SI 
values, some of which were less than 2, were expanded for further te sting. All were 
phenotyped as CD8+ (Figure 3.10)  
No T-cell clones to analogue G produced significant IFN-γ secretion in response to co-
incubation with analogue G or abacavir. However, IFN-γ secretion was observed in clones 
stimulated with the positive control PHA, indicating the ability to secrete the 
proinflammatory cytokine, but not in response to abacavir or analogue G. These results were 
consistent across both donors tested (Figure 3.10). 
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3.4.8.2. Analogue H 
 
From a total of 514 clones to analogue H across 2 healthy HLA-B*57:01 drug naïve donors, 
24 responsive clones proliferated in the presence of analogue H on first testing (Control, 
1926 ± 451.4 cpm: analogue H 35µM, 6094 ± 1216 cpm; P< 0.01). All clones were phenotyped 
as CD8+ (Figure 3.11). 
b) 
c) 
Figure 3.10. Generation of specific T-cell clones to analogue G from 2 healthy HLA-B*57:01 drug 
naïve donors. a) i) Table and ii) bar chart displaying number of responsive clones generated to 
analogue G from donors 1 and 4. b) Second testing of a panel of picked and expanded clones to 
analogue G incubated in the presence of abacavir (35µM) and analogue G (35µM). R9 medium and 
PHA (10µg/mL) were used as negative and positive controls respectively. c) Representative 
phenotyping of picked clones to analogue G (CD4-FITC/CD8-PE). 
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Figure 3.11. Generation of T-cell clones with specificity for analogue H from 2 HLA-B*57:01 
donors. a) i) Table and ii) bar chart displaying number of responsive clones generated to analogue 
H from donors 1 and 4. b) Comparison of mean cpm values  from all  responsive clones to Analogue 
H. Control (0), Analogue H (35µM). Mann Whitney test used for comparison between control and 
drug treated values. Data shown as mean of all  responsive clones vs control ± SEM *P<0.05, 
**P<0.01, *** P<0.001 
a) i) 
ii) 
b) 
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Responsive clones were generated to analogue H across both the HLA-B*57:01 donors that 
were capable of evoking a CD8+ T-cell response when incubated in the presence of the 
analogue. Furthermore, these clones also demonstrated a strong cross-reactivity profile 
when incubated in the presence of abacavir (Figures 3.12-3.13). Next, the ability of these 
clones to respond at concentrations lower than 50µM, the concentration at which abacavir 
clones responded to analogue H, was examined. All responsive clones to analogue H 
demonstrated a strong T-cell response to the analogue at concentrations 5-35µM. 
Furthermore, with the exception of clone 5, all clones specific to analogue H demonstrated 
strong cross reactivity with abacavir at low concentrations (Figure 3.12-3.13). Cross reactivity 
was detected at concentrations of abacavir as low as 5µM in some cases and displayed 
similar activation in a dose-dependent manner as observed with analogue H stimulation.  
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Figure 3.12. T-cell activity and cross reactivity of analogue H clones from donor 1. T-cell  
activation of clones specific to analogue H incubated in the presence of i) analogue H (5-35µM) 
and ii) abacavir (5-20µM). 
a) i) 
ii) 
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Figure 3.13. T-cell activity and cross reactivity of analogue H clones from donor 4 . T-cell  
activation of clones specific to analogue H incubated in the presence of i) analogue H (5-35µM) 
and ii) abacavir (5-20µM). 
Figure 3.14.  Representative phenotyping of responsive clones to analogue H from 
donors 1 and 4 (CD4-FITC/CD8-PE). 
Donor 1 Donor 4 
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3.4.9. Analogues X and J 
 
Due to the high number of responsive clones generated from each analogue a panel of 
representative clones from each donor were selected per analogue to undergo subsequent 
phenotyping and further experiments to test for antigen specificity.  
3.4.9.1. Analogue X 
 
From a total of 401 tested clones to analogue X across 2 healthy drug naïve donors expressing 
HLA-B*57:01, 99 were found to proliferate in the presence of the analogue on first testing, 
with some yielding SI values >50. (Control, 2824 ± 449.8 cpm: analogue X 35µM, 24050 ± 
2574 cpm; P< 0.0001) (Figure 3.15). 
A strong T-cell response was observed in clones generated from donor 1 incubated in the 
presence of analogue X. Cross reactivity to abacavir was also demonstrated (Figure 3.16). 
Clones generated from donor 4 presented a strong cross reactivity in the presence of 
abacavir; however, they only responded weakly to analogue X. T-cell activation was observed 
in differing magnitudes across the three responsive clones tested (Figure 3.16). All clones 
were phenotyped as CD8+ (Figure 3.17). 
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Figure 3.15. Generation of specific T-cell clones to analogue X from 2 HLA-B*57:01 donors. a) i) 
Table and ii) bar chart displaying number of responsive clones generated to analogue X from donors 
1 and 4. b) Comparison of mean cpm values  from all  responsive clones to analogue X. Control (0), 
Analogue X (35µM). Data shown as mean of all  responsive clones vs control ± SEM. Mann Whitney 
test used for comparison between control and drug treated values, *P<0.05, **P<0.01, *** P<0.001 
a) i) 
ii) 
b) 
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Figure 3.16. T-cell activity and cross reactivity of analogue X clones from donor 1 and 4. T-cell 
activation of clones specific to analogue X incubated in the presence of abacavir (35µM) and 
analogue X (35µM). 
Figure 3.17.  Representative phenotyping of picked clones to analogue X from donors 
1 and 4 (CD4-FITC/CD8-PE). 
Donor 1 
Donor 4 
Analogue X Clones 
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3.4.9.2. Analogue J 
 
From a total of 282 tested clones to analogue J across 2 healthy drug naïve donors positive 
for the HLA-B*57:01 allele, 95 proliferated in the presence of the analogue on first testing 
some yielding SI values >100 (Control, 1799 ± 150.9 cpm: analogue J 35µM, 24860 ± 2533 
cpm; P< 0.0001) (Figure 3.18). 
Clones generated to analogue J presented an enhanced T-cell response when re-challenged 
with the analogue, while also demonstrating strong cross reactivity properties with abacavir. 
These findings were consistent across the two donors, although again clones generated from 
donor 1 were more reactive than donor 4 (Figure 3.19). However, the difference in IFN-γ 
secretion was far more modest between donors with analogue J than what was observed 
with analogue X.  IFN-γ secretion from clones generated from donor 1 was immeasurable 
due to limitations with the ELIspot counting software and were assigned arbitrary values of 
1000 SFU. All clones were phenotyped as CD8+ (Figure 3.19).  
a) i) 
ii) 
a) 
i)   
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Figure 3.18. Generation of specific T-cell clones to analogue J from 2 HLA-B*57:01 donors. a) i) 
Table and ii) bar chart displaying number of responsive clones generated to analogue J from donors 
1 and 4. b) Comparison of mean cpm values  from all  responsive clones to analogue J. Control (0), 
analogue J (35µM). Data shown as mean of all  responsive clones vs control ± SEM Mann Whitney 
test used for comparison between control and drug treated values, *P<0.05, **P<0.01, *** P<0.001 
b)  
Donor 1 
Donor 4 
Figure 3.19. T-cell activity and cross reactivity of 
analogue J clones from donor 1 and 4. T-cell  
activation of clones specific to analogue J incubated 
in the presence of abacavir (35µM) and analogue J 
(35µM). b) Representative phenotyping of picked 
clones to analogue J from donors 1 and 4 (CD4-
FITC/CD8-PE). 
a)  
b) 
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3.5. Discussion 
 
Hypersensitivity reactions to abacavir take place in 4-8% of individuals receiving the drug as 
a component of antiretroviral therapy (Mallal et al. 2008). Genotyping studies are now 
commonly employed to screen individuals for the HLA-B*57:01 risk allele as a safety measure 
prior to the commencement of abacavir therapy, with those testing positive excluded from 
the regimen.  
The ability of abacavir to interact non-covalently within HLA-B*57:01 and induce a change in 
the repertoire of peptides displayed to T-cells on the surface of antigen presenting cells has 
been demonstrated (Ostrov et al. 2012; Illing et al. 2012; Norcross et al. 2012). Indeed, a 
distinct shift in the prevalence of peptides containing smaller amino acids including leucine, 
isoleucine and valine at the C-terminal of the peptide was discovered, while a marked 
reduction in the larger chain amino acids at the same position was also observed. Abacavir 
is thought to be responsible for this alteration in these self -peptides presented via its 
interactions within the F-pocket of HLA-B*57:01. These interactions induce a conformational 
change in the peptide binding groove via a reduction in the size of the F-pocket which 
accounts for accommodation of the smaller amino acids. It is also speculated that this 
alteration in the conformation of the peptide binding groove may still allow for the 
accommodation of peptides observed in the absence of abacavir, but in an altered 
conformation (Illing et al. 2013). As T-cells only display tolerance to the peptides which they 
are exposed to during their development in the thymus, exposure to these previously unseen 
peptides would be perceived as foreign epitopes and therefore initiate a CD8+ T-cell response 
(Illing et al. 2013; Illing et al. 2012).  Chessman et al., elegantly demonstrated the 
requirement for antigen processing and presentation pathways in abacavir-mediated CD8+ 
T-cell responses (Chessman et al. 2008), while the presence of another independent 
mechanism via direct interaction with the MHC T-cell receptor has also been reported (Bell 
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et al., 2013). Indeed, clones that utilise both mechanisms of T-cell activation were 
incorporated into this study. 
Here we investigated the possibility of generating safer alternative compounds to abacavir 
via the modification of the 6-amino cyclopropyl moiety, demonstrated to be imperative for 
the interaction within HLA-B*57:01 to alter the peptide repertoire. For this study fourteen 
abacavir analogues were synthesised around the azetidine ring group, a stable structure 
allowing for the construction of further substituted analogues (Figure 3.4.) (Daluge et al., 
1997; Faletto et al., 1997).   
Replacement of the cyclopropyl moiety with structural variants around the azetidine group 
revealed differential effects on both antiviral and T-cell activity of the compounds. 
Replacement with the azetidine ring alone, while having an equivalent antiviral potency to 
abacavir, resulted in the activation of CD8+ T-cells in all abacavir clones tested, while addition 
of a nitrile group at the 3-position of the azetidine ring was sufficient to abrogate the T-cell 
response. Similar to previous results the addition of branched chains again resulted in the 
loss of T-cell responses (Naisbitt et al. 2015), however this was only observed when added 
to the 3-position of the azetidine ring (B, F, I and M) not at the 1-position (A and C). 
Interestingly, the addition of a fluoride group at the 3-position of the azetidine ring (H) 
resulted in a T-cell response in abacavir-specific clones only at the higher concentration of 
50µM, while possessing equipotent antiviral activity to abacavir (EC50 2.456µM). 
While many compounds lacking the propensity to induce T-cell activity retained antiviral 
activity, none were as active as abacavir itself. Based on these findings, our next strategy was 
to employ a selection of these analogues as molecular probes to gain a greater 
understanding of their binding and interactions within HLA-B*57:01 and its relationship with 
T-cell activation. From the T-cell non-activating analogues, G and M were selected along with 
analogue X from the series of abacavir analogues published by Naisbitt et al 2015. Analogues 
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G and M were unable to stimulate T-cell activity in abacavir clones, whilst also having 
reduced cytotoxicity compared to abacavir in all cell lines. However, the antiviral profile of 
these analogues (EC50 38.55 and 33.67µM respectively) was around 15-fold lower than 
abacavir (EC50 2.05µM). Co-incubation with analogue X again failed to stimulate T-cell activity 
in the ELIspot assay. While the analogue retained antiviral activity it was to a lower level than 
abacavir (Naisbitt et al. 2015).  
Molecular modelling of the analogues revealed a distinct relationship between the binding 
of the compounds within HLA-B*57:01 and the ability to activate of CD8+ T-cells. Analogues 
G, M and X, all incapable of promoting T-cell responses, bound HLA-B*57:01 in a manner 
that yielded the presence of unfavourable steric clashes between the functional groups of 
the compounds and the amino acid residues of both the HLA-binding peptide and residues 
within the F-pocket itself such as the Tyr-123. No such clashes were observed with the 
analogues capable of activating T-cells (D and H) or abacavir itself (Figure 3.8). The presence 
of these clashes particularly with the HLA-binding peptide in the presence of the non-
activating analogues indicates their inability to bind HLA-B*57:01 and form a complex with 
HLA-binding peptide (pep-v). Conversely analogues D and H demonstrated a binding pose 
within HLA-B*57:01 with sufficient affinity to induce conformational changes within the F-
pocket allowing for the presentation of the  altered self -peptides identified by Illing et al 
(2012), Norcross et al (2012) and Ostrov et al (2012) . This indicates the potential for using 
molecular modelling as a screening tool to study the binding of compounds within HLA 
proteins to investigate their effect on T-cell activation. However, as only one HLA-binding 
peptide (pep-V) was employed for this analysis, future studies must consider the 
incorporation of a wider range of HLA-binding peptides, terminating in a broader range of 
amino acids, as well in alternate conformations as uncovered by recent studies, to uncover 
whether a similar relationship exists (Illing et al. 2013).  
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To investigate the effect of the abacavir analogues on the self -peptides presented to T-cells 
on the surface of the antigen presenting cell, peptide elution studies from HLA-B*57:01 were 
conducted and analysed via mass spectrometry. Analogue X underwent peptide elution 
assays in triplicate due to its availability in high quantities. Analogues D, H and M were 
available in much lower quantities and therefore around 10mg of each was used for these 
experiments allowing for the assay to be carried out in singlet. Peptide elution studies were 
not conducted on analogue G due to limited quantities of the compound available. 
Consistent with previous findings, co-incubation with abacavir induced strong enrichment of 
small chain amino acids isoleucine and leucine at the C-terminal of the peptide (Illing et al. 
2012; Norcross et al. 2012; Ostrov et al. 2012). A decrease in the prevalence of arginine and 
lysine at the Ω-2 position was noted in the presence of abacavir, which is thought to be 
caused by the blocking of interactions between constitutive peptides and the Asp-114 amino 
acid by the binding of abacavir. When all peptides eluted from HLA-B*57:01 were taken into 
consideration for analysis in the presence of the individual analogues, no significant change 
was observed in the prevalence of the small amino acids at the C-terminal position when 
compared to untreated cells (Figure 3.9 a)). However, removal of peptides eluted from 
untreated cells from consideration revealed a shift in the prevalence of amino acid isoleucine 
at the C-terminal position in the presence of analogues D and H, both known to have T-cell 
activating capabilities. No such increase was observed in the presence of the analogues that 
lacked the ability to activate T-cells (M and X). Of the peptides eluted in the presence of 
analogue D, 67 displayed overlap with those eluted from HLA-B*57:01 in the presence of 
abacavir both in this study and previous studies (Illing et al. 2012) while 43 were peptides 
unique to the analogue. This overlap was again observed in the presence of analogue H 
however to a lesser degree than D, 36 peptides observed with abacavir and 47 unique to 
analogue H, which may explain why T-cell activation was observed in analogue H only at 
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higher concentrations. While overlap of the peptides observed in the presence of abacavir 
was seen with analogues X and M, most terminated with a larger amino acid residue such as 
methionine, phenylalanine or tryptophan which would not typically be accommodated by an 
altered conformation of the peptide binding groove. Enrichment of C-terminal alanine was 
observed in the presence of analogue X, some of which overlapped with alanine terminating 
peptides detected in the presence of abacavir. These studies demonstrate that the 
introduction of branched chains to the functional group of abacavir by way of isopropyl (X) 
or trifluoromethyl (M) is sufficient to abrogate the cross-reactivity in abacavir-responsive T-
cell clones. Introduction of these functional groups results i n a reduction in the binding 
affinity of the compound within HLA-B*57:01 resulting in an inability to induce the 
presentation of an altered peptide repertoire to T-cells. On the other hand, the introduction 
of the azetidine ring alone or an azetidine linked fluoride group resulted in a degree of T-cell 
activation. These analogues bind with sufficient affinity to induce an alteration in the peptide 
repertoire presented to T-cells by HLA-B*57:01. The degree of T-cell activation in the 
presence of these analogues was for the most part less than abacavir, which is likely due to 
the lower number of peptides eluted with the C-terminal isoleucine when compared to 
abacavir.  
The CD8+ mediated T-cell activity in the presence of the abacavir analogues was observed in 
memory T-cells with specificity to abacavir, thereby indicating a cross reactivity profile of the 
clones. We next sought to confirm the safety of the abacavir analogues via the generation of 
analogue specific memory T-cells from PBMCs of the same HLA-B*57:01+ donors, which had 
not been previously examined. T-cell cloning was carried out with four separate analogues, 
two with a T-cell activation profile (H and J) and two unable to activate T-cells (G and X). No 
specific clones were generated to analogue G across the two HLA-B*57:01 positive donors. 
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This confirms the addition of an azetidine linked nitrile group does not activate T-cells in vitro 
and would be unlikely to if administered to patients. 
Unsurprisingly, cloning to the analogues that possessed T-cell activation properties (H and J) 
in abacavir clones, yielded a plethora of analogue specific T-cell clones that displayed strong 
T-cell activation in response to the respective analogues and also abacavir itself. These 
responses were observed at lower concentrations of both the analogue and abacavir, 
consistent with previous observations with abacavir-specific clones (Bell et al., 2013; Naisbitt 
et al., 2015) (Figure 3.12-3.13).  
Importantly, cloning to analogue X, to our surprise, yielded an abundance of responsive 
clones with strong T-cell activity to both analogue X and abacavir in donor 1 (HLA-0617). 
Similar results were observed in donor 4 (HLA-0622), with some clones displaying enhanced 
responses to abacavir than analogue X.  It was interesting to find such responsive clones 
primed to analogue X based on their lack of T-cell activity in abacavir clones in studies 
conducted both in this chapter and previous studies (Naisbitt et al. 2015). As previously 
mentioned, abacavir induced an increase in HLA-B*57:01 peptide ligands terminating in 
isoleucine (Illing et al. 2012; Norcross et al. 2012; Ostrov et al. 2012). However, unlike 
analogues D or H, analogue X induces an enrichment of 9-12 mer peptides terminating in the 
amino acid alanine (Figure 3.9) while 110 of the peptides eluted from HLA-B*57:01 in the 
presence of this analogue are also prevalent in the presence of abacavir. Given that alanine 
terminating peptides constitute a smaller part of the observed abacavir induced repertoire 
it was not surprising that cross-reactivity was absent with abacavir specific T-cell clones in 
the presence of analogue X.  In contrast, clones raised to analogue X were cross-reactive to 
abacavir, suggesting that the outgrown specificities fall within the abacavir repertoire. 
Indeed, the successful generation of analogue X-abacavir-reactive T-cell clones when priming 
to analogue X is consistent with a limited repertoire perturbation which seems to partially 
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overlap with the abacavir induced repertoire. Indeed, HLA-modelling of analogue X with an 
alanine terminating peptide would likely not yield clashes with the isopropyl group, 
warranting further study. As these results were unexpected, they indicate the importance of 
using of T-cell cloning in the assessment of the safety profile of a drug such as abacavir.  
These studies demonstrate the ability to generate compounds which are devoid of the ability 
to induce T-cell activation but retain some antiviral activity via the modification of the 6-
amino cyclopropyl moiety of abacavir. Furthermore, the use of a panel of these compounds 
as molecular probes provided considerable insight into the relationship between the binding 
of a compound within HLA-B*57:01 and the observed T-cell response. We also acknowledge 
the initially surprising findings in clones generated specifically to analogues with no T-cell 
activating properties with abacavir clones such as analogue X, where we saw considerable 
activation in response to this compound and abacavir itself. Taken together the findings in 
this chapter demonstrate the importance of a holistic approach to the design, manufacture 
and subsequent testing of a compound for efficacy and safety (Figure 3.2), employing the 
use of in vitro and in silico methods to further our own understanding of drug immune 
receptor binding.  
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Chapter 4 – An investigation into the impact of drug chirality on the induction of 
abacavir-specific CD8+ T-cell activity. 
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4.1 Introduction 
 
The interaction of abacavir within the antigen binding cleft of HLA-B*57:01 is postulated to 
induce alterations in the shape and chemistry of the peptide binding motif. This causes a 
reduction in size of the F-pocket, allowing for the accommodation of smaller C-terminal 
anchors such as valine, leucine and isoleucine compared to the more conventional larger 
chain amino acids phenylalanine and tryptophan (Illing et al. 2012; Ostrov et al. 2012; 
Norcross et al. 2012). Naisbitt et al 2015 elegantly generated pharmacologically active 
analogues of abacavir devoid of T-cell activation properties, via the introduction of N-linked 
branched carbon chains. Subsequent molecular modelling revealed unfavourable binding 
characteristics of these analogues within the antigen binding cleft of HLA-B*57:01, 
characterised by the presence of steric clashes between the analogues functional groups, 
the HLA-binding peptide, and amino acids within the F-pocket (Naisbitt et al. 2015).  
This concept was further explored in chapter 3. Fourteen new abacavir analogues were 
constructed around variants of the azetidine ring, a stable chemical structure allowing for 
analogue synthesis but also displaying favourable antiviral activity (Daluge et al., 1997). 
Although, some azetidine derivatives did not activate T-cells, these compounds did not 
possess the same antiviral activity as abacavir. Conversely, some compounds exhibited 
strong antiviral activity, but interacted with HLA-B*57:01 evoking T-cell responses. These 
data led us to synthesize additional of further chemical structures to further probe the drug 
binding HLA-B*57:01 interaction.  
Chirality is the property of an object which is non-superimposable with its mirror image, with 
compounds of this nature often referred to as stereoisomers or enantiomers. While these 
compounds show an identical arrangement of bonds connecting their atoms, the relative 
orientation of these atoms in space differs greatly.  
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With respect to their biological activity, enantiomers differ at both the quantitative and 
qualitative levels. Enantiomers may possess a plethora of biological properties in one 
conformation while being biologically inactive in the other. These differences can arise from 
differential interaction of the enantiomers with their given receptors, but also due to 
different pharmacokinetic effects such as protein binding, metabolism and transport 
(Nguyen et al. 2006; Triggle 1997).  
In basic terms, for a drug to interact with a receptor its functional components must interact 
with the corresponding regions of the drug binding site. As can be seen in Figure 4.2, while 
one enantiomer is able to interact with corresponding sites on a receptor, the alternative 
enantiomer is not, due to the inappropriate alignment of the corresponding binding groups, 
inevitably leading to loss of the drugs action.  
Figure 4.1 Chiral variants of a chemical structure. 
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The enantiomeric specific side or toxic effects of drugs is well documented, the most 
infamous relating to treatment with the antiemetic sedative drug thalidomide, commonly 
prescribed in the 1960’s to pregnant women as a treatment for morning sickness. Treatment 
with this drug resulted in serious birth defects in the offspring, associated with severe limb 
bud abnormalities and teratogenesis, a prime example of a type G ADR. It was found that 
while the R-stereoisomer of thalidomide was responsible for the sedative effects, the S-
stereoisomer accounted for the induction of the severe birth defects observed (Chamberlain 
et al. 2014; Cuthbert et al. 1962). However, due the racemic nature of thalidomide in 
solution, allowing for the spontaneous conversion between the 2 enantiomeric variants, the 
generation of a stable stereoisoform of the drug was not possible (Vargesson 2015).  
A relationship between a compounds potency and its chiral state has been demonstrated 
across a variety of drugs. The antidepressant drug citalopram functions via the antagonistic 
Figure 4.2 Interaction between 2 enantiomers of a chiral drug and its binding site. (Adapted from 
McConathy and Owens 2003). 
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block of serotonin reuptake, however the S conformation displays a pharmacological 
potency of around 30 times greater than the R counterpart (Koldsø et al. 2010).  
Similarly, calcium channel antagonists such as verapamil also demonstrate enantiomeric 
specific pharmacological potency. Verapamil’s vasodilatory properties are 10-20 times more 
potent in the S conformation (Satoh et al. 1980; Echizen et al. 1988). However, verapamil 
displays useful properties as a therapeutic agent in cancer chemotherapy, this requires use 
at high concentrations which are often associated with cardiotoxicity. Thus, for this 
medication it is the R isomer of verapamil which exhibits far lower cardiotoxicity than the S 
isoform, indicating differing uses for the same drug based on its chiral state (Nguyen et al. 
2006; Satoh et al. 1980; Echizen et al. 1988).   
The stereoisomerism of a compound has a bearing on its pharmacological action; however, 
this is not always a consequence of receptor binding and may be down to other 
pharmacological properties such as metabolism or toxicity (Triggle 1997; Nguyen et al. 2006).  
The antidepressant fluoxetine displays similar levels of potency in the R and S conformations 
in the setting of its primary pharmacological actions; however, these enantiomers undergo 
different routes of metabolism (Cârcu-Dobrin et al. 2017). As such, the plasma levels of R-
fluoxetine are less variable than the S isoform. R-fluoxetine and its metabolites inhibit 
CYP2D6 to a greater degree than S-fluoxetine and in Phase II studies the R isoform of the 
Figure 4.3. R and S conformations of citalopram. 
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drug at high concentrations resulted in prolonged cardiac repolarization leading to 
arrhythmia, something not observed in the S conformation (DeVane & Boulton 2002).  
Other examples of enantiomeric specific pharmacology include the local anaesthetic 
bupivacaine which in the R isoform exhibits a systemic toxicity 50% more frequently than the 
S isoform. Cardiotoxicity caused by direct actions of the drug on the myocardium is the most 
common ADR (Huang et al. 1998). Additionally, ketamine in the S and R conformations differ 
in both pharmacokinetic and pharmacodynamic properties. The S stereoisomer of the drug 
is around 3 times more potent at its desired pharmacological target than its R counterpart. 
However, the S isoform is known to be a primary contributor to direct stimulation of 
cardiovascular tissues and has a much greater clearance rate than the R isoform, indicating 
the presence of enantiomeric-selective hepatic metabolism (Muller et al. 2016; Zeilhofer et 
al. 1992; Nau & Strichartz 2002). Similar enantiomeric specific adverse effects exist with the 
bronchodilator drug albuterol. R-albuterol exerts bronchodilatory and anti-inflammatory 
effects including the inhibition of T-cell proliferation as well as the impediment of goblet cell 
hyperplasia and mucus occlusion of the airways (Henderson et al. 2005), although these 
effects can be negated in the presence of the S-isoform (Baramki et al. 2002). Conversely, 
the S-enantiomer of albuterol firstly exerts bronchodilatory actions to a far lesser degree 
than the R isomer, but is also associated with proinflammatory actions such as the secretion 
of IgE induced histamine and IL-4, something completely absent with the R-isoform (Cho et 
al. 2001; Henderson et al. 2005). 
In 2005 Naisbitt et al carried out studies using the oral anticoagulant phenindione which is 
associated with hypersensitivity reactions in up to 3% of patients. Drug-responsive T-cell 
clones generated specifically to phenindione produced proliferative responses when 
incubated in the presence of the drug. Of the four drug-responsive T-cell clones, three 
proliferated in response to the S stereoisomer of the alternate anticoagulant agent warfarin 
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and interestingly, one clone responded to warfarin in its R conformation. These data indicate 
that the enantiomeric-specific activation of T-cells by drugs is possible in hypersensitive 
patients (Naisbitt et al. 2005). Therefore, the use of chiral variants of the same structure 
presents as an interesting concept for investigating the safety of abacavir analogues in T-cell 
assays.  
One obvious drawback of the T-cell cloning assay for the screening of a compounds safety, 
with regard to T-cell activation, is the time period required to concisely carry out the assay. 
On average T-cell cloning to a compound takes 6-8 weeks to fully generate responsive T-cell 
clones, which can lead to various issues with cells being in culture for such long periods of 
time. Also, if cell growth during cloning is low, restimulation with PBMC feeder cells requires 
a minimum of two weeks before cells can be tested. Therefore the exploration of other 
assays for the screening of compounds in a more timely manner is at the forefront of 
research. One such assay is the dendritic cell (DC) T-cell priming assay developed (Faulkner 
et al. 2012) and further optimised (Faulkner et al. 2016) to detect drug-specific responses 
from naïve T-cells co-incubated with autologous dendritic cells and a drug for a period of 8-
14 days before restimulation with the drug and fresh DCs. Drug-specific T-cell responses can 
then be quantified using a variety of readouts. This assay demonstrated robust responses to 
a variety of drugs including SMX-NO, piperacillin, carbamazepine and the reactive species 
Bandrowski’s base. However, no responses were detected with abacavir (Faulkner et al. 
2016). Further refinement of the T-cell priming assay has been undertaken in recent years to 
consider responses from individual wells rather than a mean response across all wells, this is 
known as the T-cell multi-well assay (T-MWA).  Therefore, use of this assay was undertaken 
to examine individual responses in naïve T-cells isolated from healthy drug naïve donors 
expressing the HLA-B*57:01 allele co-incubated with abacavir and DCs for 14 days. Should 
responses be found, abacavir substituted analogues could be incorporated into the assay to 
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provide a screening protocol in a much reduced period of time compared to conventional T-
cell cloning.  
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4.2 Aims 
 
In this chapter, we further investigated the ability to remove the undesirable CD8+ T-cell 
stimulatory capacity of abacavir in HLA-B*57:01 positive individuals, while retaining the 
antiviral potency of the drug. For these studies, four further abacavir analogues were 
synthesised with substitutions in place of the 6-amino cyclopropyl moiety of the compound, 
consisting of structural variations around the open ring form of azetidine. Of these four newly 
synthesised analogues, two were structural enantiomers of the same compound. We 
investigated the safety of these compounds by analysing their T-cell induction abilities, along 
with their cellular toxicity profiles and antiviral activity. Again, using the four analogues as 
molecular probes and an enantiomer of abacavir, we aimed to investigate the binding of the 
compounds within the antigen binding cleft of HLA-B*57:01 and its relationship with the 
induction of T-cell activity. Finally, we examined the use of the T-cell multi-well assay for the 
screening of abacavir-induced T-cell responses. 
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4.3 Methods 
4.3.1 Materials 
 
Abacavir was received as a gift from GlaxoSmithKline (GSK). Human AB serum and foetal 
bovine serum were obtained from Innovative Research (Michigan, USA) and Invitrogen 
(Paisley, UK), respectively. Interleukin-2 (IL-2) was purchased from Peprotech (London, UK). 
Multisort bead separation kits were supplied by Miltenyi Biotec (Surrey, UK). Antibodies for 
staining were purchased from BD Biosciences (Oxford, UK). ELIspot kits including the coating 
and detection antibodies, streptavidin alkaline phosphate conjugate and BCIP/NBT 
substrates were purchased from Mabtech (Stockholm, Sweden). Other reagents were 
purchased from Sigma-Aldrich (Dorset-UK) unless otherwise stated. 
4.3.2 Cell Culture Medium 
 
Cell culture medium for T-cells (R9) is composed of RPMI supplemented with 10% human AB 
serum, HEPES (25mM), penicillin (1000 U/mL), streptomycin (0.1mg/mL), L-glutamine (2mM) 
and transferrin (25µg/mL).   
EBV transformed B-cells were cultured in F1 medium composed of RPMI supplemented with 
10% foetal bovine serum, HEPES (25mM), penicillin (1000 U/mL), streptomycin (0.1mg/mL) 
and L-glutamine (2mM). 
4.3.3. Generation of abacavir responsive T-cells. 
 
CD8+ T-cell cloning was carried out as described in detail in section 2.3.5 using PBMCs from 
HLA-B*57:01 positive donors selected from our established HLA-typed healthy donor cohort.  
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4.3.4 Testing clones for antigen specificity 
 
Approximately four weeks after beginning the serial dilutions abacavir-specificity was 
measured by assessing cell proliferation in the presence of the drug as described in section 
2.3.6. Following two-week mitogen expansion of responsive abacavir clones, the antigen 
specificity to abacavir was confirmed via analysis of IFN-γ secretion in response to the drug 
using the ELIspot assay as described in section 2.3.7. 
4.3.5 Synthesis of abacavir analogues 
 
The initial part of the project involved the synthesis of a stock sample of compound 1 (Figure 
3.1). With 2g of this chiral compound in hand, synthesis of the four target molecules (O-R) 
was completed (Appendix section 3). 
Compound 1 (564.55 µmol, 1.00 eq), amine (2.00 eq) and N, N-diisopropylethylamine 
(145.92mg, 1.13 mmol, 2.00 eq) were taken up into a microwave tube in isopropyl alcohol 
(2.00mL). The sealed tube was heated at 70 °C for 2 hours under microwave.  MS showed 
that the starting material was consumed completely.  The mixture was concentrated in 
vacuum to give crude product. 
Due to structural irregularities in MS data (appendix chapter 3), analogue O was removed 
from further assays. 
 
 
 
 
 
Intermediate 1 Analogues O-R 
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4.3.6 Inhibition of T-cell and B-cell proliferation  
 
To ascertain the effect of the compounds on cellular proliferation, the abacavir analogues 
were cultured in the presence of EBV transformed B-cells or PBMCs at concentrations of 0-
250µM, with abacavir as a comparator as described in section 3.3.7.  
4.3.7 CD8+ T-cell activity of abacavir analogues 
 
To measure the effect of modifying the 6-amino cyclopropyl group of abacavir with regards 
to T-cell induction, T-cell clones (5x104/50µL) were incubated with autologous EBVs 
(1x104/50µL) in the presence or absence of the three abacavir substituted analogues (10, 20, 
50µM) (total volume 200µL/96 well U-bottomed plate) for a period of 48 hours and IFN-γ 
secretion was assessed via ELIspot as described in detail in section 2.3.7.  
Figure 4.4. Synthesis and structures of abacavir analogues O-R. 
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The activity of some analogues in T-cell clones was also assessed using the proliferation 
assay. T-cell clones (5x104/50µL) were cultured in a 96 well U-bottomed plate in the presence 
of irradiated autologous EBVs (1x104/50µL) in the presence of abacavir or the substituted 
analogues at varying concentrations for a period of 72 hours (37°C; 5% CO2) (total volume 
200µL/96 well U-bottomed plate). Cells incubated with R9 medium alone were used as a 
negative control. Tritiated thymidine (0.5µCi/well) was added for the final 16 hours. Cells 
were next harvested onto a filter mat and T-cell proliferation was assessed via scintillation 
as described in section 2.3.6. 
4.3.9 HLA-B*57:01 molecular modelling 
 
The binding conformations of the four abacavir analogues were modelled within HLA -
B*57:01 using the same protocol as described in section 3.3.9. 
4.3.10 Antiviral activity and cytotoxicity of abacavir analogues 
4.3.10.1 Antiviral activity 
 
Analysis of the antiviral activity of the abacavir analogues was conducted using HIV-1 IIIB 
infected MT-4 cells by the WuXi App Tech company in Shanghai as described in section 
3.3.6.1.  
4.3.10.2 Cytotoxicity 
 
The cytotoxicity of the analogues was assessed as described in section 3.3.6.2. 
4.3.11 Magnetic bead separation of naïve T-cells. 
 
CD14+ cells were isolated via positive selection from the total PBMC population using 
magnetic beads and columns according to the manufacturer’s instructions (Miltenyi Biotech, 
Surrey-UK). For isolation of naïve T-cells, a pan negative T-cell separation was performed on 
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the non-CD14+ fraction of the cells, using anti-T-cell antibody cocktail. CD3+ T-cells, obtained 
via negative selection, were then subjected to positive sele ction for Treg (CD25+) and 
memory T-cells (CD45RO) with naïve T-cells being obtained via negative selection (CD3+, 
CD25-, CD45RO-, CD45RA+). 
4.3.12 T-cell multi-well priming assay 
 
PBMCs from two healthy, abacavir naïve, HLA-B*57:01 positive donors (HVN-021 and HVN-
158, Table 2.1) were isolated via density centrifugation as described in section 2.3.3 and cells 
were sorted via magnetic bead separation as described in section 4.3.14. For the generation 
of dendritic cells, CD14+ cells were isolated via positive selection and grown for 7 days in the 
presence of GM-CSF (800U/mL) and IL-4 (800U/mL). Dendritic cells were matured overnight 
in the presence of LPS (1µg/mL) and TNF-α (50ng/mL) prior to use. Mature dendritic cells 
(8x103cells/well) were co-cultured in a 96-well plate with naïve or memory T-cell 
(2x104cells/well) in the presence of abacavir (35µM). Cells were incubated for a period of 12-
14 days with R9 medium used as a negative control. Following incubation, cells were washed 
three times and stimulated with abacavir (35µM) for a further 2 days. Cells were then tested 
for abacavir-specific T-cell activation using proliferation as a readout via 3H thymidine 
incorporation (Section 4.3.9). The cpm values of the R9 wells were averaged and each 
individual well cpm of abacavir treated cells was divided by this value to yield an SI. SI values 
of 1.5-.1.9, 2.0-3.9 and 4 and above were considered low, moderate and high responses 
respectively. 
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4.3.13 Statistical analysis 
 
For comparison between control and test values in proliferation assays the Mann-Whitney 
test was used. Two way ANOVA was used for comparison between mean abacavir and 
analogue values in ELIspot assays.  
 
 
 
 
 
 
Figure 4.5. Schematic of T-cell multi-well priming assay. Isolated naïve T-cells are co-incubated with 
DCs in the presence or absence of abacavir for 12-14 days. Next cells are washed three times and fresh 
abacavir or R9 medium was added for a further 2 days. Finally 3H thymidine was added for a further 
16 hours and cellular proliferation was assessed. 
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4.4. Results 
4.4.1 Generation of abacavir-specific T-cell clones 
 
From a total of 2279 seeded cells across four HLA-B*57:01 positive donors, 101 were found 
to proliferate in the presence of abacavir on first testing, (Control, 1665 ± 188.5 cpm: 
abacavir 35µM, 6940 ± 729 cpm; P< 0.0001). Comparison of average cpm, confirmation of 
antigen specificity and subsequent cellular phenotyping is presented and discussed in 
chapter 2. The abacavir responsive T-cell clones used in this chapter are outlined in Table 
4.1. 
 
 
 
 
 
Donor 1: HLA-0617 Donor 3: HVN-0158 Donor 4: HLA-0622 
TCC 27 TCC 51 TCC 79 
TCC 70 TCC 60 TCC 86 
TCC 3 * TCC 65 TCC 100 
TCC 20 *  TCC 105 
Table 4.1 Abacavir responsive CD8+ T-cell clones from three HLA-B*57:01 positive donors used 
in this chapter. * Clones generated to abacavir + natural  peptide 15, these clones demonstrated a 
strong response to abacavir and were incorporated into T-cell  analogue assays. Second test data 
and phenotyping for these clones is found in chapter 5. 
                                                                                                       Chapter 4 
 
177 
 
4.4.3 Inhibition of T-cell and B-cell proliferation by abacavir and abacavir analogues 
 
To investigate if the abacavir analogues inhibited lymphocyte proliferation via direct toxic 
effects, PBMCs and EBV-transformed B-cells (1x105/well) were incubated in the presence of 
the analogues at concentrations of 0-250µM, with abacavir used as a comparator. T-cell and 
B-cell proliferation was inhibited by abacavir in a dose-dependent manner, generating 
respective IC50’s of 66.7µM and 94.6µM (Table 4.2). Analogue P demonstrated a dose-
dependent inhibition of B-cell and T-cell proliferation yielding IC50’s of 91.8µM in PBMCs,  
157µM in B-cells. Co-incubation with analogue Q resulted in inhibition of proliferation at 
higher concentrations than with abacavir in both T-cells (IC50 162µM) and B-cells (IC50 
129µM). Furthermore, analogue R inhibited proliferation of T-cells with an IC50 of 93µM while 
inhibition of proliferation in B-cells in the presence of R was not detected within the range 
of concentrations used (IC50 > 250µM) (Table 4.2).  
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Figure 4.6. Cellular toxicity of abacavir analogues. Inhibition of proliferation of a) PBMCs and b) B-cells 
incubated in the presence of abacavir analogues at concentrations of 0, 10, 25, 50, 75, 100 and 250 µM. In the 
case of B-cells, the analogues were co-incubated for a period of 48 hours then tritiated thymidine was added 
directly to the cells for a further 16 hours. Cells were then harvested onto a printed fi lter mat and radioactive 
incorporation was assessed via scintillation counting on a microBeta counter. In the case of PBMCs, c ells were 
co-incubated with the compounds for a period of 72 hours before PHA was added to promote the proliferation 
of viable cells. Following a further 24-hour incubation, tritiated thymidine was added directly onto the cells for 
a further period of 16 hours. Cells were then harvested and radioactive incorporation was measured as 
described above. 
Table 4.2. Inhibition of T-cell and B-cell proliferation in the presence of abacavir and the analogues. 
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4.4.4 Effect of abacavir analogues on the activation of abacavir-specific CD8+ T-cells 
 
The effect on CD8+ T-cell activation by the abacavir analogues was investigated using 
secretion of the proinflammatory cytokine IFN-γ as a readout due to its superiority over cell 
proliferation. Six abacavir-specific T-cell clones were co-incubated with the analogues in the 
presence of autologous APCs at concentrations of 0, 10, 20 and 50µM. Mean IFN-γ secretion 
of the six clones tested was compared with mean secretion across the same six clones in the 
presence of abacavir. Analogue P (isobutyl amino) induced strong activation of two abacavir 
clones with lesser activation observed in the other four (Figure 4.7). The effect of 
enantiomeric modification of the functional group of the abacavir analogues was explored 
with two compounds. Interestingly, the chirality of the functional groups had a pivotal role 
on the T-cell activation profile of the abacavir analogues. Analogue Q (S-sec-butyl amino) 
activated CD8+ T-cell clones in a dose-dependent manner, in some cases to a higher degree 
than abacavir. Conversely, analogue R (R-sec-butyl amino) displayed no activation of abacavir-
specific T-cell clones, demonstrating enantiomeric-dependent activation of CD8+ T-cells. 
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4.4.5 Antiviral activity and Cytotoxicity of abacavir analogues. 
 
The antiviral activity and cytotoxicity of the abacavir analogues was ascertained using the 
cytopathic effect assay (CPE) in HIV-IIIB infected MT-4 cells. Cellular viability was measured 
in MT-4 cells co-incubated with the respective analogues with virus control as comparator 
via luminescence using Cell-titer Glo reagent. This procedure was conducted on the basis 
that cellular death is instigated in MT-4 cells by HIV-IIIB infection, therefore cellular survival 
in the presence of a compound is a marker of antiviral activity. Cellular cytotoxicity was 
determined via the same methods but using MT-4 cells without prior viral infection. Antiviral 
activity and cytotoxicity of the analogues with was calculated using GraphPad Prism software 
and are displayed as EC50 and CC50, respectively (Table 4.3).    
Figure 4.7 Direct comparison of the CD8
+
 T-cell activity of abacavir analogues a) Mean IFN-
γ secretion from six abacavir-responsive T-cell  clones incubated in the presence of 
analogues P, Q and R at concentrations of 0, 10, 20 and 50µM (Solid l ine). Mean IFN-γ 
secretion from the same six abacavir clones (dotted line) used as a comparator. Error bars 
± S.E.M, comparison of abacavir and analogue values analysed using Two Way ANOVA, * 
P<0.05, ** P<0.01, *** P<0.001. b) ELIspot well images from one representative abacavir 
responsive T-cell  clone incubated in the presence of analogues  P, Q and R at concentrations 
of 0, 10, 20 and 50µM. Abacavir (ABC) at the same concentrations was used as a 
comparator. 
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With the exception of analogue P (EC50 56.72µM), no analogues possessed detectable 
antiviral activity in MT-4 cells (EC50 >500µM) in comparison with abacavir, which exhibited 
potent antiviral activity properties (EC50 7.626µM). The cellular cytotoxicity induced by the 
analogues is also displayed in Table 4.3. Abacavir analogues possess a cytotoxicity profile of 
between 2 and 6-fold lower than abacavir, revealing the diminished toxicity profile of 
analogues obtained via modifications to the 6-amino cyclopropyl moiety.  
 
 
 
 
 
4.4.6 Enantiomeric specific T-cell activation of abacavir and abacavir analogues. 
 
Structurally, analogues Q and R differ only in the chirality of their functional group (sec-butyl 
amino) substituted in place of the 6-amino cyclopropyl group of abacavir. Analogue Q adopts 
the S conformation of the functional group while analogue R exists in the R conformation. 
Despite differing only in the chirality of their functional groups, analogues Q and R displayed 
polar effects on their respective abilities to induce T-cell activation. Analogue Q (S-sec-butyl 
amino) exhibited a dose-dependent T-cell activation profile when co-incubated with 
abacavir-specific T-cell clones indicating strong cross reactivity. Conversely, analogue R (R-
sec-butyl amino) was not found to activate the same T-cell clones. Figure 4.8 shows the T-cell 
activation abilities of both analogues Q and R in six representative abacavir clones. All six 
abacavir clones were activated by analogue Q, whilst no difference in IFN-γ secretion was 
observed in the T-cell clones co-incubated with analogue R compared to control (Figure 4.8).  
Table 4.3. Antiviral activity and cytotoxicity of abacavir and analogues measured in MT-4  
cells. 
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Figure 4.8. Direct comparison of the CD8
+
 T-cell activity between enantiomer analogues Q and R. a) 
Structure of compounds and IFN-γ secretion from six abacavir responsive T-cell  clones incubated in the 
presence of analogues i) Q and ii) R. Representative IFN-γ ELIspot images of six individual abacavir responsive 
CD8
+
 T-cell  clones incubated in the presence of analogues Q or R, at concentrations of 0,10,20 and 50µM. iii) 
Abacavir incubated in the presence of one representative clone, at the same concentrations, is shown as a 
comparator.  
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4.4.7 HLA-B*57:01 molecular modelling of abacavir analogues. 
 
The same docking protocol from chapter 3 was used for analysis of the predicted binding 
poses of analogues P-R, which were subsequently compared to abacavir. All analogues were 
predicted to bind in a similar fashion to abacavir with the guanosine component of the 
molecule forming hydrogen bonds with Asp-114, Ser-116 and Ile-124 amino acids.  From 
Figure 4.8 it can be seen that T-cell activating analogues P and Q bind within the HLA-B*57:01 
antigen binding cleft in a similar conformation to abacavir which results in the absence of 
steric clashes between the compounds functional groups and the HLA-binding peptide, or 
the amino acids within the F-pocket. This indicates a favourable binding conformation 
adopted by these compounds within HLA-B*57:01 allowing for interactions to initiate a T-
cell response. Conversely, analogue R is predicted to bind to HLA-B*57:01 in such a manner 
that inhibits the activation of T-cells. This is characterised by the increased distance between 
the guanosine portion of these compounds and the amino acids within HLA-B*57:01 when 
compared to abacavir and the activating analogues. Therefore, binding of this analogue 
within the F-pocket of HLA-B*57:01 unsurprisingly yielded the presence of steric clashes 
between their respective functional groups and the residues of the HLA-binding peptide 
(pep-V).  As mentioned in chapter 3, the overlap of atomic radii within each compound with 
that of the HLA-binding peptide or amino acids within HLA-B*57:01 results in an 
unfavourable binding conformation of the compounds within HLA-B*57:01 which would not 
favour the docking of pep-V, likely leading to the binding of other distinct peptides. This 
results in a loss of T-cell activity, indicated by the lack of IFN-γ secretion with analogue R.  
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Figure 4.9. Direct comparison of the CD8
+
 T-cell activity of abacavir analogues and the 
binding orientations within the F-pocket of HLA-B*57:01. a) Crystal structure of HLA-
B*57:01 (PDB:3UPR) represented with the HLA-binding peptide and compounds. i) Crystal 
structure and binding orientations of abacavir, stick representation of pep-V (HSITYLLPV; 
pink) and the chemical structure of abacavir (cyan). Key amino acid residues which bind 
abacavir are shown as yellow sticks. Non-polar hydrogen atoms have been removed. Key 
H bond interactions are shown as black dashes. Spheres are used to i l lustrate the atomic 
radii of the atoms in the cyclopropyl group of abacavir, peptide molecule and Tyr -123 
amino acid.  Docking solution of analogues i i)  P (isobutyl amino), i i i) Q (S-
sec
-butyl amino) 
and iv) R (R-
sec
-butyl amino) in the F-pocket of HLA-B*57:01. Stick representation of the 
peptide, pep-v (HSITYLLPV) shown in pink. Amino acid protein residues shown as yellow 
sticks, with key hydrogen bond interacti ons shown as black dashes. All  non-polar hydrogen 
atoms removed. Spheres used to i l lustrate the atomic radii of the atoms in the functional 
group of the analogue, peptide and amino acids Tyr-123. b) Mean IFN-γ secretion from six 
abacavir responsive T-cell  clones incubated in the presence of analogues P, Q and R at 
concentrations of 0, 10, 20 and 50µM. Abacavir (ABC) (dotted line) used as a comparator.  
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4.4.8 Effect of chirality on abacavir-induced CD8+ mediated T-cell responses 
 
The chiral modification of abacavir at the cyclopentyl moiety has a dramatic effect on the 
ability of a compound to activate T-cells. Abacavir can induce CD8+ T-cell activation in a dose-
dependent manner as observed by IFN-γ secretion and in some cases proliferation. Such 
activation was completely abrogated with the enantiomeric modification of the cyclopentyl 
moiety of the compound. No T-cell proliferation or IFN-γ secretion was observed using T-
cells incubated in the presence of the 1R, 4S abacavir enantiomer compared to abacavir in 
its native form (Figure 4.10). Molecular modelling of 1R, 4S abacavir within HLA-B*57:01 
demonstrates an altered binding conformation within the antigen binding cleft. The distance 
between the contact points within the 2-amino purine motif of the compound and the amino 
acids Asp-114, Ser-116 and Ile-124 is much greater with the 1R, 4S enantiomer when 
compared to abacavir in its native form. This increase in distance of the contacts results in 
an altered binding conformation of the compound, which clashes with the Val -9 residue of 
the HLA-binding peptide. The large distance between the compound and the amino acids 
within HLA-B*57:01 diminishes the interactions with the amino acids within the F-pocket. 
This inhibits the induction of conformational changes in the shape of the binding motif, 
resulting in no accommodation of smaller C-terminal anchors. This consequently results in 
the loss of CD8+ T-cell activation (Figure 4.10).  
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Figure 4.10. Direct comparison of abacavir and the 1R,4S enantiomer effects on CD8
+
 T-cell activation 
and binding within the F-pocket of HLA-B*57:01. a) Abacavir responsive T-cell  clones were cultured in the 
presence of abacavir and the 1R, 4S abacavir enantiomer at concentrations of 1, 5, 10, 50 and 100µM for 
48 hours. Following the incubation period, tritiated [
3
H] thymidine was added and cells were incubated 
for a further 16 hours. Proliferation was measured via scintil lation counting. b) Representative ELIspot 
images from wells containing abacavir and 1R, 4S abacavir both at 50µM. c) Docking solution of abacavir 
(1S,4R) and abacavir enantiomer (1R,4S) in the F-pocket of HLA-B*57:01. Stick representation of the 
peptide, pep-V (HSITYLLPV) shown in pink. Amino acid protein residues shown as yellow sticks, with key 
hydrogen bond interactions shown as black dashes. All  non-polar hydrogen atoms removed. Spheres used 
to i l lustrate the atomic radii of the atoms in the functional group of the compounds. 
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4.4.9. Incorporation of naïve T-cells from healthy drug naïve HLA-B*57:01+ donors into 
the T-cell multi-well assay. 
 
Using a T-MWA, the effect of naïve T-cell priming by abacavir was assessed in two HLA-
B*57:01 positive drug naive donors (HVN-021 and HVN-158), genotyping data shown in Table 
2.1. The assay was repeated using nitroso-sulfamethoxazole (SMX-NO) as a comparator. 
Between 40-80% of wells primed to SMX-NO responded when restimulated with the same 
drug antigen, yielding SI values as high as 60 in some wells in the case of HVN-021. While not 
being as responsive as HVN-021, naïve T-cells from HVN-158 demonstrated a moderate to 
high activation profile in response to SMX-NO generating SI values of up to 8. However, 
abacavir demonstrated little to no activation of naïve T-cells in either donor. HVN-021 
displayed modest activation in the multi-well priming assay yielding SI values of up to 2. 
However, based on the low SI values observed in other wells and the complete lack of 
responsive T-cells in HVN-158 it is likely that these results were false positives (Figure 4.12). 
 
 
 
 
 
 
 
 
 
                                                                                                       Chapter 4 
 
188 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Naïve T-cell priming assay. Naïve T-cells isolated from PBMCs from HLA-B*57:01  
positive, drug naïve, donor HVN-021 were co-incubated with abacavir and SMX-NO for a period of 14 
days then rechallenged with the respective drugs. Activation of T-cells was measured via cellular 
proliferation, individual well s cpm were normalised against average cpm for control wells. SI values 
plotted to individual wells with SI values of 1.5-1.9 constituting low response, 2-3.9 moderate 
response and 4+ high response (Faulkner et al 2016). SI values plotted in bar chart with 1.5 cut off 
shown by red line. 
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Figure 4.12. Naïve T-cell multi-well dendritic priming assay. Naïve T-cells isolated from 
PBMCs from HLA-B*57:01 positive, drug naïve, donor HVN-158 were co-incubated with 
abacavir and SMX-NO for a period of 14 days then rechallenged with the respective drugs. 
Activation of T-cells was measured via cellular proliferation, individual wells cpm were 
normalised against average cpm for control wells. SI values plotted to individual wells with SI 
values of 1.5-1.9 constituting low response, 2-3.9 moderate response and 4+ high response 
(Faulkner et al 2016). SI values plotted in bar chart with 1.5 cut off shown by red line. 
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4.5 Discussion 
 
The concept of eradicating the cytotoxic T-cell response observed in response to abacavir in 
HLA-B*57:01 positive individuals via the generation of 6-amino substituted analogues was 
explored in detail in chapter 3 and in previous studies (Naisbitt et al. 2015). Continuing from 
these studies, a further four abacavir substituted analogues were synthesised, this time 
constructed around the open form of the azetidine ring, with two of these compounds being 
enantiomers of the same structure, (R-sec-butyl amino) and (S-sec-butyl amino) in order to 
investigate the ill-defined role of chirality on T-cell activation (Naisbitt et al. 2005). 
All abacavir substituted analogues used in this study demonstrated a reduced cytotoxicity 
profile when compared with abacavir in range of cells (Tables 4.2 and 4.3), suggesting that 
substitution of the 6-amino cyclopropyl moiety of the compound does not significantly 
increase cellular toxicity (Naisbitt et al. 2015).  
Introduction of the isobutyl amino group (analogue P) activated T-cell clones in a similar 
manner to abacavir. All six abacavir responsive T-cell clones were activated by analogue P, 
with two producing strong IFN-γ secretion while the other four demonstrated more modest 
cytokine secretion. The introduction of the isobutyl amino group was employed to further 
analyse the introduction of branched chained functional groups, which was explored by 
Naisbitt et al in 2015. The compound did not activate abacavir-specific T-cell clones. A further 
structural analysis indicates the similar binding of analogue P to abacavir, therefore a T-cell 
response was to be expected (Figure 4.9). Molecular modelling of analogue P revealed it to 
adopt  to a similar binding conformation to abacavir (Figure 4.9) indicating favourable 
binding affinity to form a complex with the HLA-binding peptide to induce a T-cell response. 
Analogues Q and R substitute the 6-amino cyclopropyl moiety of abacavir with the sec-butyl 
amino group in S and R conformations, respectively. Co-incubation of these compounds with 
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abacavir responsive CD8+ T-cell clones resulted in opposing effects on T-cell activation. 
Analogue Q (S-sec-butyl amino) was a strong inducer of T-cell activation while analogue R (R-
sec-butyl amino) did not activate any CD8+ T-cell clones (Figure 4.8). Molecular modelling 
revealed the unique binding poses adopted by the chiral compounds within the F-pocket of 
HLA-B*57:01’s antigen binding cleft (Figure 4.9). Analogue Q docked in a similar manner to 
abacavir, resulting in absence of steric clashes between the compound and the HLA-binding 
peptide (pep-V) or amino acids within the antigen binding cleft. This indicates a favourable 
binding posture of the compound within HLA-B*57:01 allowing for the induction of changes 
in shape and chemistry of the peptide binding groove ultimately leading to T-cell activation 
(Illing et al. 2012). Conversely, the docking conformation adopted by analogue R differs 
greatly from that of analogue Q and abacavir. The distance between the 2-amino purine 
moiety of the compound and the amino acids within HLA-B*57:01 is increased which 
indicates a lack of interaction within the peptide binding groove. Subsequently, binding of 
the compound leads to the presence of unfavourable clashes between the  functional group 
of analogue R and the Val-9 residue of the HLA-binding peptide. The presence of such clashes 
demonstrates the inability of analogue R to bind to HLA-B*57:01 with sufficient affinity to 
allow for the presentation of an altered peptide repertoire on the antigen presenting cell 
surface for recognition by CD8+ T-cells, resulting in a lack of immune activation (Illing et al. 
2012; Ostrov et al. 2012; Norcross et al. 2012). The cytotoxicity levels of analogues Q and R 
also differ based on their chirality (Tables 4.2 and 4.3), however in both cases antiviral activity 
of the analogues could not be detected within the range of concentrations used, indicating 
that the sec-butyl amino group is an unsuitable for replacement at the 6-amino cyclopropyl 
region of abacavir. 
Next, we sought to assess whether the chiral modification of abacavir would remove the T-
cell mediated reactions observed, via the use of a previously synthesised abacavir 
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enantiomer. In the standard state, 1S 4R, abacavir is associated with severe hypersensitivity 
reactions mediated by CD8+ T-cells which secrete the proinflammatory cytokine IFN-γ. 
However, the chiral modification at the cyclopentyl moiety of the structure generated a 
stable compound lacking the propensity to activate T-cells by way of both IFN-γ secretion 
and proliferation (Figure 4.9). Unfortunately this compound was found to be 
pharmacologically inactive due to the enantioselective nature of the enzyme adenosine 
phosphotransferase (Faletto et al. 1997) meaning the enantiomer (1R, 4S) possessed no 
antiviral activity. Nevertheless, this enantiomeric modification was located at the cyclopentyl 
region of the compound which interacts with the D-pocket of HLA-B*57:01, indicating that 
modifications elsewhere in the structure of abacavir can prevent the protrusion of the 
cyclopropyl moiety into the F-pocket, thereby eliminating the T-cell mediated reactions 
observed to the drug.  
Molecular modelling of the abacavir enantiomer within the F-pocket of HLA-B*57:01 
revealed an altered binding pose of the compound when compared with abacavir in its 
natural form (Figure 4.10). The increased distance between the amino acid residues within 
the antigen binding cleft and the 2-amino purine portion of the abacavir analogue revealed 
a distinct lack of binding potential within HLA-B*57:01. This would impair the ability of the 
analogue to interact within HLA-B*5701 to induce the docking of pep-V. This would lead to 
the binding of other distinct peptides likely resulting in the loss of T-cell activity.  
The naïve T-cell priming assay has been developed as a reproducible assay which is able to 
detect T-cell specific responses in non-hypersensitive individuals to a range of drugs including 
flucloxacillin, piperacillin, carbamazepine and the reactive species Bandrowski’s base with 
the most notable being SMX-NO (Faulkner et al. 2016; Naisbitt et al. 2001; Naisbitt et al. 
2002). Using the T-MWA, SMX-NO displayed strong activation of naïve T-cells from two 
donors positive for the HLA-B*57:01 risk allele yielding a percentage of responsive wells of 
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between 40 and 80% consistent with previous findings (Faulkner et al. 2012). Abacavir was 
incorporated into this study to ascertain if this model could be used as a diagnostic tool for 
abacavir hypersensitivity reactions in vitro which may allow for the quicker screening of 
abacavir substituted analogues in place of the conventional T-cell cloning assay. Naïve T-cells 
isolated from healthy drug naïve HLA-B*57:01 positive donors incubated in the presence of 
abacavir did not produce significant T-cell activation when rechallenged with the drug. 
Across the two donors abacavir yielded an overall percentage of responsive wells of 6% 
compared with the 64% value of responsive wells of cells incubated with SMX-NO. The use 
of this assay was also employed to further investigate the findings obtained by Lucas et al 
2015 which suggested the presence of pre-existing abacavir responsive memory CD8+ T-cells. 
It was hypothesised that memory T-cells primed previously from an immunological event to 
a currently unknown antigen, possibly of viral origin were present in drug naïve individuals, 
accounting for hypersensitivity reactions observed upon first exposure to the drug, the 
inability of abacavir to activate naïve T-cells in these assays supports this conclusion (Lucas 
et al. 2015).  
Taken together the data in this chapter demonstrates the important bearing that the chiral 
state of a compound has on its various functional properties. While chirality is already known 
to be pivotal in the pharmacological properties of a wide range of drugs, including 
antidepressants (McConathy & Owens 2003; Koldsø et al. 2010), asthmatics (Nowak et al. 
2006) and drugs to treat hypertension (Satoh et al. 1980) its influence on T-cell activation 
was not widely explored. We were unable to fully investigate the different effects of the 
enantiomer analogues Q and R as neither displayed antiviral activity within the concentration 
range used. However, the chiral modification of these compounds functional group resulted 
in a change in the cytotoxicity of the compounds, with the R conformation displaying lower 
cellular toxicity in two of the three cell lines similar to findings observed with other 
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therapeutics. Importantly, we uncovered that T-cell activation by compounds is enantiomer 
specific, which had only been demonstrated by a small number of studies to date (Naisbitt 
et al. 2005). Indeed, given the high frequency of the HLA-B*57:01 risk allele in the Caucasian 
populations, associated with abacavir hypersensitivity reactions the enantiomeric 
dependence of abacavir-specific memory T-cells demonstrates an interesting concept for 
future study given the notoriety of abacavir hypersensitivity reactions.  
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5.1. Introduction. 
 
Hypersensitivity reactions in response to abacavir occur exclusively in individuals carrying 
the MHC class I allele HLA-B*57:01 (Mallal et al. 2002). The association between this risk 
allele and the observed hypersensitivity reactions yields a 100% NPV, while having a PPV of 
around 55% (Mallal et al. 2008; Lucas et al. 2015).  
Neither the hapten/prohapten or the PI models have sufficiently explained activation of T-
cells and subsequent induction of hypersensitivity reactions to abacavir. The hapten model 
seems an unlikely concept for activation of T-cells by abacavir since the aldehyde metabolite, 
capable of forming covalent adducts, does not activate human T-cells (unpublished data, Bell 
et al). Furthermore, abacavir has been demonstrated to elute unbound from peptides at 
HLA-B*57:01 demonstrating the interactions to be in a non-covalent manner (Illing et al. 
2012). While the PI model accounts for activation of around 50% of abacavir-specific T-cell 
clones, it does not explain the full story (Bell et al., 2013). Chessman et al 2008 and Bell et al 
2013 both demonstrated the need for antigen processing for the activation of T-cells in 
response to abacavir. Firstly, abacavir-specific T-cell clones were activated only by 16-hour 
abacavir pulsed without the presence of soluble drug, but not in those pulsed for a shorter 
duration (1 hour). Furthermore these responses were abolished when antigen processing 
was inhibited via glutaraldehyde fixation, demonstrating the need for antigen processing and 
presentation on the surface of MHC-class I in some abacavir clones (Chessman et al., 2008; 
Bell et al., 2013).  
In 2012, three separate studies were carried out focussing solely on another mechanism of 
T-cell activation by abacavir, the altered peptide repertoire model (Illing et al. 2012; Ostrov 
et al. 2012; Norcross et al. 2012). Proteomic studies discovered that up to 25% of the 
peptides eluted from HLA-B*57:01 in the presence of abacavir were unique self-peptides not 
detected in the absence of the drug. Furthermore, most of these new peptides contained 
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small C-terminal anchor residues such as valine, leucine and isoleucine compared to the 
more traditional larger chain C-terminal amino acids, phenylalanine and tryptophan 
commonly observed with the peptides eluted in abacavirs absence (Ostrov et al. 2012; 
Norcross et al. 2012; Illing et al. 2012). This led to the theory that treatment with abacavir in 
HLA-B*57:01 positive individuals resulted in a change in the shape and chemistry of the 
peptide binding groove of HLA-B*57:01, thereby allowing for the accommodation of 
peptides with smaller C-terminal anchors for presentation on the surface of the antigen 
presenting cell. Therefore, as T-cells are tolerant of peptides they are exposed to during 
development in the thymus, recognition of this altered peptide repertoire would be 
perceived as a foreign antigen and thereby a T-cell-mediated immune response would be 
initiated (Illing et al. 2012).   
In chapter 3 we demonstrated via work with our collaborators in the Purcell Laboratory 
(Monash University, Melbourne) the shift in peptide prevalence in the presence of not only 
abacavir but to two abacavir analogues both of which evoked CD8+ mediated T-cell responses 
in abacavir-responsive T-cell clones. However, to date, the peptide sequences that induce T-
cell activity after exposure to abacavir have not been fully defined. Obtaining clear results 
from T-cell assays examining the effect of abacavir-induced self-peptides on T-cell activation 
can prove difficult as these peptides are only thought to activate T-cells in the presence of 
abacavir. Therefore, it is difficult to distinguish a T-cell response to the peptides in the 
presence of abacavir from the response to abacavir alone using established readouts such as 
cytokine secretion and T-cell proliferation, as the same peptides will load onto HLA-B*57:01 
naturally within the APC.  
Studies analysing the T-cell mediated responses to abacavir-specific peptides have been 
relatively sparse. In 2015 Lucas et al suggested the presence of pre-existing memory T-cells 
primed to a previous immunogenic event which were able to cross-react with abacavir-
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induced self-peptides, perhaps accounting for the hypersensitivity reactions observed to 
abacavir upon first exposure in some individuals (Lucas et al. 2015). In 2017 Yerly et al 
characterised the peptides specifically recognised by abacavir-responsive TCRs. This utilised 
abacavir and the crystal structure of the immunogenic self-peptide VTTDIQVKV, which 
possessed side chains exhibiting solvent exposure, indicating this peptide to be a potential 
motif for T-cell recognition. Basic Local Alignment Search Tool (BLAST) searches identified 
three viral peptide sequences originating from Human Immunodeficiency Virus (HIV) and 
Herpes Simplex Virus (HSV) that displayed structural similarity with VTTDIQVKV. 
Furthermore, one of these viral peptide sequences evoked a response in T-cell transfectants 
in the absence of abacavir, however this response was only observed in transfectants 
expressing one particular TCR (Yerly et al. 2017). Subsequent comparison with abacavir 
displayed similarity with the original peptide VTTDIQVKV, particularly in the contact regions 
with the TCR. These data suggest the ability of T-cells to cross-recognise and react with viral 
peptides, however, this characteristic is likely restricted to a small subset of T-cells (Yerly et 
al. 2017). 
Previously, a panel of 120 unique 9-mer self-peptides, eluted from HLA-B*57:01 in the 
presence of abacavir, were imported to our research laboratory from the Purcell Laboratory 
(Monash University, Melbourne). These peptides were tested by Dr Mohammad Alhaidiri to 
analyse their ability to induce a CD8+ T-cell response. Using C1R (HLA-deficient, TAP 
expressing, B-cell line transfected with HLA-B*57:01) and T2 (B-cell line transfected with 
HLA-B*57:01, TAP deficient) cells it was discovered that one peptide from the panel of 120 
(peptide 15, NTVELRVKI) induced T-cell responses in both the presence or absence of 
abacavir. However, subsequent analysis via mass spectrometry identified the presence of C-
terminal amide groups. Repetition of the experiments using peptides in their natural form, 
without C-terminal amidation, indicated no T-cell activation in the absence of abacavir. 
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However, T-cell activation was observed in a limited number of abacavir-specific T-cell clones 
in the presence of the drug (Figure 5.1-5.3). This data may suggest the activation of CD8+ T-
cells is evoked by an abacavir-induced self-peptide. Unfortunately, due to the difficulty 
distinguishing T-cell activation to abacavir in the presence or absence of the peptide with 
these assays, this was not confirmed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.T-cell responses 
prompted by abacavir-induced self-
peptide mixes. a) Abacavir-
responsive T-cell  clones incubated 
with T2 APCs and a mixture of up to 
5 abacavir-self peptides per well (1-
24) in the presence or absence of 
abacavir. T-cells were co-incubated 
with T2 APCs ± abacavir in the 
absence of peptides as a negative 
control. T-cells were also co-
incubated with C1R APCs ± abacavir 
as a positive control. b) IFN-γ ELIspot 
well images of T-cell clones co-
incubated with C1R and T2 APCs ± 
abacavir in the presence or absence 
of abacavir-induced self-peptide 
mixes (up to 5/well). 
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Figure 5.2. T-cell responses to a panel of individual abacavir-induced self-peptides in the 
presence/absence of abacavir. Abacavir-responsive T-cell clones were co-incubated with T2 
APCs ± abacavir in the presence of abacavir-induced self-peptides 11-15. T-cells were co-
incubated with C1R APCs ± abacavir as a positive control and with no APCs as a negative control. 
Figure 5.3. Activation of T-cells by abacavir-induced self-peptide 15 in natural and amidated 
form in the presence or absence of abacavir. Abacavir-responsive T-cell  clones were co-
incubated with T2 APCs ± abacavir in the presence of abacavir-induced self-peptide 15 in the 
natural and amidated form (20µM). T-cell activity was measured by means of IFN-γ secretion 
(SFU). 
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Therefore, we aimed to continue the T-cell work with peptide 15 and dissect the responses 
between the peptide in its natural and amidated form, via subjecting T-cells to a wider range 
of assays to assess the magnitude of T-cell activation induced by this abacavir-specific HLA-
B*57:01 binding peptide. 
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5.2. Aims. 
 
The aims of this chapter were to further analyse the abacavir-induced self-peptide 15 
(NTVELRVKI) in both its natural and amidated form to further dissect the effect on T-cell 
activation in the presence or absence of abacavir. Furthermore, T-cells were subjected to a 
range of assays to investigate the actions of the peptides on T-cell activation. Finally, T-cell 
cloning was conducted to peptide 15 in both the natural and amidated form and responsive 
clones were subjected to mechanistic studies to explore dose- and antigen presenting cell-
dependency and cellular phenotype for comparison with abacavir-specific T-cell clones. 
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5.3. Methods. 
 
5.3.1. Materials. 
 
Abacavir was received as a gift from GlaxoSmithKline (GSK). Human AB serum and foetal 
bovine serum were obtained from Innovative Research (Michigan, USA) and Invitrogen 
(Paisley, UK), respectively. Interleukin-2 (IL-2) was purchased from Peprotech (London, UK). 
Multisort bead separation kits were supplied by Miltenyi Biotec (Surrey, UK). Antibodies for 
staining were purchased from BD Biosciences (Oxford, UK). ELIspot kits including the coating 
and detection antibodies, streptavidin alkaline phosphate conjugate and BCIP/NBT 
substrates were purchased from Mabtech (Stockholm, Sweden). Other reagents were 
purchased from Sigma-Aldrich (Dorset-UK) unless otherwise stated. 
5.3.2. Cell culture medium.  
 
R9 medium for T-cells (R9) is composed of RPMI supplemented with 10% human AB serum, 
HEPES (25mM), penicillin (1000 U/mL), streptomycin (0.1mg/mL), L-glutamine (2mM) and 
transferrin (25µg/mL).   
EBV transformed B-cells were cultured in F1 medium composed of RPMI supplemented with 
10% foetal bovine serum, HEPES (25mM), penicillin (1000 U/mL), streptomycin (0.1mg/mL) 
and L-glutamine (2mM). 
5.3.3. Maintaining C1R and T2 cells. 
 
Cells from the class I deficient lymphoblastoid cell line, C1R and T2 were transfected with 
HLA-B*57:01 to be used in functional assays. C1R-B*57:01 cells comprise a fully functional B-
cell line transfected to express HLA-B*57:01. T2-B*57:01 cells are a B-cell line transfected to 
express HLA-B*57:01 but the transporter associated with antigen processing (TAP) has been 
knocked out, meaning T2 cells antigen processing capabilities are severely diminished.  
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Both cell lines were maintained in F1 medium supplemented as described in section 5.3.2. 
C1R-B*57:01 cells were further supplemented with geneticin (500µg/mL) (Thermo-Fischer 
Scientific, Massachusetts, USA).  
5.3.4. Generation of abacavir-specific T-cell clones. 
 
5.3.4.1. T-cell cloning. 
 
CD8+ T-cell cloning to abacavir was carried out in four HLA-B*57:01+ drug-naïve donors 
(donors 1-4) as described in detail in section 2.3.5.  
5.3.4.2. Testing clones for antigen specificity. 
 
Approximately four weeks after beginning the serial dilutions, abacavir-specificity was 
measured by assessing cell proliferation in the presence of the drug. This was conducted as 
described in section 2.3.6. The antigen specificity of the abacavir clones was confirmed using 
the IFN-γ ELIspot as described in section 2.3.7. 
5.3.5. Activation of abacavir-specific T-cell clones by peptide 15 in natural and amidated 
form. 
 
Abacavir-responsive T-cells (5x104/ 50µL) were co-incubated with C1R and T2 cells (1x104/ 
50µL) in the presence or absence of abacavir for 48 hours (37OC; 5% CO2). T-cell clones were 
also co-incubated with T2 cells and peptide 15 in the natural and amidated forms (25µM) 
both individually, and in the presence or absence of abacavir (varying concentrations 
dependent on the T-cell clone used). T-cell responses were measured using the IFN-γ ELIspot 
assay.  
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5.3.6. Dose dependency of T-cell activation by abacavir with peptide 15 in natural form. 
 
Abacavir-responsive T-cells (5x104/ 50µL) were co-incubated with autologous EBVs (1x104/ 
50µL) and abacavir (0.1-30µM) in the presence or absence of natural peptide 15 (25µM) for 
48 hours (37OC; 5% CO2). T-cell activation was quantified using the IFN-γ ELIspot assay.  
5.3.7. Dose dependency of CD8+ T-cell activation in in response to increasing 
concentrations of peptide 15 in natural and amidated form. 
 
Abacavir-specific T-cell clones (5x104/ 50µL) were co-incubated with T2 cells (1x104/ 50µL) in 
the presence or absence of abacavir (35µM) at increasing concentrations of peptide 15 in 
both the natural and amidated form (10-50µM) for a period of 48 hours (37OC; 5% CO2). T-
cell clones co-incubated with C1R APCs (1x104/ 50µL) in the presence or absence of abacavir 
were used as positive controls. T-cell activation was measured using cytokine secretion as a 
readout via the IFN-γ ELIspot assay.  
5.3.8. Antigen presenting cell pulsing assays with peptide 15 in natural form. 
 
Antigen presenting cells (C1R-B*57:01 and T2B*57:01) were incubated overnight with 
natural peptide 15 (25µM) in the presence or absence of abacavir (35µM). Ce lls pulsed 
overnight in R9 medium alone were used as a negative control and cells co-incubated with 
soluble abacavir were used as a positive control. Following pulsing, the APCs were washed 
three times in R9 medium and diluted to a cellular concentration of 2x105/mL. The pulsed 
APCs were then co-incubated with abacavir-responsive CD8+ T-cell clones (5x104/ 50µL) for 
a period of 48 hours (37OC; 5% CO2). Results were quantified using IFN-γ ELIspot.  
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5.3.9. T-cell responses to abacavir and/or peptide 15 pulsed EBVs prior washed with 
citrate phosphate buffer. 
 
Elution of MHC bound peptides was carried out using a protocol established by Burkhart et 
al. 2002. Briefly, autologous EBVs were washed three times with PBS and resuspended in 
0.5mL of cold citrate-phosphate buffer (0.131M citric acid/0.066M Na2HPO4, pH 3.0 
containing 1% BSA) for 2 minutes at 4OC. Next, the pH was neutralised with an excess of R9 
medium and the cells were washed three times in R9 medium and diluted to a concentration 
of 1x106/mL. EBVs were then pulsed with the natural peptide 15 in the presence or absence 
of abacavir for 16 hours (37OC; 5% CO2). Following pulsing, the EBVs were washed three times 
in cell culture media and co-incubated (1x104/ 50µL) with abacavir-specific T-cell clones 
(5x104/ 50µL). A pulsing experiment was carried out in parallel EBVs incubated in HBSS 
instead of citrate-phosphate buffer as a comparator. The T-cell activation in response to 
pulsed APCs was quantified using secretion of IFN-γ as a readout via the ELIspot assay.  
5.3.10. T-cell responses to natural peptide 15 in the presence of glutaraldehyde-fixed 
APCs. 
 
Autologous EBVs (2x106 cells/mL) were resuspended in 1mL of HBSS buffer. Glutaraldehyde 
(25%, 1µL) was added to the cells for 30 seconds, followed by the addition of 1mL of glycine 
(1M) for a further 45 seconds. EBVs were then washed three times and resuspended in R9 
medium to a concentration of 2x105cells/mL. Abacavir-specific T-cell clones (5x104/ 50µL) 
were then co-incubated with the glutaraldehyde fixed EBVs (1x104/ 50µL) and natural 
peptide 15 (25µM) in the presence or absence of abacavir for 48 hours (37OC; 5% CO2). T-
cells co-incubated with non-fixed EBVs in the presence or absence of abacavir were used as 
a positive control and T-cell activation was quantified using IFN-γ secretion by means of the 
ELIspot assay.  
                                                                                                       Chapter 5 
 
208 
 
5.3.11. Generation of responsive T-cell clones to the natural form of peptide 15 in the 
presence of abacavir. 
 
PBMCs isolated from one HLA-B*57:01 positive donor (Donor 1; HLA-0617) were incubated 
in the presence of abacavir (35µM) and natural peptide 15 (25µM) in R9 medium for a period 
of 14 days. On days 6 and 9 cells were fed with R9 medium containing IL-2 (200 IU/mL) to 
preserve the antigen driven expansion of T-cells. On day 14, CD8+ T-cells were positively 
selected using MultiSort kits (Miltenyi Biotec, Surrey UK) and T-cell clones were generated 
via serial dilution as described in section 2.3.5. 
5.3.11.1. Testing clones for antigen specificity. 
 
Approximately four weeks after beginning the serial dilutions, T-cell specificity to abacavir + 
natural peptide 15 was measured by assessing cell proliferation in the presence of the drug 
and peptide. Proliferation was measured by culturing T-cell clones (5x104/ 50µL) with 
irradiated autologous EBVs (1x104/50µL) in the presence of abacavir (35µM) + natural 
peptide 15 (25µM). Following 48 hour incubation, tritiated thymidine (0.5µCi) was added and 
proliferation was assessed 16 hours later via scintillation counting. The proliferative response 
of T-cell clones was expressed as radioactive counts per minute (cpm). T-cell clones with a 
stimulation index of 2 or greater were picked and expanded by mitogen restimulation in cell 
culture media containing irradiated PBMCs (5x105 cells/well), IL-2 (5µL/mL) and PHA 
(10µg/mL) for further analysis. 
5.3.11.2. Confirmation of antigen specificity of abacavir + natural peptide 15-responsive 
T-cell clones. 
 
T-cell clones were tested to confirm their specificity to abacavir + natural peptide 15 via co-
incubation (5x104/50µL) with autologous EBVs (1x104/50µL) in the presence or absence of 
abacavir (35µM) + natural peptide 15 (25µM) with R9 medium as a negative control. ELIspot 
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plates were developed according to the manufacturer’s instructions and counted using an 
ELIspot AID reader. All clones displaying a significant difference in IFN-γ secretion between 
control and abacavir + natural peptide 15 treated cells were maintained in cell culture for 
use in further experiments.  
5.3.12. Generation of responsive T-cell clones to amidated peptide 15.  
 
CD8+ T-cell cloning to amidated peptide was carried out as described in section 5.3.11 with 
the amidated form of peptide 15 (25µM) used as the primary antigen for initial proliferation 
assays, and subsequent confirmation of antigen specificity was provided via ELIspot.  
5.3.13. Statistical analysis 
 
For comparison between control and test values in the proliferation assays the Mann-
Whitney test was used. Comparison between control and test values in the ELIspot assays 
(when available) was carried out using the students two sample t-test.  
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5.4. Results. 
5.4.1. Generation of abacavir-specific T-cell clones. 
 
T-cell clones specific to abacavir were generated using serial dilution assays. From a total of 
2279 clones tested across four HLA-B*57:01 positive donors, 101 proliferated in the presence 
of abacavir on first testing, (0, 1665 ± 188.5 cpm: Abacavir 35µM, 6940 ± 729 cpm; P< 
0.0001). Results for T-cell specificity assays of abacavir clones and subsequent phenotyping 
data is discussed in detail in section 2.1. The abacavir-responsive T-cell clones used for assays 
in this chapter are displayed in Table 5.1 with their corresponding donor.  
 
 
 
 
 
 
Table 5.1 Abacavir-responsive CD8+ T-cell clones from four HLA-B*57:01 positive donors discussed in this 
chapter.  
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5.4.2. Activation of abacavir-specific T-cell clones with peptide 15 in natural and 
amidated form. 
 
To investigate the effects of the abacavir-induced self-peptide 15 in both the natural and 
amidated form, three CD8+ T-cell clones were selected and incubated with C1R and T2 APCs 
with the respective peptides in the presence or absence of abacavir. As T-cell clones 42 and 
43 responded strongly in the absence of APCs at the optimal concentration of abacavir 
(35µM), a dose titration assay was carried out prior to the study (data not shown). T-cell 
clones 42 and 43 were found to rely on APCs for activation at concentrations of 0.1µM and 
1µM respectively (data not shown). Clone 40 was not activated at 35µM in the absence of 
APCs and was therefore used at this concentration throughout.  
In the presence of T2 APCs, T-cell activation in response to abacavir was not observed with 
clone 40, and was diminished when compared to C1R APCs in clones 42 and 43 (Figure 5.4). 
Addition of peptide 15 in the natural form did, in some clones, result in enhanced T-cell 
responses in the presence of abacavir, but no T-cell activation was observed to the peptides 
in the absence of abacavir. The amidated form of peptide 15 induced T-cell responses in the 
clones in the presence of abacavir, while moderate T-cell activation was also observed in the 
absence of abacavir. However, these findings (particularly with the natural peptide), were 
not reproducible on repeated testing, nor were they observed with other T-cell clones as it 
proved difficult to distinguish the response to abacavir in the presence of the peptides from 
the response observed to abacavir alone (Figure 5.5), leading to exploration of alternate 
assays for further investigation of peptide 15. 
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Figure 5.4. Induction of T-cell activity in abacavir-responsive clones by peptide 15 in 
natural and amidated form.  Abacavir (ABC)-responsive CD8
+
 T-cell clones were co-
incubated with T2 APCs ± abacavir in the presence or absence of peptide 15 in the natural 
or amidated form (25µM). T-cells incubated with T2 APCs with no peptide were used as a 
negative control and T-cells co-incubated with C1R APCs ± abacavir were used as a positive 
control. (ABC used at different concentrations/clone depending on the concentr ation for 
the clones dependence on APCs).   
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Figure 5.5. Repetition of T-cell induction by addition of peptide 15 in natural and 
amidated form. Abacavir (ABC)-responsive CD8
+
 T-cell  clones were co-incubated with T2 
APCs ± abacavir in the presence or absence of peptide 15 in the natural or amidated form 
(25-50µM). T-cells incubated with T2 APCs with no peptide were used as a negative control 
and T-cells co-incubated with C1R APCs ± abacavir were used as a positive control. (ABC 
used at concentrations  of 1µM and 20µM for clones 43 and 46 respectively.   
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5.4.3. Dose dependency on T-cell activation by abacavir with the natural peptide 15.  
 
To investigate whether the addition of peptide 15 would enhance the re sponse to abacavir 
in clones at lower concentrations of the drug, dose titration assays were conducted. Initially, 
T-cell clones were incubated with C1R and T2 APCs at increasing concentrations of abacavir 
in the presence or absence of peptide 15 in both the natural and amidated forms (25µM) 
(Figure 5.6). No enhancement of T-cell activity was observed in clones incubated alongside 
T2 APCs with the natural form of peptide 15 in the presence of abacavir when compared with 
abacavir alone. Furthermore, low levels of T-cell activation were detected in clones co-
incubated with T2 APCs in the presence of the amidated peptide. However, this level of T-
cell activation was consistent at all doses, but also without drug, indicating that the presence 
of abacavir had no bearing on T-cell activation by the amidated peptide. 
Next, the dose response assay was expanded to a broader range of abacavir-specific T-cell 
clones, using autologous EBVs in place of C1R and T2 APCs. T-cell clones were incubated with 
autologous EBVs at increasing concentrations of abacavir (0-30µM) in the presence or 
absence of the natural peptide 15. No distinguishable difference in T-cell activation was 
observed in response to abacavir across four of the five abacavir clones in the presence of 
the peptide, compared to abacavir alone. One clone (TCC 46) displayed an enhanced 
response to abacavir in the presence of the peptide at concentrations of 10µM and below 
(Figure 5.7). Based on these findings, this clone was selected for further study.  
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Figure 5.6. Effect of abacavir concentration on T-cell activity induced by peptide 
15. Abacavir-responsive CD8
+
 T-cell clones were co-incubated with T2 APCs at 
increasing concentrations of abacavir (0-35µM) in the presence or absence of 
peptide 15 in the natural or amidated form (25µM). T-cells incubated with T2 APCs 
with no peptide in the presence of abacavir (0-35µM) were used as a negative 
control and T-cells co-incubated with C1R APCs with the same abacavir 
concentrations were used as a positive control. 
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Figure 5.7. Abacavir-specific T-cell activation in the presence of abacavir and natural peptide 15.  
a) IFN-γ ELIspot well images of five abacavir-specific CD8
+
T-cell  clones (TCC) co-incubated with 
autologous EBVs at abacavir concentrations of 0-30µM in the presence or absence of the natural peptide 
15 (+ and -). b) T-cell activation quantified by IFN-γ secretion from T-cell clones and compared in the 
presence or absence of peptide 15. 
a) 
b) 
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5.4.4. Dose dependency of CD8+ T-cell activation in in response to increasing 
concentrations of peptide 15 in natural and amidated form. 
 
Three CD8+ T-cell clones were co-incubated with C1R and T2 APCs and peptide 15 in both 
forms at concentrations of 10µM, 25µM and 50µM in the presence or absence of abacavir. 
In all three clones used, the eradicated response to abacavir observed in T-cells incubated 
with the T2 APCs was not reinstated by the addition of natural peptide 15 at any 
concentration. Stimulation with the amidated peptide resulted in modest T-cell activation at 
50µM in two of the clones, but the presence of the drug had no influence on induced T-cell 
activity (Figure 5.8).  
Using T-cell clone 46, dose response assays to both natural peptide 15 and abacavir were 
conducted. T-cells were co-incubated with T2 APCs at increasing concentrations of abacavir 
(0-100µM) and the natural peptide (0-100µM). As expected, an increase in T-cell activation 
was observed with an increase in concentration of abacavir, however no enhanced T-cell 
activity was triggered by increasing the concentrations of natural peptide 15 compared to 
abacavir alone (Figure 5.9.).  
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Figure 5.8. Dose dependency of T-cell activation on concentration of peptide 15 in the natural and 
amidated form (N.P and A.P. respectively). a) IFN-γ ELIspot well images and b) direct comparisons of 
three individual abacavir-responsive T-cell clones. T-cells were co-incubated with T2 APCs ± abacavir at 
increasing concentrations of peptide 15 in the natural or amidated form (10, 25, 50 µM).  
                                                                                                       Chapter 5 
 
219 
 
 
 
 
 
 
 
 
 
Figure 5.9. T-cell activation dependency on concentration of abacavir and the natural 
peptide 15. Abacavir-responsive CD8
+
 
T-cells were co-incubated with T2 APCs at 
increasing concentrations of both abacavir (ABC; 0-100µM) and natural peptide 15 (0-
200µM). T-cell  clones co-incubated with C1R APCs at increasing abacavir concentrations 
(0-100µM) were used as a positive control.  
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5.4.5. APC pulsing assays with peptide 15 in natural form. 
 
Stimulating T-cells with 16 hour abacavir pulsed EBVs is shown in some clones to result in the 
induction of IFN-γ secretion (Chapter 2), indicating these clones employ the altered peptide 
model as a means of T-cell activation (Illing et al. 2012). Two abacavir-specific T-cell clones 
which demonstrated strong T-cell responses in the presence of abacavir pulsed EBVs, were 
co-incubated with C1R and T2 APCs pulsed for 16 hours in the presence of abacavir ± natural 
peptide 15. The observed T-cell response in the presence of C1Rs (TCC 46, P<0.01), (TCC 71, 
P<0.05) was abrogated in the presence of the T2 APCs. However, co-stimulation with natural 
peptide 15 and T2 APCs did not induce T-cell activation (Figure 5.10).    
 
 
Figure 5.10. T2 APCs were pulsed with abacavir (ABC; 35µM) in the presence or absence of the natural 
peptide 15 (25µM) for 16h. Pulsed APCs were then co-incubated with abacavir-specific T-cells for 48h 
and T-cell activation was quantified using IFN-γ ELIspot. ABC pulsed C1R APCs were used as a positive 
control and APCs pulsed in just R9 medium were used as a negative control.  
*P<0.05, **P<0.01, ***P<0.001. 
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5.4.6. Activation of abacavir T-cell clones in response to abacavir + peptide pulsed, acid 
washed APCs.  
 
To assess if the introduction of a new peptide, following displacement of the peptide bound 
at the MHC, could result in an increased T-cell response in the presence of abacavir, 
autologous EBVs were incubated in cold citrate-phosphate buffer (0.131M citric acid/0.066M 
Na2HPO4, pH 3.0 containing 1% BSA) prior to pulsing with abacavir alone or abacavir ± natural 
peptide 15. Cells incubated with HBSS instead of citrate-phosphate buffer were used as a 
comparator. No comparable difference was observed in T-cells co-incubated with acid 
washed EBVs pulsed with abacavir in the presence of natural peptide 15 when compared to 
pulsing with abacavir alone. Furthermore, no measurable difference was observed across the 
three clones between cells washed with citrate-phosphate buffer prior to pulsing and those 
washed with HBSS instead.  
 
 
 
 
 
 
 
 
Figure 5.11. CD8
+ 
T-cell response of abacavir-specific clones with pulsed autologous EBVs. IFN-γ 
ELIspot well images of three abacavir-specific CD8
+
T-cell  clones co-incubated with autologous EBVs 
pulsed with abacavir (ABC) (35µM), peptide 15 (25µM) and abacavir + peptide 15. EBVs pulsed with 
cell  culture media alone were used as a negative control. Acid wash: EBVs were washed with cold 
citrate-phosphate buffer (0.131M citric acid/0.066M Na
2
HPO
4
, pH 3.0 containing 1% BSA) prior to 
pulsing. No acid wash; EBVs were washed with HBSS prior to pulsing.  
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5.4.7. T-cell activation to abacavir + natural peptide 15 in the presence of 
g lutaraldehyde fixed APCs.  
 
To remove the processing capabilities of the autologous EBVs, fixation with glutaraldehyde 
prior to co-incubation with T-cells was conducted. T-cells were co-incubated with the 
glutaraldehyde fixed EBVs in the presence of abacavir or abacavir + natural peptide 15. T-
cells incubated with non-fixed EBVs in the presence of abacavir were used as a positive 
control. Indeed, fixation of the EBVs eradicated the T-cell response to abacavir, however 
addition of the natural peptide was not sufficient to evoke IFN-γ secretion in the presence or 
absence of the drug (Figure 5.12). 
 
 
 
 
 
Figure 5.12. Activation of abacavir-specific T-cell clones co-incubated with autologous EBVs fixed 
with glutaraldehyde in the presence of abacavir (35µM) and abacavir + natural peptide 15 (25µM). 
T-cells incubated with unfixed APCs ± abacavir (35µM) were used as a comparator. 
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5.4.8. Generation of T-cell clones to the natural form of peptide 15 in the presence of 
abacavir. 
 
To test the possibility of yielding T-cell clones responsive to abacavir and the natural form of 
peptide 15, T-cell cloning was carried out using established methods described in detail in 
section 2.3.5. The procedure was conducted following the same methods, only the natural 
peptide 15 (25µM) was added alongside abacavir at the priming and testing for antigen 
specificity stages. From a total of 96 clones tested, 25 proliferated in response to abacavir + 
the natural peptide on first testing (0, 1201 ± 189.4 cpm; abacavir (35µM) + natural peptide 
15 (25µM), 9987 ± 1673 cpm; P<0.0001). Antigen specificity was confirmed by culturing the 
generated T-cell clones with abacavir and the natural peptide for 48 hours and measuring 
IFN-γ secretion via ELIspot (Figure 5.13). Only those clones producing significant increase in 
IFN-γ secretion between control and abacavir + natural peptide 15 were maintained in cell 
culture. All responsive clones to abacavir + the natural peptide 15 were phenotyped as CD8+ 
(Figure 5.15). 
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Figure 5.13. Generation of T-cell clones responsive to abacavir and natural peptide 15 . a) 
Mean proliferative response and b) Table showing percentage of responsive clones generated 
to abacavir in the presence of the natural peptide 15 from donor 1. c) Antigen specificity of T-
cell  clones generated to abacavir in the presence of natural peptide 15. T-cell  clones (5x10
4
) 
were cultured in the presence of irradiated autologous antigen presenting cells (1x10
4
) in the 
presence or absence of abacavir (35µM) + natural peptide 15 (25µM) for 48 hours. Tritiated 
thymidine (0.5µCi) was added for 16 hours and proliferation was measured using scintillation 
counting. Clones yielding an SI<2 were considered positive. d) Representative ELIspot well 
images from three T-cell  clones tested for antigen specificity in the presence of abacavir 
(35µM) + natural peptide 15 (25µM).  
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5.4.9. Generation of T-cell clones to amidated peptide 15.  
 
T-cell cloning was carried out to the amidated form of peptide 15 using methods described 
in detail in section 2.3.5. Cloning was carried out using the same methods as before, with the 
amidated peptide 15 (25µM) used at the priming and testing for antigen specificity stages in 
the place of abacavir. From a total of 184 clones, 73 proliferated in response to the amidated 
peptide on first testing (0, 1619 ± 265.7 cpm, amidated peptide (25uM), 7321 ± 1417 cpm; 
P<0.0001). Antigen specificity was confirmed by culturing the generated T-cell clones with 
the amidated peptide for 48 hours and measuring IFN-γ secretion via ELIspot (Figure 5.14). 
All responsive clones to the amidated peptide 15 were phenotyped as CD8+ (Figure 5.15). 
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Figure 5.14. Generation of T-cell clones responsive to amidated peptide 15. a) Mean proliferative 
response and b) Table showing percentage of responsive clones generated to ami dated peptide 
15 from donor 1. c) Antigen specificity of T-cell clones generated to amidated peptide 15. T-cell  
clones (5x10
4
) were cultured in the presence of irradiated autologous antigen presenting cells 
(1x10
4
) in the presence or absence of the amidated peptide (25µM) for 48 hours. Tritiated 
thymidine (0.5µCi) was added for 16 hours and proliferation was measured using scintillation 
counting. Clones yielding an SI<2 were considered positive. d) Representative ELIspot well images 
from three T-cell  clones tested for antigen specificity in the presence of amidated peptide 15 
(25µM).  
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Figure 5.15. Cell phenotyping for expression of CD4 and CD8 on the surface of abacavir + 
natural peptide 15 or amidated peptide 15 T-cell clones. Cells (50µL) were stained with 
antibodies CD4-FITC and CD8-PE and incubated for 20 minutes at 4
o
C. Cells were then washed 
and flow cytometry used to analyse cellular phenotype (BD FACSCANTO II). 
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5.4.10. Activation of peptide specific T -cell clones with peptide 15 in natural and 
amidated form in the presence or absence of abacavir. 
 
To test the responsiveness of the T-cell clones generated to either abacavir + natural peptide 
15 or the amidated peptide 15 alone, a selection of clones were tested with the individual 
peptides in the presence or absence of abacavir, with abacavir alone as a comparator. Clones 
generated to abacavir + natural peptide 15 displayed no distinguishable difference in T-cell 
activation when incubated with abacavir in the presence of the natural peptide, compared 
to abacavir alone. Furthermore, these clones were activated by the amidated peptide but to 
a much lesser degree than with the amidated peptide in the presence of abacavir. No T-cell 
activity was observed in these clones when stimulated with the natural peptide 15 alone.  
Clones generated to the amidated peptide produced strong T-cell activity when co-incubated 
with the peptide in its amidated form, but yielded no T-cell activity when stimulated with the 
natural form of peptide 15. Furthermore, these clones displayed no IFN-γ secretion when 
stimulated with abacavir. Interestingly, the observed response to the amidated peptide was 
diminished in the presence of abacavir in clone 11 (Figure 5.16).  
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Figure 5.16. CD8
+
 T-cell activity of clones to natural peptide 15 + abacavir and amidated peptide 
15. A panel of responsive clones generated to peptide 15 in the natural form + abacavir (blue) 
and the amidated peptide 15 in abacavirs absence (yellow) were exposed to six individual 
conditions. Abacavir alone (ABC, 35µM), natural peptide 15 (25µM) ± abacavir. Amidated peptide 
15 (25µM) ± abacavir for 48h (37
O
C, 5% CO
2
). T-cell  activity was quantified by measuring IFN-γ 
secretion by means of the ELIspot assay. 
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5.4.11. Dose dependent activation of abacavir + natural peptide 15 specific clones. 
 
Next, the dose dependent activation of clones with abacavir in the presence or absence of 
natural peptide 15 were assessed. Distinguishing between the T-cell responses observed in 
the presence of abacavir + natural peptide from the response to abacavir alone can be 
difficult, therefore, titrating the dose down a concentration gradient allows for easier 
distinction of T-cell activation. Two clones responsive towards abacavir + natural peptide 15 
were co-incubated with autologous EBVs at increasing concentrations of abacavir (0-30µM) 
in the presence or absence of natural peptide 15 (25µM). Clone 3, displayed an enhanced T-
cell response in the presence of the peptide at all concentrations within the range used 
(Figure 5.17), however the same distinction between peptide-treated and untreated cells 
was not as clearly observed with clone 20, particularly as at concentrations of 5µM and below 
higher T-cell activity to abacavir was observed in the absence of the peptide. Furthermore, 
upon repetition of the assay (Figure 5.18), the distinction in response to abacavir between 
peptide-treated and untreated cells with clone 3 was not observed. A small enhancement of 
T-cell activity in the presence of natural peptide 15 was observed at 2.5µM, but not at any 
of the concentrations below which would have been expected if the peptide was producing 
the enhanced T-cell response.  The same absence of a distinguishable T-cell response 
between abacavir-treated and abacavir + natural peptide- treated cells was again observed 
with clone 20 (Figure 5.17).  
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Figure 5.17. Abacavir-specific T-cell activation in the presence of abacavir and natural peptide 15. a) 
IFN-γ ELIspot well images of two abacavir + natural peptide 15 specific CD8
+
T-cell clones co-incubated 
with autologous EBVs at abacavir concentrations of 0-30µM in the presence or absence of the natural 
peptide 15 (25µM). b) T-cell  activation quantified by IFN-γ secretion from T-cell clones and compared 
in the presence or absence of peptide 15 (SFU). 
Figure 5.18. Abacavir-specific T-cell activation in the presence of abacavir and natural peptide 
15. a) IFN-γ ELIspot well images of two abacavir + natural pepti de 15 specific CD8
+
T-cell  clones co-
incubated with autologous EBVs at abacavir concentrations of 0 -30µM in the presence or absence 
of the natural peptide 15 (25µM). b) T-cell  activation quantified by IFN-γ secretion from T-cell  
clones and compared in the presence or absence of peptide 15 (SFU). 
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5.4.12. Activation of T-cell clones with APCs pulsed with natural peptide 15 ± abacavir. 
 
The APC pulsing assays to abacavir in the presence or absence of natural peptide 15 were 
repeated using the two specific T-cell clones generated to abacavir in the presence of peptide 
15. All conditions were the same as described in section 5.4.6. Again, no comparable 
difference in IFN-γ secretion between cells co-incubated with abacavir pulsed EBVs and those 
co-incubated with EBVs pulsed with abacavir + natural peptide 15 was observed in either 
clone. Next, the assay was repeated, but prior to pulsing with abacavir or abacavir + peptide, 
EBVs were incubated in cold citrate-phosphate buffer to remove the bound peptides as 
described in section 5.4.2. As observed previously with abacavir clones, no increase in T-cell 
activation was observed in cells co-incubated with abacavir + peptide 15 pulsed APCs 
compared to those incubated with APCs pulsed with abacavir alone following acid washing 
of the cells.  
 
Figure 5.19. CD8
+ 
T-cell response of abacavir + natural peptide 15 specific clones with pulsed 
autologous EBVs.
.
 IFN-γ ELIspot well images of two abacavir + natural peptide 15 specific CD8
+
T-cell  
clones co-incubated with autologous EBVs pulsed with abacavir (ABC) (35µM), natural peptide 15 
(25µM) and abacavir + natural peptide 15. EBVs pulsed with cell  culture media alone were used as 
a negative control. Acid wash: EBVs were washed with cold citrate-phosphate buffer (0.131M citric 
acid/0.066M Na
2
HPO
4
, pH 3.0 containing 1% BSA) prior to pulsing. No acid wash; EBVs were washed 
with HBSS prior to pulsing.  
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5.4.13. APC dependency of amidated peptide 15 specific T-cell clones. 
 
Three clones generated with specificity for peptide 15 in the amidated form were co-
incubated with the peptide in the presence or absence of autologous EBVs with T-cell 
activation quantified via the IFN-γ ELIspot assay. T-cell activation in the presence of amidated 
peptide 15 was severely blunted in the absence of APCs in all three peptide specific T-cell 
clones. The assay was repeated using the same three amidated specific T-cell clones but with 
the natural form of peptide 15 in place of its amidated counterpart. Co-incubation with the 
natural peptide induced no activation of T-cells in either the presence or absence of APCs 
(Figure 5.20). 
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Figure 5.20. APC dependency of CD8
+
 
T-cell activation to the amidated peptide 15. 
Three amidated peptide 15-specific T-cell clones were co-incubated with the amidated 
peptide 15 (25µM) for 48 hours in the presence or absence of EBVs (37
O
C; 5% CO
2
). T-
cell activation was measured by IFN-γ secretion via means of the ELIspot assay (SFU). b) 
The assay was repeated on the same three amidated peptide 15-specific T-cell clones but 
using the natural form of peptide 15 instead of the amidated version.  
TCC 
TCC 
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5.4.14. Activation of amidated peptide 15-specific T-cell clones is not dependent on 
abacavir. 
 
To investigate the dependence on abacavir for the induction of CD8+ T-cells with specificity 
to the amidated form of peptide 15, two specific clones were co-incubated with autologous 
EBVs at increasing concentrations of the amidated peptide (0-200µM) in the presence or 
absence of abacavir (35µM) for 48 hours (37OC; 5% CO2). T-cell activation was measured via 
quantification of IFN-γ secretion using the ELIspot assay. The presence of abacavir had little 
to no bearing on the magnitude of T-cell activation instigated by the amidated peptide 15 in 
the two specific clones (Figure 5.21). With one clone (TCC 11), an enhanced response was 
observed at 50µM of the amidated peptide in the presence of abacavir, compared to peptide 
alone. However, no enhancement was observed at any concentration below indicating that 
abacavir was unlikely to contribute to this response.  
 
Figure 5.21. Dependency on dose and presence of abacavir on activation of amidated peptide 
specific CD8
+ 
T-cell clones.  Two amidated peptide 15 specific T-cell clones were co-incubated 
with autologous EBVs at increasing concentrations of the amidated peptide 15 (0-200µM) in the 
presence or absence of abacavir (35µM) for 48h (37
O
C; 5% CO
2
). T-cell activation was measured 
using IFN-γ secretion as a readout via means of the ELIspot assay (SFU).  
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5.5. Discussion. 
 
Abacavir hypersensitivity reactions in individuals expressing the HLA-B*57:01 allele present 
a major clinical problem due to the high prevalence of the risk allele, particularly in caucasian 
individuals. Indeed, prospective genotyping for HLA-B*57:01 expression is now common 
practice in the medical setting prior to treatment with abacavir, with those testing positive 
for the allele excluded from abacavir therapy (Mallal et al. 2008). However, the underlying 
mechanisms mediating the observed hypersensitivity reactions to abacavir remain a 
contested topic. Neither the hapten or the PI model have been able to sufficiently explain 
the T-cell mediated reactions observed in the presence of the drug due to abacavir co-eluting 
from MHC unbound to peptides and the requirement for antigen processing and 
presentation for T-cell responses to take place (Illing et al. 2012; Chessman et al. 2008).  
The altered peptide repertoire model hypothesises that abacavir induces a change in the 
array of peptides presented on the surface of antigen presenting cells for recognition by T-
cells. As T-cells would perceive these peptides to be foreign, due to no previous exposure, 
an immunological response would be initiated. Indeed, studies to investigate this found an 
overall shift in the prevalence of new altered self-peptides mainly terminating in small chain 
C-terminal anchors such as valine, isoleucine and leucine eluted from HLA-B*57:01 in the 
presence of abacavir, that were not detected in its absence (Illing et al. 2012; Ostrov et al. 
2012; Norcross et al. 2012). This incepted the theory that abacavir-induced a conformational 
change in the shape and chemistry of the antigen binding cleft of HLA-B*57:01, leading to a 
reduction in its size which would accommodate the amino acids containing small C-terminal 
anchors, meaning their subsequent presentation to T-cells would initiate an immune 
response (Illing et al. 2012; Ostrov et al. 2012; Norcross et al. 2012).  
A panel of 120 of these eluted abacavir-induced self-peptides were received by our research 
group from our collaborators in the Purcell Laboratory (Monash University, Melbourne) 
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which were subsequently tested for T-cell activating properties by Dr Mohammad Alhaidiri. 
From these 120 self-peptides, peptide 15 was initially found to activate T-cells in the 
presence of abacavir in its natural form, while in its amidated form T-cell activation was 
observed in the absence of abacavir.  
NTVELRVKI (peptide 15) belongs to the dolichyl-diphosphooligosaccharide-protein 
glycosyltransferase subunit 2. This protein is located in the endoplasmic reticulum and plays 
a direct role in protein glycosylation which constitutes part of protein modification 
(http://www.uniprot.org/uniprot/P04844). In this chapter we sought to assess in detail the 
effect of this abacavir-induced self-peptide on a wider range of T-cell clones firstly using 
techniques previously employed, then expanding to a greater range of assays for further 
dissection between the properties of peptide 15 (NTVELRVKI) in the natural and amidated 
forms. 
First, assays using C1R and T2s as APCs with and without the addition of the peptides and 
abacavir were repeated. In T2B*57:01 cells, the transporter associated with antigen 
presentation (TAP) is knocked out meaning they cannot process and present endogenously 
generated peptides to T-cells in the manner employed by C1Rs. Co-incubation of some 
abacavir-specific T-cell clones with T2 APCs blunted the T-cell response observed in the 
presence of abacavir. In some T-cell clones, exogeneous addition of natural peptide 15 to the 
T-cells enhanced the response to abacavir in the presence of T2 APCs to a similar level 
observed in the presence of C1Rs, however, this was not observed universally across all 
clones. Addition of peptide 15 in the amidated form resulted in a T-cell response in most 
clones tested, but activation was also observed in the absence of abacavir. Unfortunately, 
results obtained with some T-cell clones in the presence of natural peptide 15 were not 
observed in other abacavir-responsive T-cell clones, nor upon repetition with the same 
clones. 
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Distinguishing the T-cell response to abacavir in the presence of the natural peptide from 
that to abacavir alone proved to be difficult, therefore we next looked at co-incubating T-
cells down a concentration gradient of abacavir in the presence or absence of the peptide in 
both forms. In the presence of the amidated peptide, the T-cell response was constant at all 
concentrations of abacavir used, but also without drug, indicating that the presence of 
abacavir had no influence on the induction of T-cell activity by the amidated form of peptide 
15. Furthermore, no activation of T-cells was observed when they were co-incubated with 
T2 APCs in the presence of the natural peptide regardless of the abacavir concentration 
suggesting that addition of the natural peptide was not sufficient to reinstate the T-cell 
activity that was abrogated by the loss of antigen processing (Figure 5.6).  
Next, we assessed if the use of autologous EBVs in place of the C1R and T2s may allow for a 
distinction between responses in the presence or absence of the peptide in dose titration 
assays. Abacavir-specific T-cell clones co-incubated with abacavir at increasing 
concentrations displayed no enhanced T-cell activity in the presence of the natural peptide 
compared to abacavir alone, again suggesting that the peptide has little influence on T-cell 
activity. Abacavir clones were then exposed to the natural and amidated peptides at 
increasing concentrations in the presence or absence of the drug to investigate if T-cell 
activity induced by the peptide was dependent on dose. However, in the presence of T2 APCs 
the inhibited response to abacavir was not altered via the addition of the natural peptide at 
any concentration, while some modest activation was observed in the presence of the 
amidated peptide, there was no distinguishable difference between the abacavir-treated 
and untreated cells. Finally, to investigate dose dependency of both the drug and the 
peptide, T-cells were co-incubated with increasing concentrations of abacavir and the 
natural peptide. While an increase in T-cell activation was observed with increasing abacavir 
concentration, no distinguishable enhancement of T-cell activity was noted with the 
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increasing concentrations of natural peptide 15 (Figure 5.9), again suggesting that the natural 
peptide plays little role in the activation of a T-cell response to abacavir.  
Next, we investigated the effect of using C1R and T2 APCs pulsed with natural peptide 15 in 
the presence or absence of abacavir on T-cell activation. In chapter 2, we reported that T-
cell activation was observed following co-incubation with abacavir-pulsed EBVs (16 hour), 
consistent with previous findings (Bell et al., 2013). Strong T-cell responses were observed in 
cells co-incubated for 16 hour with abacavir pulsed C1R APCs, but not pulsed T2 APCs. Pulsing 
T2 APCs with abacavir in the presence of the natural peptide did not stimulate T-cells (Figure 
5.10). Repetition of the assay using autologous EBVs in place of the C1Rs and T2s displayed 
no enhanced T-cell activation with abacavir when co-exposed to the natural peptide, 
compared to abacavir alone (Figure 5.11). This suggested that perhaps in the natural form, 
peptide 15 does not possess sufficient binding affinity to be able to bind to HLA -B*57:01 
presented on the surface of the APC, nor to displace the peptide already bound. To 
investigate this, APCs were washed with the weak acid citrate-phosphate buffer prior to 
pulsing to displace the peptides bound to surface MHC (Burkhart et al. 2002; Sugawara et al. 
1987). No enhanced T-cell activation was detected in cells pulsed with abacavir in the 
presence of the natural peptide compared to abacavir alone in any of the T-cell clones. 
Furthermore, no difference was observed in T-cell activation between clones incubated with 
the weak acid washed APCs and those incubated with APCs washed in HBSS instead. This 
suggests an inability of natural peptide 15 to bind to surface MHCs or alternatively that it 
binds but is not involved in T-cell activation. Finally, we investigated T-cell responses after 
glutaraldehyde fixation of EBVs. Glutaraldehyde fixation completely abrogated the T-cell 
response to abacavir, however, addition of the natural peptide did not reinstate the T-cell 
response (Figure 5.12).  
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Taken together, these findings suggest that abacavir-responsive T-cell clones possess little to 
no affinity for peptide 15 in its natural form, indicating that the peptide plays little to no role 
in the induction of T-cell responses or that the induction of T-cell responses by peptide 15 
was limited to a small subset of T-cells.   
The next step was to generate specific T-cell clones to the natural peptide in the presence of 
abacavir and to the amidated peptide in the absence of abacavir. T-cell clones were 
generated to the natural peptide in the presence of abacavir, yielding an overall 26% 
response rate of clones at the first testing stage. The return was much higher with the 
peptide in its amidated form with just under 40% of the clones tested displaying specificity 
for the peptide. Clones activated with the natural peptide in the presence of abacavir 
displayed no T-cell activation when incubated with the natural peptide alone. The clones 
were also activated by the amidated peptide in the presence of abacavir as well as in its 
absence, however, the latter was to a lesser degree.   
We next sought to repeat the APC pulsing assays on T-cell clones generated to abacavir in 
the presence of the natural peptide. This assay was carried out firstly using autologous EBVs 
pulsed with the natural peptide in the presence or absence of abacavir. No increase in T-cell 
activity was observed in either clone co-incubated with abacavir in the presence of the 
natural peptide compared to abacavir alone. Furthermore, when EBVs were acid washed 
prior to pulsing in the respective conditions, co-incubation with abacavir clones again 
demonstrated no enhancement in T-cell activity in clones specific to abacavir + natural 
peptide 15 (Figure 5.19). These data suggest that natural peptide 15 possessed little to no T-
cell stimulatory properties i.e. clones were only responding to abacavir and the repertoire of 
peptides generated endogenously.  
Focus was next shifted to the responsive T-cell clones generated to the amidated form of 
peptide 15, many of which indicated strong CD8+ T-cell activity when retested in the presence 
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of peptide in the ELIspot assay (Figure 5.14). Indeed, activation of clones to the amidated 
peptide were shown to be dependent on the presence of antigen presenting cells (Figure 
5.20). The assay was repeated using amidated peptide-specific T-cell clones but co-incubated 
with the peptide in natural form instead of amidated. No T-cell activation was observed in 
either the presence or absence of APCs to the natural peptide, confirming the C-terminal 
amidation of the peptide to be the governing factor in the induction of a T-cell response.  
The findings with the amidated peptide were intriguing if not related to the activation of T-
cells with abacavir. Previous unpublished data has shown that the peptide activates clones 
with specificity to other drugs, including sulfamethoxazole which has no association with 
HLA-B*57:01. Such findings would indicate that the amidated peptide functions as a 
mimotope, which mimics the actions of an epitope to induce a T-cell response (Gevorkian et 
al. 2005a; Casey et al. 2006). Amidation of peptides is a technique employed to enhance the 
biological activity of synthesised peptides as it increases their ability to enter cells and 
protects against degradation via the actions of proteases (Nuijens et al. 2012; Wollack et al. 
2009). Furthermore, studies have indicated that the C-terminal amidation of peptides can 
increase their potency for biological activity by at least 10-fold (Merkler 1994; Merkler et al. 
1993), suggesting that the amidated peptide may have been capable of more aggressive 
binding and interactions with the MHC, allowing for the induction of a T-cell response.   
These findings seem to suggest the inability of the NTVELRVKI peptide to induce a T-cell 
response to abacavir. However, the response may be limited to a small number of T-cells 
further expanding the variability of abacavir-responsive T-cell clones as explored in chapter 
2. As this study focused solely on one abacavir-induced self-peptide, a wider range of 
peptides must be explored to fully gain a holistic insight into the role of abacavir-induced 
altered self-peptides in the induction of T-cell responses to abacavir.  
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6.1. Introduction. 
 
Hypersensitivity reactions to abacavir observed exclusively in individuals expressing the HLA-
B*57:01 allele are known to be mediated by CD8+ T-cells (Chessman et al., 2008; Mallal et 
al., 2008; Adam et al., 2012; Bell et al., 2013; Naisbitt et al., 2015). As previously mentioned, 
neither the hapten/prohapten nor the PI models adequately explain the mechanisms of the 
immune-mediated hypersensitivity reactions observed with abacavir. Three separate studies 
in 2012, cast light on a new mechanism of hypersensitivity observed uniquely with abacavir 
(Illing et al. 2012; Norcross et al. 2012; Ostrov et al. 2012). These studies postulated that 
abacavir may induce a conformational change in the binding cleft of HLA-B*57:01 leading to 
an alteration in the range of peptides displayed on the surface of the APC for T-cell 
recognition. A shift in prevalence of the small C-terminal anchors including leucine, 
isoleucine and valine was observed in the presence of abacavir. This shift in prevalence was 
only observed at the C-terminal position of the peptides, corresponding to the F-pocket of 
HLA-B*57:01 (Illing et al. 2012), casting new light on the role that the peptides might play in 
the activation of T-cells in abacavir hypersensitivity. 
Subsequent studies concerning abacavir hypersensitivity reactions have tended to focus on 
peptides as a mainstay for investigation into activation of T-cells induced by the drug. Lucas 
et al indicated that T-cell reactions observed to abacavir upon first exposure in some 
individuals were caused by the presence of memory T-cells previously primed to an unknown 
antigen which were capable of cross-reacting with the abacavir HLA-B*57:01-endogenous 
peptide ligand complexes (Lucas et al. 2015). Metushi et al, identified using the drug 
acyclovir, a relationship between the peptide binding affinity for HLA -B*57:01 in the 
presence of a drug and the observed CD8+ T-cell response. Acyclovir, found to be devoid of 
T-cell activity, induced an increase in peptide affinity for HLA-B*57:01 of around 2-5 fold, 
while an increase in the region of 1000 fold was observed with abacavir. This  indicated a 
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relationship between the binding affinity of a drug within HLA-B*57:01 and the induction of 
T-cell responses (Metushi et al. 2015). 
Furthermore, Naisbitt et al demonstrated via the use of abacavir substituted analogues that 
T-cell reactivity could be abolished via substitution at the 6-amino cyclopropyl moiety. 
Subsequent in silico modelling of some analogues within HLA-B*57:01 indicated a binding 
conformation adopted that would not allow for the presentation of altere d peptides to T-
cells (Naisbitt et al. 2015). Indeed, in similar studies conducted in chapters 3 and 4 we 
demonstrated that compounds which do not activate T-cells will not bind HLA-B*57:01 in a 
manner to instigate a shift in peptide prevalence. Furthermore, using mass spectrometry we 
found that with non-activating abacavir analogues there was no apparent shift in the peptide 
repertoire presented to T-cells on the surface of APCs.  
Using viral peptide sequences which displayed structural similarity to an immunogenic self –
peptide, Yerly et al 2017 explored the relationship between solvent exposure by the peptide 
side chains and TCR recognition (Yerly et al. 2017). One abacavir-specific transfectant was 
activated with peptide VTQQAQVRL in the absence of abacavir which corresponded to the 
Herpes Simplex Virus (HSV ½ 230-238). However, this response was only observed in one 
abacavir TCR transfectant indicating that the observed cross-reactions exclusivity to a small 
subset of abacavir memory T-cells (Yerly et al. 2017). 
In the previous chapter we explored the ability of abacavir-induced self-peptides to activate 
T-cells. We focussed on a panel of 120 peptides received from our collaborators in the Purcell 
Laboratory (Monash University, Melbourne). One peptide from this panel was found to 
evoke T-cell responses in the presence or absence of abacavir in the amidated form. In 
chapter 5, this peptide was subjected to detailed analysis to further dissect the responses 
that were observed. It was found that in the natural form the peptide possessed no 
significant T-cell inducing ability in either the presence or absence of the drug. In the 
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amidated form the peptide possessed non-specific T-cell activating properties; however, the 
presence of abacavir bore no influence on the T-cell responses observed. Furthermore, T-cell 
clones specific to other drugs including those with no HLA-B*57:01 association (SMX) were 
activated by this peptide, suggesting the peptide may function as a mimotope (Casey et al. 
2006).  
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6.2. Aims. 
 
In this chapter we investigated a further panel of 39 abacavir-induced self-peptides received 
from the Purcell Laboratory (Monash University, Melbourne) which have underwent prior 
studies to examine the kinetics of peptide display on the surface of the APCs over a time 
course of abacavir exposure. Based on the results of these assays, a panel of five abacavir-
induced self-peptides were selected to perform T-cell cloning in both the presence and 
absence of abacavir, with responsive clones generated being subjected to further T-cell 
assays, to assess their influence on the induction of T-cell responses to abacavir.   
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6.3. Methods. 
6.3.1. Materials. 
 
Abacavir was received as a gift from GlaxoSmithKline (GSK). Human AB serum and foetal 
bovine serum were obtained from Innovative Research (Michigan, USA) and Invitrogen 
(Paisley, UK), respectively. Interleukin-2 (IL-2) was purchased from Peprotech (London, UK). 
Multisort bead separation kits were supplied by Miltenyi Biotec (Surrey, UK). Antibodies for 
staining were purchased from BD Biosciences (Oxford, UK). ELIspot kits including the coating 
and detection antibodies, streptavidin alkaline phosphate conjugate and BCIP/NBT 
substrates were purchased from Mabtech (Stockholm, Sweden). Other reagents were 
purchased from Sigma-Aldrich (Dorset-UK) unless otherwise stated. 
6.3.2. Cell Culture Medium 
 
R9 medium for T-cells (R9) is composed of RPMI supplemented with 10% human AB serum, 
HEPES (25mM), penicillin (1000 U/mL), streptomycin (0.1mg/mL), L-glutamine (2mM) and 
transferrin (25µg/mL).  
EBV transformed B-cells were cultured in F1 medium composed of RPMI supplemented with 
10% foetal bovine serum, HEPES (25mM), penicillin (1000 U/mL), streptomycin (0.1mg/mL) 
and L-glutamine (2mM). 
6.3.3. Maintaining C1R and T2 cells 
 
Cells from the class I deficient lymphoblastoid cell lines, C1R and T2 were transfected with 
HLA-B*57:01 to be used in functional assays. Both cell l ines were maintained as described in 
section 5.3.3. 
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6.3.4. Generation of abacavir-specific T-cell clones. 
 
Generation of abacavir-specific T-cell clones was carried out as described in section 2.3.5, 
subsequent testing for antigen specificity of the T-cell clones was assessed using T-cell 
proliferation assays described in section 2.3.6. Antigen specificity of the abacavir clones was 
confirmed using the ELIspot assay described in section 2.3.7. Cellular phenotyping on 
abacavir-specific T-cell clones was investigated using methods described in section 2.3.8. 
6.3.5. T-cell activation in the presence of abacavir-induced self-peptides. 
 
Abacavir-induced self-peptides were assigned a number from 1 to 39 for identification in T-
cell assays. Each peptide sequence with its corresponding number is displayed in Table 6.1. 
Abacavir-responsive T-cells (5x104/ 50µL) were co-incubated with T2 APCs and the mixtures 
of self-peptides (2 peptides/well) in the presence and absence of abacavir (varying 
concentrations dependent on the T-cell clones used) for 48 hours (37OC; 5% CO2).  T-cells 
were also co-incubated with C1R or T2 APCs in the absence of peptides (1x104/ 50µL) in the 
presence or absence of abacavir as positive and negative controls, respectively. T-cell 
responses were measured using the IFN-γ ELIspot assay, due to its superiority over the 
proliferation assay. Peptide mixes that produced a T-cell response with T2 APCs in the 
presence of abacavir which surpassed the response in T2 APCs to abacavir alone were 
selected for individual analysis.  
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Table 6.1. A panel of abacavir-induced self-peptides eluted from HLA-B*57:01 in the 
presence of the drug. 
PEPTIDE SEQUENCE 
1 KIADFGWSV 
2 ATFKGIVRAI 
3 ASAIIIQRW 
4 IVFPGSTGHI 
5 KTFIGTVRV 
6 FAYDGKDYL 
7 KVFKLQTSL 
8 KSIARVLTV 
9 HTIQIRQDW 
10 KSIFVFTHV 
11 ASSSQIIHI 
12 VTTDIQVKV 
13 GSFGKVFLV 
14 YTDNLVRVW 
15 RVLPPSHRVTW 
16 LTSELITHI 
17 KSTALQTWL 
18 RTLLEDGTFKV 
19 KTIETSPSL 
20 KSYELPDGQVI 
21 HSTDRVVLI 
22 KTFTTQETI 
23 LSSPVTKSF 
24 KAIDYIRFL 
25 KTLEGEFSV 
26 ITKTVVENI 
27 STIRLLTSL 
28 SSAEVKVTI 
29 NTVELRVKI 
30 VSVKDIQAHL 
31 RTLPVDFHI 
32 KSYELPDGQVITI 
33 KTIKLWNTL 
34 IAINLFTNV 
35 TSLKSRVTI 
36 SGMGVIVHI 
37 STLHLVLRL 
38 GTYQDVGSLNI 
39 KTFKDVGNLL 
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6.3.6. Activation of T-cell clones with titrated concentrations of abacavir and abacavir-
induced self-peptides.  
 
Abacavir-responsive T-cells were co-incubated with T2 APCs at increasing concentrations of 
abacavir (0-100µM) and one representative abacavir self-peptide (peptide 4 (0-200µM)) for 
48 hours (37OC; 5% CO2). T-cells were co-incubated with C1R APCs in the presence of abacavir 
at the same concentration range as a positive control, with T-cell activity measured by means 
of IFN-γ ELIspot.  
6.3.7. T-cell activation induced by abacavir self-peptides in the presence of pulsed APCs. 
 
T2 APCs were incubated overnight with a selection of individual peptides (25µM) in the 
presence and absence of abacavir (35µM). APCs pulsed overnight in R9 medium alone were 
used as a negative control while abacavir pulsed C1R APCs were employed as a positive 
control. Following pulsing, the APCs were washed three times in R9 medium and diluted to 
a concentration of 1x104/ 50µL. The APCs were then co-incubated with abacavir-responsive 
CD8+ T-cell clones (5x104/ 50µL) for a period of 48 hours (37OC; 5% CO2). T-cell activity was 
measured using IFN-γ ELIspot.  
6.3.8. T-cell activation induced by abacavir self-peptides in the presence of 
g lutaraldehyde fixed EBVs. 
 
Autologous EBVs (2x106 cells/mL) were washed and resuspended in 1mL of HBSS buffer. 
Glutaraldehyde (25%, 1µL) was added to the cells for 30 seconds, followed by 1mL of glycine 
(1M) for a further 45 seconds. The EBVs were then washed three times and resuspended in 
R9 medium to a concentration of (2x105cells/mL). Abacavir-specific T-cell clones (5x104/ 
50µL) were co-incubated with the glutaraldehyde fixed EBVs (1x104/ 50µL) and individual 
abacavir self-peptides (25µM) in the presence and absence of abacavir for 48 hours (37OC; 
5% CO2). T-cells were co-incubated in the presence and absence of abacavir with non-fixed 
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EBVs as a positive control. T-cell activation was quantified using IFN-γ secretion by means of 
the ELIspot assay.  
6.3.9. Self-peptide presentation over a time course of abacavir exposure. 
 
Kinetic studies to analyse the presentation of peptides over a time course of abacavir 
exposure were conducted by Dr Patricia Illing at Monash University (Melbourne, Australia).  
HLA class I molecules were isolated from 108 CIR.B*57:01 cells using solid phase bound pan 
class I antibody W6/32 (produced in house from hybridoma) and fractionated by RP-HPLC as 
described previously (Purcell et al. 2001; Tan et al. 2011). UV absorbance at 215 nm was used 
to monitor the elution of material from the column and the area under the curve for the β2-
microglobulin (β2m) peak recorded as a measure of the purified HLA within the sample. 500 
µL peptide containing fractions were combined into 3 pools, concentrated using a speed 
vacuum concentration system (LABCONCO, USA) and equalised to a volume of 30 µL with 
0.1% formic acid (FA, Thermo Scientific). Liquid chromatography-multiple reaction 
monitoring (LC-MRM)-MS experiments were performed using a Tempo nanoLC (Eksigent) 
autosampler and cHiPLC nanoflex (Eksigent) coupled to an SCIEX QTRAP 5500 mass 
spectrometer. 10 µL samples were loaded onto a cHiPLC trap column (ChromXP C 18-CL 
column 0.5mm x 200µm i.d., 3 µm particle size, nominal pore size 120 Å) at a flow rate of 5 
µL/min in 2% acetonitrile (ACN), 0.1% formic acid (FA) for 10 min, an analytical cHiPLC column 
(ChromXP C18-CL 15cm x 75µm i.d., 3 µm particle size, nominal pore size 120 Å) switched in 
line, and the peptides eluted at 300 nL/min over a gradient of buffer A (0.1% FA) and B (98% 
ACN, 0.1.% FA) as follows: 0–1 min 2% B, 1-3 min 2–10% B, 3–40 min 10–35.5% B, 40–45 min 
35.5–80% B, 45–50 min hold at 80% B, 50–53 min 80–2% B, re-equilibration at 2% B for 7 
min. The QTRAP 5500 was operated in MRM mode in unit resolution for Q1 and Q3, with any 
MRM transition exceeding 600 counts triggering an Enhanced Product Ion (EPI) scan (10,000 
Da/sec; rolling CE; unit resolution, 6 second exclusion window).  MRM parent-product ion 
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transitions were designed based on the prominent product ions observed for targeted 
peptides in LC-MS/MS data acquired previously (Illing et al. 2012). Detection of these 
transitions overlapping at a particular retention time (RT) was used as an indicator of peptide 
presence. Peptide identity was validated through fragmentation observed in the EPI scan or 
comparison to synthetic peptides. Transitions were also designed for the detection of 
abacavir which is observed as a singly charged ion of mass:charge ratio (m/z) +287.2 with 
fragment ions of 190.9 (collision energy [CE] 30), 174.0 (CE 45), 164.1 (CE 39) and 150.0 (CE 
46). A relative measure of peptide/abacavir abundance within the immunopeptidome was 
calculated as the total area under the curve for the detected transitions (using Skyline 
software 64bit 2.6.0.6851 [MacCoss Laboratory] (MacLean et al. 2010) for the peptides, and 
Peakview® Version 1.2 [SCIEX] for abacavir) divided by the area of the β2m peak observed on 
RP-HPLC separation of the immunoaffinity eluate. Mean abundance was calculated from 
three biological replicates for each timepoint and normal ised to the maximum mean 
detection of the peptide/abacavir. 
6.3.10. Generation of specific T-cell clones to peptide mixes ± abacavir. 
 
A selection of five individual abacavir-induced self-peptides were selected for T-cell cloning 
in one HLA-B*57:01 positive healthy drug naïve donor in both the presence and absence of 
the drug.  
PBMCs isolated from a HLA-B*57:01 positive healthy drug naïve donor, HLA-0622 (Table 2.1), 
were incubated with the mixture of five selected abacavir self -peptides (5µM) in the 
presence and absence of abacavir (35µM) for a period of 14 days. On days 6 and 9 cells were 
maintained with R9 medium containing IL-2 (2µL/mL) to preserve the antigen-driven 
expansion of T-cells. On day 14, CD8+ T-cells were positively selected using MultiSort kits 
(Miltenyi Biotec, Surrey UK) and T-cell clones were generated via means of serial dilution as 
described in section 2.3.5.  
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6.3.11. Testing for antigen specificity. 
 
Approximately four weeks after beginning the serial dilutions T-cell specificity to the 
abacavir-induced peptides in the presence and absence of the drug was assessed via cellular 
proliferation in the presence of the peptides ± abacavir.  This was conducted by analysing 
proliferation via 3H thymidine incorporation. This process was carried out using the same 
methods as described in section 2.3.6 and antigen specificity was confirmed via the 
measurement of IFN-γ secretion using the ELIspot assay as described in section 2.3.7. For 
these steps the peptide mix (5µM) ± abacavir (35µM) was used as the antigen instead of 
abacavir alone. 
T-cell clones which responded in the presence of the peptide mix ± abacavir were 
subsequently tested to the individual abacavir self-peptides from the mix in both the 
presence and absence of abacavir, using the same methods described above.  
6.3.12. Dose dependency of abacavir ± peptide-specific T-cell clones.  
 
T-cell clones were incubated with autologous EBVs at decreasing concentrations of abacavir 
(2-0.1µM) in the presence and absence of the individual abacavir self-peptides (5µM) for a 
period of 48 hours (37OC; 5% CO2). T-cell activity was quantified via measuring IFN-γ secretion 
by means of the ELIspot assay.  
6.3.13. APC pulsing assays to abacavir ± individual peptides. 
 
Autologous EBVs were pulsed for time periods of 1, 4 and 16 hours with individual abacavir-
induced self-peptides in the presence and absence of abacavir (35µM) (37OC; 5% CO2). 
Following pulsing EBVs were washed three times, resuspended in R9 medium (0.2x106/mL) 
and co-incubated with T-cells for a period of 48 hours (37OC; 5% CO2). T-cells were also co-
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incubated with soluble abacavir as a positive control.  Activation of T-cells was measured via 
the ELIspot assay.  
6.3.14. T-cell activation by abacavir-induced self-peptides in the presence of 
g lutaraldehyde fixed APCs. 
 
Autologous EBVs underwent cellular fixation via the use of glutaraldehyde as described 
previously in section 5.3.10. Following cellular fixation, EBVs were co-incubated with T-cells 
and individual abacavir-induced self-peptides in the presence and absence of the drug for 48 
hours (37OC; 5% CO2). T-cells were incubated with abacavir in the presence of non-fixed EBVs 
as a positive control. Activation of T-cells was measured by means of IFN-γ secretion via the 
ELIspot assay.  
6.3.15. Statistical Analysis 
 
For comparison between control and test values in proliferation assays the Mann-Whitney 
test was used. 
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6.4. Results  
6.4.1. Generation of abacavir-specific T-cell clones. 
 
T-cell clones specific to abacavir were generated by means of serial dilution assays described 
in section 2.3.5 – 2.3.7. From a total of 2279 clones tested across four HLA-B*57:01 positive 
donors, 101 proliferated in the presence of abacavir on first testing, (0, 1665 ± 188.5 cpm: 
Abacavir 35µM, 6940 ± 729 cpm; P< 0.0001). The abacavir-responsive T-cell clones used for 
assays in this chapter are displayed in Table 6.2 with their corresponding donor. Results for 
T-cell specificity assays of these abacavir clones and subsequent cellular phenotyping data is 
discussed in detail in section 2.3. All clones to donor 2 lost antigen specificity prior to 
commencement of assays in this chapter.  
6.4.2. T-cell activation in the presence of abacavir-induced self-peptides. 
 
All 39 peptides were initially screened as mixes of 2/well with T2 APCs in the presence and 
absence of abacavir. C1R APCs (a fully functional APC expressing HLA-B*57:01) in the 
presence and absence of abacavir were used as a positive control. T2 APCs were used in 
order to abrogate the antigen processing capabilities of the cells, thereby investigating the 
ability of the exogenously added peptide (± abacavir) to activate T-cells. While the T-cell 
response to abacavir in the presence of T2 APCs was not completely abolished with some T-
cell clones it was diminished when compared to the response in the presence of C1R APCs. 
Therefore, subtle increases in IFN-γ secretion observed in the presence of a peptide mix 
Table 6.2. Abacavir-specific T-cell clones used for assays in this chapter 
* Denotes clone generated to abacavir in the presence of the natural peptide 15, T-cell  specificity 
data and cellular phenotyping discussed in section 5.3.11. 
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when compared to T2 APCs with no peptides were selected for individual analysis (data not 
shown).  
Figure 6.1 shows the results from a representative assay from two abacavir-responsive T-cell 
clones in the presence of a panel of selected individual self-peptides ± abacavir with T2 APCs. 
In both abacavir-responsive T-cell clones no response was observed in the presence of the 
individual peptides that was of greater magnitude than T-cells in the presence of T2 APCs 
and abacavir alone. This was mainly due to the self-presentation observed with one of the 
clones in the presence of abacavir, making the distinction between responses to abacavir in 
the presence of the peptides and the absence very difficult. Therefore, to investigate the 
dependency on concentration of the peptides and abacavir on T-cell activation, T-cells were 
co-incubated with T2 APCs at increasing concentrations of abacavir and one self -peptide. 
Peptide 4 was selected for use as it gave the strongest response in the individual peptide 
assays. The increasing abacavir concentrations enhanced the T-cell response observed in the 
presence of T2 APCs, but at lower concentrations and the absence of the drug, no T-cell 
activity was induced by the addition of peptide 4 (Figure 6.1). 
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Figure 6.1. Drug-specific T-cell responses to abacavir in the presence of individual self-
peptides. a) ELIspot well images of abacavir-responsive T-cell  clones co-incubated with 
individual self-peptides in the presence and absence of the drug. C1R APCs were used as a 
positive control. b) Abacavir-specific T-cell  clones co-incubated with T2 APCs at increasing 
concentrations of the drug (0-100µM) and one representative abacavir-induced self-peptide 
(peptide 4, 0-200µM). T-cells were incubated with C1R APCs at the same abacavir 
concentrations as a positive control. 
a) 
b) 
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6.4.3. T-cell activation induced by abacavir self-peptides in the presence of pulsed or 
g lutaraldehyde fixed APCs 
 
As the self-presentation of some abacavir clones was evident in the presence of T2 APCs, we 
next focussed on abrogating the IFN-γ secretion to abacavir via pulsing or glutaraldehyde 
fixation. The observed IFN-γ secretion in response to abacavir was not detected when T2 
cells were used as APCs. However, pulsing of T2 APCs with the abacavir-induced-self-
peptides in the presence and absence of the drug had no effect on the T-cell responses lost 
to abacavir (Figure 6.2). The effects of abacavir-induced peptides on activation of abacavir-
specific T-cell clones was next investigated using EBVs previously fixed with glutaraldehyde 
with the individual peptides added exogenously in the presence and absence of abacavir. In 
the two abacavir-specific T-cell clones examined, T-cell activation with abacavir was 
abrogated via glutaraldehyde fixation of APCs. However, T-cell activity was not reinstated by 
the addition of the abacavir self-peptides in either the presence or absence of the drug.  
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a) 
b) 
Figure 6.2. Abacavir-induced self-peptide responses in the presence of pulsed or fixed APCs. a) 
T-cell  activity of abacavir-specific T-cell clones incubated with T2 APCs pulsed with the abacavir-
induced self-peptides in the presence and absence of the drug. C1R APCs pulsed in the presence 
and absence of abacavir were used as a positive control. b) Two abacavir-responsive T-cell  clones 
co-incubated with glutaraldehyde fixed autologous EBVs in the presence and absence of abacavir 
with the induced self-peptides (4, 5, 11, 13, 32 and 37) added exogenously. T-cell  clones were 
incubated with abacavir in the presence of unfixed APCs as a positive control.  
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6.4.4. Change in peptides eluted from HLA-B*57:01 in the presence of abacavir. 
 
Analysis of peptides eluted from HLA-B*57:01 over a time course of abacavir exposure was 
conducted using methods described in Illing et al., 2012. The proportion of abacavir eluted 
(shaded area) spiked during the first five hours of exposure before sharply decreasing, most 
likely due to being internalized within the APC. The elution of abacavir then increases 
exponentially over the next ten hours of exposure as it is presented on the cellular surface  
(Figure 6.3). With the exception of peptide 24, all abacavir induced peptides increased in 
presentation on the APC surface over a time course of abacavir exposure, demonstrating a 
dependence on the presence of abacavir for their accommodation within the peptide binding 
groove of HLA-B*57:01. Conversely, peptides eluted from HLA-B*57:01 in the absence of 
abacavir (canonical motif) demonstrate little to no dependence on the presence of abacavir 
for their exposure on the surface of the antigen presenting cell, with many decreasing in 
exposure following the introduction of abacavir. Based on these findings five peptides were 
selected for T-cell cloning in the presence and absence of abacavir (Table 6.3). These peptides 
had multiple intracellular and extracellular origins (Table 6.4). 
 
Table 6.3. Number and sequence of abacavir-induced self-peptides used for cloning assays in the 
presence and absence of the drug.  
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Figure 6.3. Presentation of self-peptides eluted from HLA-B*57:01 over time in the presence and 
absence of abacavir. MRM-MS analysis of peptide ligands isolated from HLA-B*57:01 of 108 CIR.B*57:01 
cells after 0-16 hours, or constant, abacavir treatment (35µM). Peptides were isolated as in Illing et al. 
Nature 2012. 4 MRM parent-product ion transitions were used to detect each peptide/abacavir. 
Detection of all  4 transitions at the same retention time, correlated with elution time of synthetic 
peptides or a transition triggered full  MS/MS scan, was used as evidence of peptide identification. 
Peptide and abacavir abundances were calculated as the sum peak area of the transitions and 
normalised to the amount of β2m isolated with the peptides. Peptide and abacavir abunda nces are 
shown as a proportion of the maximum normalised sum peak area detected across all experiments and 
are portrayed as the mean of the three biological replicates.  Error bars depict the standard error of the 
mean.  Peptide IDs: Residue 1, Ω-2, Ω and length. Residues that have key interactions with the antigen 
binding cleft that are blocked by abacavir are shown in red. 
 
Canonical Peptides 
Peptides used for cloning  
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6.4.5. Generation of T-cell clones responsive to the peptide mix ± abacavir. 
 
Next to investigate if T-cell clones could be generated that were specific to the abacavir self-
peptides in the presence and absence of the drug, a panel of five peptides were selected 
based on the results of the T-cell assays to undergo T-cell cloning in one HLA-B*57:01 positive 
healthy drug naïve donor, HLA-0622 (Table 2.1).  
6.4.6. T-cell cloning to the abacavir self-peptide mix.  
 
From a total of 148 clones tested, 34 proliferated weakly in response to the abacavir self-
peptide mix alone on first testing (Control, 1031 ± 135.9 cpm; Peptide Mix (5µM), 2494 ± 
378.7 cpm; P<0.0001). Second testing of the responsive T-cell clones via the ELIspot assay 
revealed no T-cell clones to possess antigen specificity toward the peptide mix in either the 
Table 6.4. Sequences, corresponding proteins and cellular locations of the abacavir-induced self-
peptides used in the T-cell cloning assays.  
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presence or absence of abacavir. This confirmed these clones to have generated a false 
positive result at the first testing stage (Figure 6.4). 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
TCC 
Figure 6.4. Generation of T-cell clones to the mix of abacavir-induced self-peptides in the 
absence of the drug. a) Mean proliferative response from T-cells tested to the abacavir-induced 
self-peptide mix (5µM) in the absence of the drug. Data shown as mean of all  responsive clones 
vs control ± SEM, *P<0.05, **P<0.01, ***P<0.001. b) Antigen specificity of individual T-cell clones 
to the self-peptide mix. c) Table representative of total clones generated to the abacavir self-
peptide mix. d) Representative ELIspot images of clones second test in response to the peptide 
mix (5µM) as a means of confirming antigen specificity.  
a) b) 
c) 
d) 
HLA-622 peptide mix clones 1st test 
                                                                                                       Chapter 6 
 
265 
 
6.4.7. T-cell cloning to the self-peptide mix + abacavir. 
 
From a total of 88 clones tested, 9 proliferated in response to abacavir + the peptide mix 
upon first testing (Control, 497.4 ± 45.33 cpm; ABC (35µM) + peptide mix (5µM), 4393 ± 1325 
cpm; P<0.0001). Second testing revealed strong activation of some T-cell clones in response 
to the peptide mix + abacavir. These clones were subjected to further analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5. Generation of specific T-cell clones to the mix of abacavir-induced self-peptides 
in the presence of the abacavir. a) Mean proliferative response from T-cells tested to abacavir 
(35µM) + the induced self-peptide mix (5µM). b) Antigen specificity of individual T-cell  clones 
to abacavir (35µM) + the self-peptide mix. c) Table representative of total clones generated to 
abacavir + the self-peptide mix. d) Representative ELIspot images of clones second test in 
response to abacavir + the peptide mix (5µM) as a means of confirming antigen specificity. 
*P<0.05, **P<0.01, ***P<0.001. 
a) b) 
c) 
d) 
HLA-622 ABC+ peptide mix 1st test. 
TCC 
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6.4.8. Cross reactivity of T-cell clones to abacavir, abacavir + peptide mix and the 
peptide mix alone. 
 
A panel of T-cell clones specific to abacavir and abacavir + the peptide mix were tested across 
four conditions; 1) Ø, 2) abacavir (35µM), 3) abacavir (35µM) + peptide mix (5µM), 4) peptide 
mix alone (5µM) to assess their potential for cross-reactivity. T-cell clones generated to the 
peptide mix in the presence of abacavir produced strong IFN-γ secretion when co-incubated 
with the peptide mix in the presence of abacavir as well as when incubated with abacavir 
alone (Figure 6.6). Abacavir-responsive T-cell clones also secreted IFN-γ when co-incubated 
with the peptide mix in the presence of the drug and to the drug alone. Interestingly, two 
abacavir-specific T-cell clones (TCC 119 and 121) also secreted low levels of IFN-γ when 
incubated with the peptide mix in the absence of the drug (Figure 6.6).  
 
 
 
Figure 6.6. Cross reactivity of T-cell clones generated to abacavir and abacavir + peptide mix. 
Representative ELIspot images of T-cell clones generated to various conditions co-incubated 
with abacavir (35µM), abacavir (35µM) + peptide mix (5µM) and peptide mix alone (5µM). 
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6.4.9. T-cell activity in response to individual self-peptides in the presence and absence 
of abacavir. 
 
To differentiate between the T-cell responses observed to abacavir in the presence of the 
peptides from those observed to abacavir alone, dose titration assays using decreasing 
concentrations of abacavir in the presence and absence of the individual self-peptides from 
the peptide mix were conducted. One T-cell clone specific to the peptide mix in the presence 
of abacavir was employed for this assay (TCC 8). This T-cell clone was tested in the presence 
and absence of the five individual abacavir-specific peptides (5µM) with abacavir at 
decreasing concentrations (0-2µM). The magnitude of IFN-γ secretion from the abacavir-
treated clone decreased in line with the decrease in abacavir concentration as expected. 
However, in the presence of the abacavir-induced self-peptides, clear enhancement of IFN-
γ secretion was observed at the low concentrations of the drug (Figure 6.7).   
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Figure 6.7.  T-cell activity of abacavir + peptide mix-specific T-cell clones in the presence and absence  
of abacavir and the individual self-peptides. a) ELIspot well images and bar graphs comparing IFN-γ 
secretion to abacavir in the presence and absence of peptides. One clone specific to abacavir in the 
presence of the self-peptide mix co-incubated with abacavir at decreasing concentrations (2-0.1µM) in 
the presence and absence of the individual abacavir-induced self-peptides.  
a) 
b) 
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6.4.10. T-cell activity of abacavir clones to individual self-peptides in the absence of the 
drug. 
 
Two abacavir-specific T-cell clones displayed strong T-cell activity when co-incubated with 
the peptide mix in the presence of the drug, while also secreting IFN-γ in response to the 
peptide mix in the absence of abacavir (Figure 6.6). Both clones were co-incubated with 
autologous EBVs in the presence of the individual peptides with no drug to examine if the 
individual peptides could induce a T-cell response. The natural form of peptide 15 
(NTVELRVKI) from chapter 5 was also incorporated into this assay. Clone 119 secreted low 
levels of IFN-γ in the presence of peptide 37, but not the other peptides.  However, T-cell 
clone 121 displayed clear T-cell responses when incubated with peptides 4 and 32 (Figure 
6.8).  
 
 
 
 
 
 
Figure 6.8. Secretion of IFN-γ by T-cell clones stimulated with abacavir-induced self-
peptides. ELIspot well  images from two abacavir-specific CD8+ T-cell  clones co-incubated 
with abacavir-induced self-peptides 4, 13, 24, 32, 37 and the natural form of peptide 15 from 
Chapter 5.  
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6.4.11. Antigen presenting cell pulsing assays with individual abacavir self-peptides. 
 
Using these abacavir-specific T-cell clones and the abacavir self-peptides 4 and 32, APC 
pulsing assays were carried out at time periods of 1, 4 and 16 hours to the individual peptides 
in the presence and absence of abacavir. As previously shown, 16 hours is the optimal pulsing 
time for a strong T-cell response for abacavir. Figure 6.9 shows the differences in abacavir 
response based on the duration of APC pulsing employed. At the 16 and 1 hour pulsi ng stage, 
little difference is observed between the responses to abacavir in the presence of the 
peptides and abacavir alone. However, at the 4 hour time point a clear increase in T-cell 
activity is observed in clones co-incubated with APCs pulsed to abacavir in the presence of 
peptide 32 when compared to pulsing with abacavir alone. 
This experiment was then repeated at just the 4 hour timepoint using abacavir T-cell clone 
119 in the presence of APCs pulsed to the individual peptides 4 and 32 in the presence and 
absence of abacavir. Strong T-cell activity is induced by co-incubation with APCs pulsed with 
both the individual abacavir self-peptides in the presence of the drug, compared with cells 
pulsed to the drug alone. This indicates a clear role for the peptides in the induction of a T-
cell response to abacavir.  
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Figure 6.9. T-cell activation with abacavir pulsed APCs is enhanced in the presence of abacavir -
induced self-peptides. a) i) ELIspot well  images and i i) bar charts comparing the IFN-γ secretion from 
abacavir clone 119 co-incubated with APCs pulsed for periods of 1h, 4h and 16h in the presence of 
abacavir (ABC, 35µM), ABC + Peptide 4 (5µM) and ABC + Peptide 32 (5µM). b) A 4h pulse time was 
selected and the assay was repeated to examine the effects of peptides 4 and 32 (5µM) on T-cell  
activation in the presence of abacavir pulsed APCs with mock pulsed APCs as a comparator. i) ELIspot 
well images and ii) bar chart comparing IFN-γ secretion. 
a i) ii) 
b i) 
ii) 
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6.4.12. T-cell activation induced by abacavir self-peptides in the presence of 
g lutaraldehyde fixed APCs. 
 
Lastly, it was assessed whether exogenous addition of the abacavir self-peptides could 
reinstate the observed T-cell response to abacavir abolished via the glutaraldehyde fixation 
of APCs. Peptides 4 and 32 were again used along with abacavir T-cell clone 119. In the 
presence of fixed APCs, the T-cell response to abacavir was severely diminished compared 
to the response in the presence of unfixed APCs. However, exogenous addition of both 
peptides 4 and 32 enhanced IFN-γ secretion from T-cells in the presence of abacavir and fixed 
APCs. No T-cell activation was observed to either peptide in the absence of the drug.  
 
 
Figure 6.10. T-cell activation induced by peptides 4 and 32 in the presence of abacavir and 
glutaraldehyde fixed APCs. IFN-γ secretion from abacavir-specific T-cell clone 119 co-incubated 
with glutaraldehyde fixed APCs with peptides 4 and 32 in the presence and absence of abacavir. 
Abacavir alone was used as a comparator.   
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6.5. Discussion. 
 
CD8+ T-cell responses elicited by abacavir occur via two independent mechanisms in a 
processing dependent manner and via direct interaction with HLA-B*57:01 on the surface of 
APCs (Chessman et al., 2008; Bell et al., 2013). The former is hypothesised to be initiated via 
a mechanism unique to abacavir. As previously described, abacavir binds non-covalently to 
HLA-B*57:01 altering the shape and chemistry of the antigen binding cleft thereby allowing 
for the binding and subsequent presentation of a range of neo self-peptides not previously 
presented to T-cells. This is believed to induce a T-cell response as T-cells are only tolerant 
to peptides they are previously exposed to during development in the thymus. This means 
that recognition of these altered peptides would be adjudged to be similar to a foreign 
antigen (Illing et al. 2012; Ostrov et al. 2012; Norcross et al. 2012; Llano & Brander 2012).  
The use of C1R and T2 cells as APCs provided a strong mechanistic basis for the investigation 
of the abacavir self-peptides exogenously added to the assays. C1R cells comprise a fully 
functional B-cell line which in this case has been transfected to express the HLA-B*57:01 
allele only. T2 cells also comprise a B-cell line which has been transfected to express the HLA-
B*57:01 allele, however, the transporter associated with antigen presentation (TAP) was 
knocked out, meaning that MHC class I molecules remain in the ER, with only a small number 
transported to the cell surface (Wolpert et al. 1997; Kleijmeer et al. 1992). Therefore, co-
incubation with T2 APCs should abolish or at least diminish the T-cell mediated response 
observed in the presence of the C1R APCs, allowing for investigation into whether the 
addition of altered self-peptides exogenously could reinstate the response to abacavir. 
However, some abacavir-specific T-cell clones display characteristics of self-presentation in 
the presence of the drug, thereby inducing an equal T-cell response with the T2 APCs 
observed with the positive control in C1Rs. This makes it impossible to distinguish responses 
to the drug in the presence of the peptides from those to the drug alone, reducing the 
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number of T-cell clones that can be effectively used for assays in this manner. While C1R and 
T2 APCs were used for some initial assays in this chapter the primary focus was shifted to the 
use of autologous EBVs with the antigen uptake and processing capabilities knocked out via 
glutaraldehyde fixation (Fonteneau et al. 2003) or interfered with by abacavir pulsing for 
short periods of time that do not allow for full antigen processing and presentation to occur 
(Bell et al., 2013). This allowed for more accurate quantification of T-cell responses to 
abacavir in the presence of altered self-peptides compared to the drug alone (Chessman et 
al. 2008). 
Figure 6.3 displays the results of a kinetics study conducted by Dr Patricia Illing at Monash 
University in Melbourne.  It compares the changes in presentation of abacavir-induced self-
peptides with those eluted from HLA-B*57:01 in the absence of the drug (canonical motif) 
and in the presence of abacavir, thereby demonstrating dependence on abacavir for 
presentation of these altered self-peptides. With the exception of peptide 24 (KAIDYIRFL) all 
abacavir-induced self-peptides increased in presentation over time when exposed to 
abacavir. While those peptides eluted from a canonical motif, demonstrated little to no 
increase in presentation over a timecourse of abacavir exposure, with many showing a 
decrease in prevalence. This shows that abacavir plays no role on the increased prevalence 
of the peptides eluted from a canonical motif, while the abacavir-induced self-peptides were 
wholly dependent on abacavir for their presentation, apart from peptide 24. This led us to 
focus on generating specific T-cell clones to the five abacavir-induced self-peptides (4, 13, 
24, 32 and 37) in the presence and absence of abacavir.   
Responsive T-cell clones could not be generated to the self-peptides in the absence of 
abacavir. Conversely, in the presence of abacavir, responsive T-cell clones were generated 
to the peptides, with clones producing strong IFN-γ secretion upon second testing with 
abacavir and the peptides. As the responsive clones demonstrated strong T-cell activity to 
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the peptides in the presence of abacavir but also to the drug alone, it was difficult to 
accurately distinguish between the responses at the optimal concentration of abacavir. 
Therefore, dose titration assays were conducted using decreasing concentrations of abacavir 
in the presence and absence of the individual peptides. Indeed, secretion of IFN-γ in response 
to abacavir was diminished at lower concentrations of the drug, however, addition of the 
individual abacavir self-peptides enhanced the response to abacavir in the T-cell clones 
(Figure 6.7). This indicates that the peptides eluted from HLA-B*57:01 in the presence of 
abacavir (Illing et al. 2012) play a key role in the induction of T-cell responses to abacavir. 
However, as no T-cell response was observed in the presence of the peptides without 
abacavir, abacavir appears to be imperative for the binding and presentation of these altered 
peptides in order to initiate a T-cell response, most likely by altering the peptide binding 
groove to allow for the stable accommodation of the peptides for presentation to T-cells 
(Ostrov et al. 2012).  
Two abacavir-responsive T-cell clones generated were found to evoke T-cell activation in 
response to the abacavir self-peptide mix in the presence and the absence of the drug (Figure 
6.8). Clone 119, produced low levels of T-cell activation to self-peptide 37 in the absence of 
abacavir. However, using both pulsing and cellular fixation assays, to remove or reduce 
antigen processing, robust levels of IFN-γ were observed to peptides 4 and 32 in the presence 
of abacavir compared to the low T-cell activity observed with T-cells incubated with abacavir 
alone. Abacavir-specific T-cell clone 121 secreted high levels of IFN-γ in the presence of the 
same two self-peptides in the absence of abacavir. Unfortunately due to issues with cell 
numbers with this clone, the fixation and pulsing assays could not be utilized. These findings 
were surprising, due to the fact that neither clone had been exposed to the abacavir self-
peptides exogenously during the priming stage, indicating that the previous exposure to 
these peptides must have occurred naturally during the T-cell priming to abacavir, suggesting 
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a distinct role for the presentation of altered peptides in the T-cell responses to abacavir 
(Illing et al. 2012; Ostrov et al. 2012; Norcross et al. 2012; Yerly et al. 2017).  
IFN-γ secretion was observed with peptide 24 in the presence of abacavir at lower 
concentrations of the drug when compared to the drug alone in the dose titration assays 
(Figure 6.7). This peptide contains an arginine residue at the Ω-2 position, which would 
normally have interactions with the binding cleft in the absence of abacavir. These 
interactions are blocked following abacavirs binding to HLA-B*57:01, therefore it is likely that 
presentation of this peptide in the presence of the drug would be in an altered conformation 
which may account for the T-cell activation observed (Illing et al. 2013). This peptide also 
possesses multiple intracellular origins including ER and Golgi (Table 6.4), which may explain 
its expression in the absence of abacavir as it can be easily loaded onto MHCs on canonical 
motifs.   
T-cell responses to the abacavir self-peptides in the absence of the drug had not previously 
been observed with other abacavir-responsive T-cell clones. From chapter 2 and previous 
studies it is known that abacavir clones possess differing properties including sensitivity to 
the drug, the mechanism of activation employed and the repertoire of cytokines secreted 
upon activation (Adam et al., 2012, 2014; Bell et al., 2013). Therefore the notion that 
differing characteristics of T-cell clones could extend as far as some possessing the ability to 
respond to individual peptides while others do not is not inconceivable (Adam et al. 2012; 
Lucas et al. 2015; Yerly et al. 2017). These findings are in line with a recent study from Yerly 
et al in which a T-cell response was found to take place in response to a peptide in the 
absence of abacavir. However this was exclusive to T-cells transfected with only one specific 
TCR, indicating that polyclonal T-cell responses comprise multiple T-cell subsets each with 
different activation characteristics (Yerly et al. 2017). Indeed, the fact that T-cell responses 
to individual peptides in the absence of abacavir was found on one clone would agree with 
                                                                                                       Chapter 6 
 
277 
 
these findings, warranting further study to investigate structural characteristics of the 
interactions of the peptide with T-cells.  
The natural form of peptide 15 from chapter 5 (peptide 29) also increased in prevalence in 
the presence of abacavir, despite having no T-cell activation properties (Chapter 5). This 
suggests that peptide interactions with T-cells play an important role in the governance of 
an induction of T-cell responses. This casts light on TCR expression, which we know from 
chapter 2 displays considerable variation across abacavir clones (Yerly et al. 2017). Indeed, 
TCR expression is already known to be pivotal in other drugs associated with hypersensitivity 
reactions such as carbamazepine (Ko et al. 2011). Finally, the fact that two abacavir-specific 
clones were able to recognise self-peptides which they had not been exposed to previously 
suggests a strong role for these peptides in immune reactions to abacavir, however as this 
was only observed in two clones, casts strong light on the variability in T-cell responses 
between abacavir clones as described in chapter 2.  
The successful use of the pulsing and glutaraldehyde assays to analyse the effect of the 
addition of some abacavir-induced self-peptides represents a promising assay for future 
research. The successful reinstatement of IFN-γ secretion by the addition of two self-
peptides presents as exciting data for the research into the ever increasing role of peptides 
in the T-cell-mediated hypersensitivity reactions to abacavir.    
Here we conclude that the elucidation of the contribution of abacavir and the self -peptides 
to the induction of T-cell responses remains difficult to define as the endogenous peptides 
are constantly displayed on the surface of APCs naturally. However our data shows that the 
abacavir-dependent self-peptides do seem to contribute to the activation of T-cells. 
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Chapter 7. 
Final Discussion. 
 
Adverse drug reactions (ADRs) represent a major clinical problem due to their association 
with increases in morbidity and mortality in patients, which contributes to a major financial 
burden on the NHS (Pirmohamed et al. 2004). ADRs can be broadly classified into two 
categories; Type A and Type B reactions. Type A reactions (augmented) comprise those 
reactions which are predictable, usually dose-dependent and are related to the primary or 
secondary pharmacology of the drug. Type B reactions (bizarre) are unpredictable, dose 
independent reactions which are usually immune-mediated meaning many of the reactions 
will be off target. Unlike type A, type B reactions are often severe leading to immediate 
cessation of the offending drug as continued use could be fatal. This represents a major 
impediment to the drug discovery and development process.  
The involvement of HLA-alleles in the mediation of an individual’s susceptibility to ADRs has 
been demonstrated across a range of drugs including carbamazepine (Chung et al. 2004; 
Ozeki et al. 2011; McCormack et al. 2011), allopurinol (Hung et al. 2005), flucloxacillin (Daly 
et al. 2009), dapsone (Zhang et al. 2013) and lamotrigine (Man et al. 2007; McCormack et al. 
2012). However, perhaps the most commonly known association of risk HLA alleles with 
immune-mediated reactions is the hypersensitivity reactions experienced to the 
antiretroviral agent abacavir, linked exclusively with HLA-B*57:01 (Mallal et al. 2002; 
Hetherington et al. 2002). Indeed, studies focussing on genetic screening for HLA-B*57:01 
prior to the commencement of abacavir therapy has been conducted (Hughes et al. 2008; 
Mallal et al. 2008). Hughes et al randomized patients into two distinct groups, one which 
underwent prospective genotyping for HLA-B*57:01 while the other did not. The incidence 
of clinically suspected HSR was almost 50% reduced in the genetic screening arm of the study 
in comparison with the control group (Hughes et al. 2008). Furthermore, a prospective 
                                                                                                       Chapter 7 
 
279 
 
randomized study conducted by Mallal et al completely eradicated immune-mediated 
hypersensitivity reactions to abacavir, yielding a NPV of 100%, while the incidence of 
clinically diagnosed HSR was significantly abrogated by prospective genotyping (Mallal et al. 
2008). Due to the high frequency of the HLA-B*57:01 risk allele, particularly in the Caucasian 
population, the practice of prospective genotyping for the allele in patients prior to 
prescription of abacavir, demonstrated to be a cost effective measure, is now a common 
application in the clinical setting (Schackman et al. 2008).  
T-cell clones responsive to abacavir have been generated from PBMCs of healthy, drug naïve 
individuals positive for HLA-B*57:01 (Adam et al., 2012, 2014; Bell et al., 2013; Lucas et al., 
2015; Naisbitt et al., 2015). These responsive abacavir clones were exclusively CD8+ T-cells 
which were capable of interacting via processing dependent and independent pathways 
yielding an overall varied expression of TCR Vᵦ (Bell et al., 2013).  
Prior to the commencement of my PhD studies, Dr Mohammad Alhaidiri conducted 
experiments on abacavir focusing on two primary research arms. Firstly, the generation of 
sixteen abacavir 6-amino substituted analogues. The replacement of the cyclopropyl moiety 
with N-linked branched carbon chains at the 6-amino position of the compound abrogated 
the CD8+-mediated T-cell reactions observed with abacavir. Two of these compounds 
retained antiviral activity, albeit to a lesser degree than abacavir (Naisbitt et al. 2015). Due 
to the reduced antiviral activity of these compounds however, none were sufficient for the 
replacement of abacavir in the therapeutic setting, leading to the synthesis of a further 
eighteen analogues in total for my studies to be analysed.  
The second arm of Dr Alhaidiri’s work focused on the induction of T-cell responses by 
abacavir clones to a range of self-peptides whose expression on the surface of APCs is 
induced by the presence of abacavir. From a panel of 120 peptides received from our 
collaborators at Monash University in Melbourne Australia, one peptide (NTVELRVKI) was 
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identified as being able to induce a T-cell mediated immune response in the presence of 
abacavir in its natural form, while in amidated form the peptide evoked T-cell responses in 
both the presence and absence of abacavir. However, responses to the natural peptide were 
observed in the presence of abacavir, only in a select number of clones.  
Therefore, my studies focussed on three primary objectives: 1) to generate a panel of 
abacavir-responsive T-cell clones, which would undergo subsequent analysis of their cellular 
phenotype and their profiles of T-cell activation in response to the drug; 2) to generate and 
test a series of novel structural analogues of abacavir, this study investigated the potential 
for further modifications to be made to the structure of the drug, to eradicate the 
undesirable T-cell mediated hypersensitivity reactions, without loss of the antiviral potency 
of the drug; and 3) identify the contribution of the abacavir-induced self-peptides eluted 
from HLA-B*57:01 on the induction of T-cell responses to the drug.  
The successful generation of abacavir-specific T-cell clones was heavily dependent on the 
expression of HLA-B*57:01 in the healthy donors. The yield of clones responsive at the first 
testing stage was varied across the four donors employed in this study, ranging from as low 
as 0.4% in donor 2 (HLA-0957) to a high of 12.5% in donor 4 (HLA-0622). Some donors yielded 
no responsive T-cell clones at the first testing stage (data not shown). Across the four HLA-
B*57:01+ donors the overall percentage of responsive clones at the first testing stage was 
4.5% which was slightly lower than previous studies but this figure was skewed by the low 
yield of responsive clones from donor 2 (HLA-0957). Indeed, activation of abacavir-
responsive T-cell clones was consistent with previous findings where the clones may interact 
via 2 pathways, which relied on and were exclusive of antigen processing (Bell et al., 2013). 
Some abacavir-responsive clones became reliant on antigen processing mechanisms as the 
concentration of the drug decreased. However, this was not true for al l abacavir-responsive 
clones as in many cases T-cell activation was observed at fractional concentrations of the 
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drug in the absence of antigen processing. This suggests that these clones interact directly 
with the drug and possess self-presenting capabilities. APC pulsing assays discriminate 
between these two pathways of T-cell activation, clones which respond via the altered 
peptide model present strong IFN-γ secretion in this presence of APCs pulsed for 16 hours, 
ample time for antigen processing and presentation to occur. Clones which respond via direct 
interaction display a far diminished secretion of IFN-γ in the presence of pulsed APCs when 
compared to soluble abacavir. For my studies clones utilizing both pathways of T-cell 
activation were used in assays with the abacavir analogues, while those activated only in the 
presence of APCs were used for the peptide studies. However, as previously mentioned, due 
to the short life span of a T-cell clone in culture as well as the potential for losing antigen 
specificity, self-presenting clones were used for some assays involving peptides, but low 
concentrations of the drug were used where the need for APCs was apparent.   
Consistent with previous findings all T-cell clones generated in the presence of abacavir were 
CD8+ and the TCR Vᵦ expression was varied across all the clones tested (Adam et al., 2012; 
Bell et al., 2013). Unfortunately, due to limitations with the cost of TCR Vᵦ phenotyping kits 
and the relatively short life of a T-cell clone in cell culture, it was not possible to carry out 
TCR Vᵦ analysis on all responsive abacavir clones. A varied T-cell cytokine secretion profile 
was noted across the abacavir clones tested (Figure 2.14). While consistency was observed 
across clones with regard to secretion of the proinflammatory cytokine IFN-γ and the effector 
molecule granzyme B, there was also a consistent lack of secretion of the anti -inflammatory 
cytokine IL-10 or the cytokines IL-17 or IL-22, indicating a strong inflammatory response to 
abacavir. Variation was observed in the secretion of other cytokines and effector molecules. 
Secretion of IL-5 was observed in one clone tested while some clones secreted IL-13. 
Secretion of the effector molecules perforin and FasL was also varied across the clones 
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indicating the employment of multiple mechanisms for instigation of cell death across the 
range of abacavir clones utilized.  
As mentioned above the concept of eradicating the undesirable T-cell activity exhibited in 
response to abacavir via substitution of the 6-amino cyclopropyl moiety of the compound, 
known to be imperative for abacavirs interactions within the F-pocket of HLA-B*57:01, has 
previously been explored (Daluge et al., 1997; Faletto et al., 1997; Naisbitt et al., 2015). 
Continuing from Naisbitt et al, eighteen further abacavir substituted analogues were 
synthesised to assess the potential to generate structures that may replace abacavir in the 
therapeutic setting. Through the introduction of azetidine ring variant structures, the 
responses were eradicated in abacavir-specific T-cell clones. However, while compounds 
deficient in T-cell responses retained antiviral activity (Figure 7.1), it was not to the same 
degree as abacavir, making these analogues unsuitable for imple mentation into drug 
discovery. Nevertheless, introduction of the azetidine ring demonstrated the potential to 
generate abacavir substituted analogues with the ability to retain antiviral activity (Figure 
7.1). 
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Figure 7.1. Comparison of antiviral and T-cell activity of the eighteen abacavir substituted 
analogues with abacavir as a comparator. Compounds with antiviral activity of 40µM or below 
were considered to have retained antiviral activity. T-cell activity above 100 SFU was 
considered as activation of T-cells.  
Antiviral Activity (µ ) C50 
IF
N
-γ
 s
e
cr
e
ti
o
n
 (S
FU
)  
Analogues A-R
0 50
0
100
200
300
400
500
600
300 400 500
Abacavir
Analogue A
Analogue B
Analogue C
Analogue D
Analogue E
Analogue F
Analogue G
Analogue H
Analogue I
Analogue J
Analogue K
Analogue L
Analogue M
Analogue N
Analogue P
Analogue Q
Analogue R
Antiviral Activity (uM) EC50
IF
N
-Y
 S
e
c
re
ti
o
n
 (
S
F
U
)
                                                                                                       Chapter 7 
 
284 
 
Conversely, analogues with equipotency to abacavir with regard to antiviral activity (D and 
H) evoked the activation of CD8+ T-cells in a similar manner to abacavir. While T-cell activity 
to analogue H was only detected at the higher concentrations of the drug, T-cell cloning to 
the analogue itself produced responsive CD8+ T-cells which were activated by both the 
analogue and abacavir at lower concentrations. This suggested that analogue H possesses 
similar chemical properties to abacavir with respect to HLA binding and T-cell activation. 
The next step in our research was to analyse the interactions of the compounds within HLA-
B*57:01 and the relationship with the induction of T-cell activity. Analogues with the ability 
to induce T-cell activation were found to bind within HLA-B*57:01 in a similar conformation 
to that of abacavir, allowing for the repertoire of induced self -peptides described in 2012 
(Illing et al. 2012; Ostrov et al. 2012; Norcross et al. 2012) to be presented on the antigen 
presenting cell surface for T-cell recognition. Analogues with no T-cell activation potential, 
were found to bind HLA-B*57:01 in a hindered manner, making it unlikely that a repertoire 
of neo self-peptides could bind in their presence, illustrated by the unsustainable steric 
clashes between the functional groups of analogues X, G, M and R and the residues of the 
HLA binding peptide or amino acids within the F-pocket of HLA-B*57:01 (Naisbitt et al. 2015). 
Interestingly, we demonstrated that activation of abacavir-specific CD8+ T-cells was not only 
dependent on the functional group at the 6-amino cyclopropyl position of the compound, 
but on the chiral state of the functional group in question. Analogues Q and R, which differed 
only in their enantiomeric state, activated and were devoid of T-cell responses in abacavir 
clones, respectively. While studies have seldom been conducted to analyse the effect of 
enantiomers on T-cell activity, these findings concur with other results which indicate the 
enantioselectivity of T-cells (Naisbitt et al. 2005). Unfortunately, the enantiomeric state of 
each analogue bore little effect on their respective antiviral activities presenting the sec-
butyl amino functional group to be unsuitable for implementation into the structure of 
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abacavir for replacement in therapy. However, these findings cast light on a new avenue for 
focus with regard to the synthesis of further abacavir analogues. If the chiral state of the sec-
butyl amino group yields such a polar effect on the induction of T-cell activity then it would 
be sensible to assume that chiral variants of other functional groups may also possess this 
effect. Therefore, enantiomers of functional groups such as the azetidine ring (analogue D) 
and azetidine-fluro (analogue H) could conceivably be analysed to investigate the bearing on 
T-cell activation. However, chiral modification at the 6-amino cyclopropyl region of abacavir 
was not the only modification that was capable of eradicating the unwanted CD8+ mediated 
T-cell activity experienced in HLA-B*57:01 positive individuals. The abacavir enantiomer 1R, 
4S abacavir, which differed in the chiral state of the cyclopentyl moiety located at the 
opposite end of the compound was also found to be completely free of T-cell activation when 
incubated with abacavir-specific T-cell clones. While this compound did not yield any 
antiviral potency, due to the enantioselective nature of enzyme adenosine 
phosphotransferase, responsible for the metabolism of the prodrug (Faletto et al. 1997), in 
silico modelling within HLA-B*57:01 revealed an unfavourable binding conformation of the 
compound. This indicated that the enantiomer was unable to interact within the F-pocket of 
HLA-B*57:01, presumably due to loss of interactions between the cyclopurine moiety and 
amino acids, thus preventing the cyclopropyl moiety from protruding into the F-pocket to 
induce the conformational change. This again incepts a new avenue to pursue in research 
into the construction of the benchmark abacavir analogue which can possess optimal 
antiviral activity whilst being devoid of the adverse CD8+ mediated T-cell activity. It is likely 
that alteration of other parts of the abacavir molecule would hinder the binding of the 
compound within HLA-B*57:01 to prevent the induction of such T-cell responses. Indeed, 
such a theory has been postulated (Ostrov, unpublished data) via the introduction of 
modifications to the cyclopurine moiety of abacavir. This suggests the generation of two 
separate abacavir analogues comprising of firstly substitution of the amine group protruding 
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from the cyclopurine moiety with a methyl group. The second of these analogues comprised 
substitution of the nitrogen groups in the cyclohexane ring with carbon atoms (Figure 7.2).  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 7.2. Structures of currently unsynthesised potential abacavir analogues with 
substitutions in the cyclopurine moiety (Ostrov, unpublished data). 
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As mentioned earlier, the predicted hindered binding of abacavir analogues within HLA -
B*57:01 results in the inhibition of an altered repertoire of self-peptides being presented to 
T-cells, observed in the presence of abacavir. This was confirmed via use of peptide elution 
assays conducted in chapter 3 by our collaborators in the Purcell Laboratory (Monash 
University, Melbourne). Indeed, the presentation of neo self -peptides on the surface of APCs 
was detected in the presence of the abacavir substituted analogues which induced T-cell 
activity, while those with no T-cell activity did not induce an increase in the prevalence of the 
smaller chain C-terminal anchors isoleucine and leucine, confirming our findings with regard 
to interactions of these compounds within HLA-B*57:01 and the relationship with the 
induction of CD8+ mediated T-cell activity. Based on these findings, it would be safe to 
presume that analogues G, M and X would be safe and well tolerated compounds. However, 
incorporation of analogues G and X into T-cell cloning assays produced results which were 
somewhat unexpected. Analogue G was well tolerated within the T- cell cloning assays 
generating no responsive T-cell clones, confirming this compounds safety and lack of 
immunogenicity. On the other hand, while analogue X evoked no activation of abacavir-
specific T-cell clones, cloning to analogue X itself yielded a plethora of responsive T-cell 
clones which were not only capable of generating strong responses to the analogue, but also 
produced potent cross-reactivity with abacavir. At first glance these findings were 
perplexing, given the fact that analogue X had previously represented the benchmark of 
abacavir analogues with regard to lack of T-cell activity. Also, analogue X did not induce an 
increase in the prevalence of C-terminal anchors leucine or isoleucine, one could have 
presumed that it may have interacted via a different mechanism. However, closer analysis of 
the peptides eluted from HLA-B*57:01 in the presence of analogue X and abacavir, cast light 
on these surprising findings. As mentioned in chapter 3, co-incubation of C1R-B*57:01 cells 
with analogue X induces an increase in the prevalence of peptides terminating in the amino 
acid alanine. Given the similar properties of alanine to isoleucine and leucine (Biro 2006), 
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replacement at the C-terminal with this amino acid would possess similar properties. 
Furthermore, the alanine terminating amino acids prevalent in the presence of X are also 
observed in the presence of abacavir meaning that T-cell clones with specificity to the alanine 
terminating peptides would also recognise these peptides in the presence of abacavir, hence 
a T-cell response would be evoked. Although given the massive shift in isoleucine abundance 
in the presence of abacavir, it is likely that most abacavir clones will possess specify only to 
peptides terminating in isoleucine suggesting why the T-cell responses to analogue X are 
absent in abacavir clones.  
These peptide elution studies may be important in the screening of new compounds. 
However, based on their low throughput, they present as logistically difficult experiments to 
carry out readily, and as previously stated require a large quantity of the compounds in 
question, hence why some compounds from this study could only be screened in singlet (D, 
H, M) and others were excluded (G). Taken together, these findings demonstrated the ability 
to generate abacavir substituted analogues which could retain antiviral activity and were 
devoid of T-cell activation. Further studies using a selected panel of these compounds 
highlighted the pivotal role of their interactions within HLA-B*57:01 and the effect this had 
on the peptides presented to T-cells. Based on this, it would seem sensible to investigate the 
interactions of potential new compounds within HLA-B*57:01 using the methods mentioned, 
prior to their synthesis, considerably reducing the number of compounds generated with T-
cell activating properties. This would refine the process for the  design and synthesis of the 
next panel of abacavir analogues allowing for easier deduction of whether a compound will 
activate abacavir-specific T-cells then allowing compounds devoid of T-cell activity to be 
forwarded for further analysis such as peptide elution work and T-cell cloning to the 
compounds themselves (Figure 7.3).  
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Figure 7.3. New experimental design and synthesis of abacavir substituted analogues. 
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Figure 7.3 presents an updated paradigm for the synthesis and generation of abacavir 
substituted analogues, with the emphasis on computational chemistry carried out in more 
detail before the synthesis of the analogues. This would refine the number of analogues 
synthesised to only those expected to be devoid of T-cell activity with a degree of certainty, 
then allowing for further studies to be conducted on the promising analogue s in a much 
shorter period of time. Furthermore, the use of in silico docking could be expanded on 
promising analogues with no T-cell activity and strong antiviral properties to examine the 
effect of the compounds on other alleles, to assess if the T-cell burden is merely shifted to 
another allele.  
Since the elegant studies carried out by three independent groups in 2012 (Illing et al. 2012; 
Norcross et al. 2012; Ostrov et al. 2012), the primary focus of abacavir hypersensitivity 
research has been directed towards the analysis of the neo self-peptides presented on the 
surface of the antigen presenting cell. Indeed, prior to my studies Dr Mohamad Alhaidiri 
identified one peptide (NTVELRVKI) that was capable of initiating T-cell activation in the 
presence of abacavir in the natural form, while in the amidated form T-cell activity was 
observed in the absence of the drug. Unfortunately, expansion of these studies to our T-cell 
clones was unable to detect T-cell activation in the presence of peptide 15 in its natural form, 
whilst in the amidated form strong T-cell activity was again detected. This may have 
presented the opportunity for the amidation of peptides for use in the assays, however the 
amidated form of peptide 15 was shown to activate T-cell clones to other drugs in a non-
specific manner suggesting it to function as a mimotope (Hartmann et al. 2010; Casey et al. 
2006; Gevorkian et al. 2005b). Carrying on from this work a panel of 39 abacavir-induced 
self-peptides were received, which underwent prior studies to examine their presentation 
on the surface of HLA-B*57:01 in the presence of abacavir over time. Initial T-cell assays with 
these peptides proved for the most part fruitless, they revealed a small number of peptides 
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which may have indicated an enhancement of T-cell activity in their presence. These peptides 
were investigated further via the use of the T-cell cloning assay to the peptides in both the 
presence and absence of abacavir. While it was consistently demonstrated that T-cell clones 
specific to the peptides in the absence of the drug could not be generated, in the presence 
of abacavir, a panel of responsive clones were detected. Furthermore, at low concentrations 
of abacavir the addition of the peptides individually yielded an enhancement in the T-cell 
response to abacavir, demonstrating that the peptides seem to play a role in the activation 
of T-cells. Perhaps most interestingly, two abacavir-specific CD8+ T-cell clones were found to 
respond to some self-peptides in the absence of abacavir. Considering these clones were not 
exposed to the self-peptides exogenously during the priming stage of the experiment, 
exposure must have taken place naturally with the altered peptides presented in the 
presence of abacavir. Indeed, exogenous addition of these peptides reinstated the blunted 
response to abacavir achieved via the use of either short time point APC pulsing or APC 
fixation with glutaraldehyde. Expansion of the fixation assay to clones primed to the peptide 
mix + abacavir revealed a modest increase in T-cell activity in the presence of most of the 
peptides. However, this was not as strong a response as observed with the two abacavir 
clones. Since these responses were not observed in previous abacavir clones, this suggested 
that the TCR expression of abacavir clones plays a pivotal role on the ability to interact with 
peptides presented on the APC surface. The expression of TCRs is known to be a major factor 
in T-cell reactions to the anti-epileptic drug carbamazepine with the expression of the V β11 
and Vα22 subtypes being the most prominent among the patients with CBZ induced SJS/TEN 
(Ko et al. 2011). With abacavir, the TCR expression is less restricted given that responsive 
abacavir clones possess a varied repertoire of TCRs (Figure 2.15) (Bell et al., 2013). However, 
the expression of TCRs could be imperative for the mediation of responses to some abacavir 
self-peptides and not others. Unsurprisingly, the two abacavir T-cell clones capable of 
responding to peptides in the absence of the drug, expressed rare TCRV β which were not 
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detected in previous abacavir clones, one of which was not detectable by the TCRV β kit which 
constitutes around 85% of TCRVβ repertoire. Consistent with reports from Yerly et al, it is 
likely that the T-cell reactions directed against the abacavir-induced self-peptides is 
restricted to multiple subsets of abacavir-specific T-cells and is mediated by the TCR 
expression on the T-cell (Yerly et al. 2017).  
The aim of my studies was to gain a further insight into the mechanisms involved in the 
hypersensitivity reactions experienced to the antiretroviral drug abacavir. Here, we have 
demonstrated a pivotal role for the abacavir-induced self-peptides only present at HLA-
B*57:01 in the presence of the drug. Furthermore, reactions directed against these self-
peptides can take place even in the absence of abacavir, suggesting a critical role for the TCR 
expression on T-cells. While we were not able to synthesise an abacavir analogue which 
sufficiently met all the criteria to be considered as a replacement for abacavir in therapy, we 
demonstrated that it is possible to generate such analogues which can retain antiviral activity 
and not activate T-cells. Our findings have now led the incorporation of new avenues in the 
analogue field, including the consideration of a functional groups chiral state and also not 
restricting the modification of the abacavir structure to just the cyclopropyl moiety. Taking 
all these factors into consideration, it seems only a matter of time before the optimal 
analogue is discovered, with no T-cell activity and an equipotent antiviral activity to abacavir. 
Studies have demonstrated the ability to use mouse models for investigation into drug 
hypersensitivity reactions with drugs including abacavir, carbamazepine, lamotrigine and 
phenytoin among others (Whritenour et al. 2014; Zhu et al. 2015), however to determine the 
underlying mechanisms and the role of viral load in hypersensitivity reactions to abacavir, 
transgenic mice expressing HLA-B*57:01 should be considered. Indeed, some success was 
observed via the use of HLA-B*57:01 transgenic mice, to analyse the role of abacavir and the 
innate immune system in the induction of idiosyncratic liver injury (Song et al. 2018).   
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Regulatory factors of the immune system have long been considered as responsible elements 
for the variation in immune responses to an antigen. For instance, the overexpression of PD-
1 is apparent in the CD8+ virus specific T-cells in HIV infected mice. Furthermore, the blockade 
of the PD ligand restores the CD8+ T-cell function and thereby reduces viral load (Day et al. 
2006). The presence of HIV infection results in a reduction in CD4+ T-cells, including Tregs. 
Therefore, as immune tolerance relies in part on cell extrinsic mechanisms such as those 
provided by CD4+ Tregs, this presented as a promising target for research. Indeed, a study 
conducted by the Norcross group looked to address this matter (Cardone et al. 2018) via the 
generation of transenic mice (Tg) expressing the HLA-B*57:01 risk allele. While CD8+ T-cells 
isolated from drug naïve HLA-B*57:01 Tg mice were activated in vitro, the addition of 
abacavir to the same Tg mice in vivo yielded little to no T-cell activity. However, the depletion 
of CD4+ T-cells via the use of anti-mouse CD4+ mAb (anti-CD4) prior to abacavir treatment, 
resulted in clear signs of hypersensitivity reactions in the Tg mice characterised by scarring, 
infiltration of CD8+ T-cells, in both the dermis and epidermis as well as increased ear 
thickness. This was not observed in wild type mice or non-CD4 depleted (Cardone et al. 
2018). 
Hypersensitivity reactions to abacavir yield a 100% NPV, but only a PPV of 55% meaning that 
just more than half of the HLA-B*57:01 expressing individuals will develop a hypersensitivity 
reaction when exposed to the drug (Mallal et al. 2008). To date, while the contribution of 
both genetic and non-genetic factors have been suggested as a reason for this, no definitive 
factor has been identified. Based on the results discussed, the answer to this question may 
simply lie in immune tolerance, in one such instance by the presence of CD4+ Tregs known 
to have strong immunosuppressive abilities (Gibson et al. 2017). As depletion of CD4+ T-cells 
results in the amplification of CD8+ mediated T-cell responses to abacavir in Tg mice, it does 
not seem inconceivable that this may also play a role in humans, suggesting that the viral 
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load of HIV itself, which severely diminishes CD4+ cells in patients, could play a critical role in 
the regulation of the on the induction of T-cell responses to abacavir in individuals expressing 
the HLA-B*57:01 risk allele, with those possessing a lower viral load being more tolerant. 
However, while an association with HIV infection and cutaneous reactions exists (Coopman 
et al. 1993) no association between HIV viral load and susceptibility to cutaneous reactions 
has been found with other anti-infectious agents such as sulfonamides (Eliaszewicz et al. 
2002). Therefore, it is likely that a complex interplay between both the innate and the 
adaptive immune system coupled with exogenous factors governs the susceptibility to 
hypersensitivity reactions with abacavir, accounting for why just under half of those 
expressing HLA-B*57:01 will not experience hypersensitivity reactions upon exposure and 
why some individuals experience such reactions on f irst exposure to the drug. 
Since its identification as an agent to induce hypersensitivity reactions and the subsequent 
association of these hypersensitivity reactions with HLA-B*57:01 (Mallal et al. 2008; 
Hetherington et al. 2002; Mallal et al. 2002), abacavir has remained the gold standard of a 
HLA-associated drug hypersensitivity reaction. Here, we set out to gain a greater 
understanding of the T-cell mediated reactions to abacavir in HLA-B*57:01 expressing 
individuals with a view to designing safer therapeutics which retain the antiviral potency of 
abacavir but not the T-cell activating properties. In this thesis we have demonstrated the 
ability to generate stable substituted analogues of abacavir which retain antiviral activity, 
but lack the propensity to induce an undesirable T-cell response. Furthermore, we 
demonstrated that the induction of such T-cell responses showed considerable dependency 
on the chirality of the compounds structure, not just at the 6-amino cyclopropyl moiety but 
at other regions of the compound.  
To conclude, numerous advances have been made in the study of abacavir-induced 
hypersensitivity reactions over the years; however, the story remains far from finished. We 
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demonstrate the importance of a holistic approach into both the understanding of these 
reactions and the design and analysis of newly generated therapeutics. Incorporation of 
multiple research paradigms are paramount for the studies into a drug’s potential to induce 
T-cell mediated ADRs in susceptible individuals. This will ultimately lead to a greater 
likelihood of predicting and subsequently eradicating such reactions, ultimately removing 
the need for personalised therapy regimens. 
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Appendix 
 
Appendix Section 1  
Amino acid sequence differences between HLA-B*57:01 and the abacavir insensitive alleles 
HLA-B*57:03 and HLA-B*58:01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Table 1. Comparison of amino acid sequences between HLA-B*57:01 and abacavir 
insensitive alleles HLA-B*57:03 and HLA-B*58:01. Sequences were determined using sequence 
alignment tool of the EMBL European Bioinformatics Institute (www.ebi.ac.uk). Red boxes indicate 
amino acid differences at positions 114 and 116 between HLA-B*57:01 and HLA-B*57:03. Blue 
boxes highlight amino acid differences between HLA-B*57:01 and HLA-B*58:01. 
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Appendix Section 2. Synthesis of chapter 3 substituted abacavir analogues. 
The abacavir substituted analogues used in chapter 3 were synthesised following a general 
procedure outlined in section 3.3.2. Synthesis of individual analogues was carried out as 
described below. 
Analogue A 
 
 
The crude product was purified by prep.TLC purification to give Analogue A (54.8 mg, 182.4 umol , 32 % yield) as 
a  white solid.  
LCMS: ET4430-1-P1A6 (M+H+): 301.1 
1H NMR: ET4430-1-P1A1 400 MHz MeOD  
δ7.70 (s , 1H), 6.15 (t, J = 3.6 Hz, 1H), 5.88 (t, J = 2.4 Hz, 1H), 5.47-5.51 (m, 1H), 4.80 (s , 1H), 4.35 (s , 1H), 4.21 (s, 
1H), 3.61-3.65 (m, 2H), 2.98 (s , 1H), 2.76-2.98 (m, 1H), 2.73-2.75 (m, 1H), 1.68-2.02 (m, 1H), 1.65-1.67 (m, 1H), 
1.57 (d, J = 6.4 Hz, 3H). 
Analogue B 
 
The crude product was purified by prep.TLC purification to give Analogue B (104.8 mg, 331.3 umol , 58 % yield) as 
a  white solid. 
LCMS: ET4430-5-P1A6 (M+H+): 317.1 
1H NMR: ET4430-5-P1A2 400 MHz MeOD  
δ7.73 (s , 1H), 6.15 (t, J = 3.6 Hz, 1H), 5.88 (t, J = 2.4 Hz, 1H), 5.48-5.49 (m, 1H), 4.20 (s , 1H), 3.57-3.65 (m, 2H), 3.54 
(s , 2H), 2.98 (s , 1H), 2.73-2.76 (m, 1H), 1.65-1.70 (m, 1H), 1.63 (d, J = 5.6 Hz, 3H). 
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Analogue C 
 
 The crude product was purified by prep.TLC purification to give Analogue C (109.5 mg, 348.3 umol , 62% yield) as 
a  white solid. 
LCMS: ET4430-17-P1A5 (M+H+): 315.2 
1H NMR: ET4430-17-P1A1 400 MHz MeOD  
δ7.64 (s , 1H), 6.12-6.15 (m, 1H), 5.86 (t, J = 2.4 Hz, 1H), 5.45-5.47 (m, 1H), 4.38 (s , 1H), 3.56-4.00 (m, 2H), 2.96-
2.97 (m, 1H), 2.72-2.75 (m, 1H), 2.18-2.21 (m, 1H), 1.62-1.68 (m, 6H). 
 
Analogue D 
 
 The crude product was purified by prep.TLC purification to give  Analogue D (57.3 mg, 200.1 umol , 35% yield) as 
a  white solid. 
LCMS: ET4430-5-P1A6 (M+H+): 287.1 
1H NMR: ET4430-2-P1A5 400 MHz MeOD  
δ7.71 (s , 1H), 6.14-6.16 (m, 1H), 5.86-5.88 (m, 1H), 5.47-5.50 (m, 1H), 4.80 (s , 1H), 3.56-3.65 (m, 2H), 2.98 (s , 1H), 
2.72-2.76 (m, 1H), 2.44-2.47 (m, 2H), 1.63-1.69 (m, 1H) 
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Analogue E 
 
The crude product was purified by prep.TLC purification to give Analogue E (126.1 mg, 366.1 umol , 65% yield) as 
a  white solid. 
LCMS: ET4430-24-P1A5 (M+H+): 301.2 
1H NMR: ET4430-24-P1A3 400 MHz MeOD  
δ7.73 (s , 1H), 6.14-6.16 (m, 1H), 5.86-5.88 (m, 1H), 5.47-5.51 (m, 1H), 4.57 (s , 2H), 4.14 (s , 1H), 3.61-3.71 (m, 3H), 
2.98-3.32 (m, 1H), 2.72-2.98 (m, 1H), 1.64-1.70 (m, 1H), 1.16 (d, J = 6.0 Hz, 6H) 
 
Analogue F 
 
The crude product was purified by prep.TLC purification to give Analogue F (71.0 mg, 225.8 umol , 40% yield) as a  
yel low solid. 
LCMS: ET4430-6-P1A6 (M+H+): 315.2 
1H NMR: ET4430-6-P1A5 400 MHz MeOD  
δ7.71 (s , 1H), 6.14-6.16 (m, 1H), 5.86-5.88 (m, 1H), 5.47-5.51 (m, 1H), 4.03 (s, 1H), 3.57-3.65 (m, 2H), 2.97-2.98 
(m, 1H), 2.72-2.76 (m, 1H), 1.64-1.70 (m, 1H), 1.35 (s , 6H) 
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Analogue G 
 
 The crude product was purified by prep.TLC purification to give Analogue G (79.9 mg, 256.6 umol , 45% yield) as 
a  white solid. 
LCMS: ET4430-18-P1A (M+H+): 312.2 
1H NMR: ET4430-18-P1A6 400 MHz MeOD  
δ7.63 (s , 1H), 6.08-6.09 (m, 1H), 6.02 (s, 2H), 5.82-5.83 (m, 1H), 5.34-5.37 (m, 1H), 4.68-4.71 (m, 1H), 4.48-4.52 
(m, 2H), 4.32-4.33 (m, 1H), 3.88-3.92 (m, 1H), 3.40 (t, J = 5.6 Hz, 2H), 2.56-2.83 (m, 1H), 2.42-2.54 (m, 1H), 1.50-
1.55 (m, 1H) 
 
Analogue H 
 
The crude product was purified by prep.TLC purification to give Analogue H (65.0 mg, 213.6 umol , 38% yield) as 
a  white solid. 
LCMS: ET4430-7-P1A5 (M+H+): 305.2 
1H NMR: ET4430-7-P1A1 400 MHz MeOD  
δ7.75 (s , 1H), 6.14-6.16 (m, 1H), 5.87-5.88 (m, 1H), 5.50-5.86 (m, 2H), 4.65 (s, 2H), 4.36-4.42 (m, 2H), 3.56-3.65 
(m, 2H), 3.28-3.54 (m, 1H), 2.73-2.98 (m, 1H), 1.64-1.71 (m, 1H) 
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Analogue I 
 
The crude product was purified by prep.TLC purification to give Analogue I (134.5 mg, 390.2 umol , 69% yield) as 
a  white solid. 
LCMS: ET4430-25-P1A (M+H+): 345.2 
1H NMR: ET4430-25-P1A3 400 MHz MeOD  
δ7.73 (s , 1H), 6.15 (s , 1H), 5.87 (s , 1H), 5.50 (s , 1H), 3.57-3.65 (m, 2H), 3.32 (s , 1H), 2.98 (s , 1H), 2.83-2.87 (m, 1H), 
2.72-2.76 (m, 1H), 1.65-1.68 (m, 1H), 1.28-1.34 (m, 1H), 1.17 (s , 6H) 
 
Analogue J 
 
 The crude product was purified by prep.TLC purification to give Analogue J (83.4 mg, 263.6 umol , 47% yield) as 
a  white solid. 
LCMS: ET4430-8-P1A6 (M+H+): 317.2 
1H NMR: ET4430-8-P1A2 400 MHz MeOD  
δ7.73 (s , 1H), 6.15 (t, J = 3.6 Hz, 1H), 5.88 (t, J = 2.0 Hz, 1H), 5.50 (t, J = 5.6 Hz, 1H), 4.53 (s , 1H),4.37-4.39 (s , 1H), 
4.36 (s , 1H), 3.57-3.65 (m, 2H), 3.55 (s , 3H), 2.98 (s , 1H), 2.73-2.78 (m, 1H), 1.63-1.70 (m, 1H). 
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Analogue K 
 
Compound 1 (135 mg, 447 umol , 1.0 eq), Analogue K (135 mg, 894 umol , 2.0 eq) and DIPEA (289 mg, 2.2 mmol, 
5.0 eq) were dissolved in i -PrOH (3 mL).  The solution was heated at 70 °C under microwave for 2 hr.  LC-MS 
showed the reaction was completed.  The reaction solution was concentrated and the residue was dissolved in 
EtOAc (20 mL).  The organic phase was washed with water (20 mL).  The water phase was extracted with EtOAc 
(10 mL*3).  The combined organic layers were washed with brine (10 mL), dried over Na 2SO4, fi ltrated and 
concentrated to give Analogue K (100 mg, 290 umol , 65% yield) as an off white solid. 
1HNMR: ET5353-5-P1A 400 MHz MeOD  
δ 7.78 (s , 1H), 6.17-6.18 (m, 1H), 5.89-5.91 (m, 1H), 5.51-5.55 (m, 1H), 4.33 (d, J = 16 Hz, 4H), 3.57-3.68 (m, 2H), 
3.00-3.01 (m, 1H), 2.75-2.81 (m, 1H), 1.67-1.73 (m, 1H), 1.41-1.45 (m, 1H), 0.65-0.70 (m, 2H), 0.50-0.53 (m, 2H). 
LCMS: ET5353-5-p1a (M+H)+: 345.2 
SFC: ET5353-5-P1: 100% 
Analogue L 
 
Compound 1 (135 mg, 447 umol , 1.0 eq), Analogue L (118 mg, 894 umol , 2.0eq) and DIPEA (289 mg, 2.2 mmol, 
5.0 eq) were dissolved in i-PrOH (3.0 mL).  The solution was heated at 70 °C under microwave for 2 hr.  LC-MS 
showed the reaction was completed.  The reaction solution was concentrated and the residue was dissolved in 
EtOAc (20 mL).  The organic phase was washed with water (20 mL).  The water phase was extracted with EtOAc 
(10 mL*3).  The combined organic layers were washed with brine (10 mL), dried over Na 2SO4, fi ltrated and 
concentrated to give the crude product.  The crude product was purified by prep-TLC (Dichloromethane: 
Methanol =10:1) to give Analogue L (75 mg, 231 umol , 52% yield) as a  white solid. 
1HNMR: ET5353-6-p1a 400 MHz MeOD  
δ 7.79 (s , 1H), 6.17-6.19 (m, 1H), 5.89-5.91 (m, 1H), 5.52-5.55 (m, 1H), 4.65 (d, J = 8 Hz, 2H), 4.29 (d, J = 8 Hz, 2H), 
3.57-3.68 (m, 2H), 3.00 (s , 1H), 2.73-2.81 (m, 1H), 1.74 (s , 3H), 1.68-1.73 (m, 1H). 
LCMS: ET5353-6-p1 (M+H)+: 326.2 
SFC: ET5353-6-P1A: 100% 
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Analogue M 
 
Compound 1 (135 mg, 447 umol , 1.0 eq), Analogue M (159 mg, 894 umol , 2.0 eq) and DIPEA (289 mg, 2.2 mmol, 
5.0 eq) were dissolved in i -PrOH (3 mL).  The solution was heated at 70 °C under microwave for 2 hr.  LC-MS 
showed the reaction was completed.  The reaction solution was concentrated and the residue was dissolved in 
EtOAc (20 mL).  The organic phase was washed with water (20 mL).  The water phase was extracted with EtOAc 
(10 mL*3).  The combined organic layers were washed with brine (10 mL), dried over Na 2SO4, fi ltrated and 
concentrated to give the crude product.  The crude product was purified by prep-TLC (Dichloromethane: 
Methanol =10:1) to give Analogue M (65 mg, 176 umol , 39% yield) as a white solid. 
1HNMR: ET5353-7-p1c 400 MHz MeOD  
δ 7.79 (s , 1H), 6.17-6.19 (m, 1H), 5.90-5.91 (m, 1H), 5.50-5.54 (m, 1H), 4.60 (s , 2H), 4.29 (d, 2H), 3.57-3.68 (m, 2H), 
3.00 (s , 1H), 2.73-2.81 (m, 1H), 1.67-1.74 (m, 1H). 
LCMS: ET5353-7-p1a (M+H)+: 371.2 
SFC: ET5353-7-P1A: 100% 
Analogue N 
 
Compound 1 (135 mg, 447 umol , 1.0 eq), Analogue N (123 mg, 894 umol , 2.0 eq) and DIPEA (289 mg, 2.2 mmol, 
5.0 eq) were dissolved in i -PrOH (3 mL) in a microwave tube. The solution was heated at 70 °C under microwave 
for 2 hr.  LC-MS showed the reaction was completed.  The reaction solution was concentrated and the residue 
was  dissolved in EtOAc (20 mL).  The organic phase was washed with water (20 mL).  The water phase was 
extracted with EtOAc (10 mL*3).  The combined organic layers were washed with brine (10 mL), dried  over 
Na 2SO4, fi l trated and concentrated to give the crude product.  The crude product was puri fied by prep-TLC 
(Dichloromethane: Methanol =10:1) to give  Analogue N (65 mg, 197 umol , 44% yield) as a white solid. 
1HNMR: ET5353-8-p1a 400 MHz MeOD  
δ 7.76 (s , 1H), 6.17-6.19 (m, 1H), 5.91-5.94 (m, 1H), 5.22 (s , 1H), 4.28 (s , 2H), 4.16 (s , 2H), 3.57-3.68 (m, 2H), 3.32 
(s , 3H), 3.00 (s , 1H), 2.75-2.81 (m, 1H), 1.66-1.73 (m, 1H), 1.55 (s , 3H). 
LCMS: ET5353-8-p1a (M+H)+: 331.2 
SFC: ET5353-8-P1: 100% 
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Appendix Section 3. Synthesis of chapter 4 substituted abacavir analogues 
The abacavir substituted analogues processed in chapter 4 were synthesised following the 
same procedure as described in section 3.3.2. Synthesis of individual abacavir analogues is 
outlined below. 
 
 
The crude product was purified by prep.TLC purification to give Analogue O (136.9mg) as  a white solid. 
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The crude product was purified by prep.TLC purification to give Analogue P (100mg) as  a  white solid. 
 
 
 
The crude product was purified by prep.TLC purification to give Analogue Q (97.6mg) as  a white solid. 
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The crude product was purified by prep.TLC purification to give Analogue R (56.8mg) as  a white solid. 
 
 
 
